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Abstract 
 
Introduction: Historical trials demonstrated clinical benefit of therapeutic hypothermia 
(TH) in unconscious cardiac arrest survivors. However, recent research raised 
important unanswered questions about this concept. Cardiac arrest associated 
mortality and morbidity including psychological trauma for survivors and caregivers 
remain alarmingly high, warranting further research in this field. TH has also been 
shown to offer additional protection against reperfusion injury in experimental models of 
myocardial ischaemia. However, co-administration of TH in conscious patients 
undergoing treatment for acute myocardial infarction (AMI) is potentially challenging. 
Methodology: (i) Rhinochill®, a novel intranasal cooling device is compared to 
Blanketrol for TH induction in unconscious cardiac arrest survivors, investigating 
efficacy and clinical outcome at hospital discharge. (ii) The emotional burden of cardiac 
arrest in patients and their caregivers is documented and the impact of simple 
interventions on quality of life is assessed. (iii) The feasibility of co-administration of TH 
in conscious patients undergoing emergency treatment of AMI is investigated.  
Results: (i) Rhinochill® is found to be more efficient in TH induction when measured 
from the tympanic membrane. However, Rhinochill® did not offer any superior clinical 
benefit. (ii) Simple psychological interventions are shown to improve quality of life in 
cardiac arrest survivors. (iii) Co-administration of endovascular cooling is shown to be 
feasible in conscious patients undergoing AMI treatment with minimum disruption to 
patient care.  
Discussion: Delays in TH administration may offset any potential benefit that it can offer 
in neuroprotection and therefore, earlier targeted brain cooling with more efficient 
portable devices is worth investigating. Improving quality of life of cardiac arrest 
survivors has been shown to be cost effective and therefore, investing in resources to 
better identify and help those at risk is justified. Delivery of TH in conscious heart attack 
patients is feasible and safe but more efficient endovascular cooling devices are 
required and these will need to be assessed in larger trials to assess the effect on 
clinical outcomes.  
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Overview 
Hypothermia has been used as a therapeutic agent for many centuries in different 
forms of illness with variable success rates. Better understanding of the different stages 
of neuronal cell damage following cardiac arrest generated potential therapeutic targets 
aimed at minimising hypoxic brain injury. TH is one such intervention which 
demonstrated neuro-protective properties by influencing several of these downstream 
processes in a beneficial manner in vitro and in vivo. Landmark trials in early 2000s 
showed that mild to moderate TH was associated favourable clinical outcomes in 
human survivors of cardiac arrest. More recently, this theory was challenged 
suggesting that there are no significant differences in clinical outcomes in cardiac 
arrest survivors with temperature managed at 33°C over those maintained at 36°C. 
Unlike previous trials, fever was prevented in both groups by active temperature 
management. Post-hoc analysis of this latest trial revealed that a considerable amount 
of time elapsed before TH was applied and target temperature was achieved. The time 
lost in achieving target temperature could potentially offset any neuro-protective 
properties of TH.  
Cardiac arrest is a leading cause of morbidity and mortality, irrespective of whether 
methods are applied to reduce core body temperature or prevent pyrexia and therefore, 
research to investigate more efficient methods of neuroprotection is warranted in this 
setting. Rhinochill® is a portable intranasal cooling device which is capable of delivering 
uninterrupted targeted brain cooling in intubated patients. In this thesis, the efficiency of 
Rhinochill® is investigated over conventional Blanketrol for TH induction in cardiac 
arrest survivors admitted to a tertiary heart attack centre.  
Follow up of these patients highlighted that cardiac arrest survivors and their caregivers 
suffer from substantial psychological trauma and cognitive impairment leading to poor 
quality of life (QoL) perceptions and reduced participation in society. Recent data 
suggested that simple supportive measures provided by healthcare professionals can 
help to improve QoL, which was also associated with socio-economic benefits. A 
similar model of supportive network was set up in this single centre and its feasibility 
and subsequent impact was investigated. 
And finally, there is emerging evidence to suggest that TH offers additional myocardial 
protection against reperfusion injury in the setting of AMI on restoration of circulation by 
minimising infarct size. In keeping with this theme, the feasibility of simultaneous 
administration of Thermoguard (Zoll, USA), a modern endovascular cooling device in 
patients undergoing emergency primary percutaneous intervention for AMI was tested. 
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1. Chapter 1: Introduction 
1.1.  Cardiac Arrest and Therapeutic Hypothermia (TH)  
1.1.1. Definition of cardiac arrest 
It is defined as ‘the abrupt cessation of cardiac pump function which may be reversible, 
but will lead to death in the absence of prompt intervention’ (Myerburg RJ, Castellanos 
A 2001). Many important organs in the body including the brain, liver, kidneys and the 
heart itself are heavily dependent on a healthy functioning heart for blood and 
nutritional supply including oxygen. Therefore, any period of pump failure/cessation 
results in hypoxic damage to these organs, that can result in debilitating morbidity and 
mortality. 
 
1.1.2. Incidence of cardiac arrest 
The annual worldwide incidence of cardiac arrest in the general population is estimated 
to be around 1-2/1000 persons but this has regional and countrywide variations 
(Myerburg RJ, Castellanos A 2001). In 2013, the emergency medical services (EMS) 
attempted to resuscitate approximately 28,000 out-of-hospital cardiac arrest (OHCA) 
patients in England and reported an overall survival to hospital discharge rate of 8.6% 
(NHS England 2013), which is similar to the United States of America (USA) 
(SCAFoundation 2014), but considerably lower than some of our European 
counterparts, where survival to hospital discharge rate approached 25% (Lindner, 
Soreide et al. 2011, Grasner, Herlitz et al. 2011). About 80% of OHCA were at home 
and 20% in public areas at the time of the incident. Only 20% of OHCA patients were 
found to be in shockable rhythm (ventricular fibrillation or ventricular tachycardia) 
(Nicholas P, Virdi G, Fothergill R September 2013). The survival rates are known to be 
better if patients are found to be in shockable rhythm as opposed to non-shockable 
rhythm (asystole or pulseless electrical activity) (Lindner, Soreide et al. 2011, Grunau, 
Reynolds et al. 2016). In contrast, the reported incidence of in-hospital cardiac arrest 
(IHCA) in the UK is 1.6 per 1000 hospital admissions and overall unadjusted survival 
rate to hospital discharge has been reported at 18.4% (Nolan, Soar et al. 2014). The 
better IHCA survival rate to hospital discharge can be partly explained by easier and 
quicker access to the chain of survival (Nolan, Soar et al. 2006).   
The Essex Cardiothoracic Centre (CTC) is a busy tertiary unit that serves a population 
of 1.7million in the eastern county. Every year the centre carries out approximately 750 
primary percutaneous interventions (PPCIs) for acute myocardial infarctions (AMIs). 
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Cardiac arrest account for about 100 emergency cardiac catheter laboratory 
admissions.  
1.1.3. Causes of cardiac arrest 
Cardiovascular disease (CVD) remains the leading cause of death worldwide (WHO 
factsheet 2016 September 2016) and mortality from cardiac arrest is most often related 
to ischaemic heart disease (Reichenbach, Moss et al. 1977, Davies 1992). 
Consequently, a large proportion of cardiac arrest patients, who can be successfully 
resuscitated, are taken to a tertiary heart attack centre with emergency cardiac catheter 
laboratory facilities to perform PPCI in order to treat the potential culprit coronary artery 
lesion. Other cardiovascular diseases such as cardiomyopathies, primary arrhythmias 
and non-cardiac causes such as intoxication, trauma and suffocation make up the 
remainder of the aetiology of cardiac arrests (Myerburg RJ, Castellanos A 2001). 
Whilst prompt resuscitation and early identification and correction of the underlying 
cause remain the clinical priority in a cardiac arrest situation, one can speculate that 
any delay in restoring circulation can result in significant damage to vital end organs 
including the heart itself, brain, kidney and liver.  
1.1.4. Implication of cardiac arrest – Hypoxic brain injury 
One of the major complications of cardiac arrest is irreversible brain injury or hypoxic-
ischaemic brain injury caused by deprivation of oxygenated blood supply (Busl, Greer 
2010). The length of delay in restoring circulation is directly proportional to the degree 
of irreversible brain damage sustained (Ames, Wright et al. 1968), which can present 
clinically as transient retrograde amnesia at the very least, to the worst outcome being 
coma or even death. Therefore, the focus of effective treatment in cardiac arrest is 
rapid restoration of circulation followed by attempts at minimising irreversible brain 
injury. The molecular mechanism of hypoxic brain injury will therefore provide better 
insight about therapeutic targets in minimising hypoxic insult to the brain tissue.  
1.1.5. Molecular mechanism of Hypoxic brain injury   
1.1.5.1. Pathophysiology 
In the early phase, within 10-12 minutes after the onset of ischaemia, the concentration 
of brain nutrients including glucose, glycogen and adenosine triphosphate (ATP) have 
been shown to deplete completely resulting in primary energy failure (Wagner, Lanier 
1994). This is followed by electrolyte imbalance within the intracellular and extracellular 
space (discussed in section 1.1.5.2), which create an environment for necrotic cell 
death. In animal models, neuronal damage and irreversible brain damage have been 
demonstrated within several minutes of cerebral hypoxia depending on the animal 
model and conditions (Miller, Myers 1972), although some animal models showed 
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considerable resilience to the degree of damage and reversibility (Hossmann, 
Zimmermann 1974). In humans, earlier research demonstrated that 95% of the brain 
tissue is damaged within 15 minutes of global ischaemia in the context of cardiac arrest 
(Ames, Wright et al. 1968), although in practice, the extent of tissue damage, the 
severity of neurological deficit and the potential for recovery are directly linked to the 
duration of the circulatory arrest.  
The clinical manifestation of the brain cell damage can appear within few hours but can 
also be delayed for days after the initial insult, depending on the duration of the initial 
ischaemia (Lipton 1999). In the delayed phase (hours to days), the cerebrovascular 
auto regulation centre of the brain dictates the brain vasculature to go into a state of 
vasodilation to allow maximum perfusion in this compromised situation and the 
viscosity of blood decreases with prolonged ischaemia, so blood accumulates in areas 
of low resistance such as the capillaries and interstitial spaces, resulting in brain 
oedema (Fischer, Ames 1972).  
 
Figure 1-1 Cascade of biochemical reactions following hypoxic-ischemic brain injury 
This schematic diagram demonstrates biphasic pattern of brain injury over time. In the 
initial early phase, there is a failure in aerobic energy metabolism resulting in necrotic 
cell death. This is followed by a delayed phase lasting for hours to days during 
reperfusion and reoxygenation, where inflammatory changes and breakdown of the 
blood brain barrier can result in apoptotic cell death. Scientists have been trying to 
develop optimal neuro-protective strategies that can be implemented between these 2 
phases, the ‘therapeutic window’, to rescue injured cells which are still alive (Lara-
Celador, Goni-de-Cerio et al. 2013). HI: hypoxic ischaemic, BBB: blood brain barrier 
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1.1.5.2. Biochemical changes 
The biochemical changes during hypoxic ischaemic brain injury are driven by anoxic 
depolarisation of the cell membrane resulting in changes in intracellular and 
extracellular electrolyte composition and ATP depletion (Xie, Zacharias et al. 1995). 
There is an intracellular influx of sodium and calcium ions and efflux of potassium and 
hydrogen ions into extracellular space. The increased calcium concentration within the 
intracellular space triggers the initiation of many calcium dependent pathways including 
the calpain system that is involved in altering signal transduction, remodelling of 
membrane structures and apoptosis (Goll, Thompson et al. 2003). High energy ATP is 
used up within a couple of minutes of ischaemia (Katsura, Rodriguez de Turco et al. 
1993) and lactic acid is released as an alternate source of energy along with hydrogen 
ions resulting in acidosis. The neurons can survive academia (pH 6.1-6.5) for 10-12 
minutes (Hoxworth, Xu et al. 1999), after which the cell function deteriorates and cell 
oedema ensues.  
 
Figure 1-2 Schematic diagram of biochemical changes during hypoxic brain injury 
Panel A displays the normal pathways controlling cellular [Ca2+]. Panel B displays the 
events leading up to [Ca2+] overload during ischaemia and reperfusion. A drop in pH 
triggers Na+/H+ exchanger mediated Na+ influx, resulting in Na+ overload. Reverse-
mode Na+/Ca+ exchange across the plasma membrane then results in Ca2+ overload 
and subsequent mitochondrial [Ca2+] overload. Taken from (Brookes, Yoon et al. 2004)  
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In addition to the electrolyte imbalances, a number of destructive enzymes, including 
lipases, proteases and nucleases are activated, which along with glutamate, an 
excitotoxic neurotransmitter contribute to progressive neuronal damage (Busl, Greer 
2010). There is also an increase in free radical formation (Piantadosi, Zhang 1996) and 
nitric oxide production (Endoh, Maiese et al. 1994) in anoxic conditions, which 
culminates in further neuronal cell loss. 
1.1.5.3. Functional changes 
In the early stages of hypoxic-ischaemic insult, the mitochondrial structure and function 
undergoes destructive changes with calcium accumulation, resulting in further release 
of free radicals, lack of ATP repletion and inability to maintain cell structure, resulting in 
cell death (Busl, Greer 2010). Neuronal protein synthesis is also diminished as a 
consequence of increased cytosolic calcium and N-Methyl-D-Aspartate (NMDA) 
receptor activation (Raley-Susman, Lipton 1990). Up-regulation of glutamate receptors 
induces heat shock proteins and immediate early genes such as the BCL-2 group of 
proteins which can offer some protection against free radicals (Kane, Ord et al. 1995). 
 
1.1.5.4. Reperfusion pathophysiology and reperfusion injury 
Return of spontaneous circulation (ROSC) following a cardiac arrest marks the re-
establishment of nutrient and oxygen supply to the brain. However, despite a 
functioning systemic circulation, cerebral circulation may remain impaired for hours 
(Ames, Wright et al. 1968). After ROSC, a brief period of hyperaemia that lasts for 
about 15 minutes is followed by a more protracted period of multifocal cerebral 
hypoperfusion that can last for up to 24 hours (Crumrine, LaManna 1991). This is most 
prominent in the microvasculature of the brain, which forms about 50% of the brain 
volume (Ginsberg, Myers 1972). Blood viscosity remains high in cerebral circulation 
due to inorganic nutrients and water being shifted into brain parenchyma from plasma. 
The resulting oedema from surrounding brain tissue further attenuates blood flow in the 
compromised capillary lumen along with greater adhesion of leukocytes to vascular 
endothelium and red blood cell sludging. Consequently, the mismatch from increased 
oxygen demand and pathophysiological hypoperfusion results in secondary hypoxia 
(Hossmann 1997).  
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Figure 1-3 Schema of ischaemia/reperfusion processes leading neuronal cell death  
Taken from (Pundik, Xu et al. 2012) 
 
 
Prior to ROSC, there is a toxic build-up of free radicals, nitric oxide and glutamate in 
the blood. The reinstatement of circulation allows these toxic components to reach 
cerebral circulation along with polymorphonuclear leukocytes, which induce 
perioxidative changes resulting in reperfusion injury (Bottiger, Schmitz et al. 1998). 
Additionally, the sheer nature of blood flow can cause further damage by causing 
microhaemorrhages to the damaged capillaries and inducing cerebral oedema (Busl, 
Greer 2010, Erecinska, Thoresen et al. 2003). These pathophysiological changes at 
the molecular level after ROSC constitute reperfusion injury and suggest that the brain 
sustains prolonged injury even hours after ROSC, some of which may not be 
reversible. However, it can be postulated that if the natural progression of these 
detrimental biochemical changes could be slowed down or better still, brought to a halt, 
any injured cells, which are not irreversibly damaged, will have the best chance of 
recovery. TH is believed to be an intervention which could play a key role in preventing 
reperfusion injury. The possible mechanism of this benefit will be discussed below. 
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1.1.6. The role of TH in minimising Hypoxic brain injury 
1.1.6.1. Definitions of normothermia and TH 
The thermoregulatory system in the brain hypothalamus allows maintenance of core 
temperature in the region of 36.5°C to 37.5°C in the human body despite fluctuations in 
environmental temperatures, often defined as normothermia (NICE, National Institute 
for Clinical Excellence 2016). In extremely hot environment, the hypothalamus sends 
downstream signals promoting heat loss through sweating and vasodilation. In very 
cold temperatures, the body preserves heat by vasoconstriction, increased metabolism 
and shivering.  
The intentional reduction of core body temperature  to less than 36°C is defined as 
induced hypothermia (Polderman, Herold 2009). And, the iatrogenic application of  
induced hypothermia in a controlled environment to suppress or prevent deleterious 
effects such as shivering is defined as TH (Polderman, Herold 2009). TH can be further 
categorised into mild (34.0-35.9°C), moderate (32.0-33.9°C), moderately deep (30.0-
31.9°C) or deep (<30°C) hypothermia. Deep hypothermia in the range of 20-28°C was 
used to perform open heart operations in 1950s, which allowed longer procedures to 
be performed in compromised conditions, but it was associated with terminal 
arrhythmia, coagulopathy and increased mortality (Walpoth, Locher et al. 1990, 
Walpoth, Walpoth-Aslan et al. 1997). Following a period of dormancy, several groups 
investigated the feasibility of mild to moderate TH in animal models in the 1980s 
(Leonov, Sterz et al. 1990, Busto, Dietrich et al. 1987) and human subjects (Bernard, 
Gray et al. 2002, Hypothermia after Cardiac 2002). They found that TH in the mild to 
moderate range (as defined above) was feasible and its application was associated 
with improved clinical outcomes.   
 
1.1.6.2. The role of TH in minimising Hypoxic brain injury  
TH has been trialled for many centuries in different forms of illness, including brain 
injury. Although several theories have been proposed and experimented, the exact 
mechanism of the therapeutic benefit of hypothermia in minimising brain injury is quite 
complex as it can influence several aspect of the damage cascade that follow a period 
of ischaemia. What is evident from experience of looking after patients suffering 
cardiac arrest is that, brain injury can continue for many days after the initial insult. The 
understanding from the molecular level of brain injury allowed researchers to 
investigate the possible beneficial role of TH at various time points from the original 
insult.   
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In the acute phase (minutes to hours), TH has been shown to reduce the metabolic 
rate by 6-7% for every 1°C drop in body temperature (Polderman 2009), which results 
in reducing brain oxygen demand, preserving ATP and reducing lactic acid formation 
(Zhao, Zhang et al. 2011).  In 1954, a group of scientists demonstrated that there was 
reduced oxygen consumption and reduced blood flow with temperature reductions in a 
small experiment with dogs, resulting in beneficial effect on intracranial pressure 
(Rosomoff, Holaday 1954). One of the most significant benefits of TH in the acute 
phase seems to be the reduction in reflex hyperaemia following ROSC, as this sudden 
rush of blood carries toxic materials and can cause further damage to the 
microcirculation through haemorrhages (Erecinska, Thoresen et al. 2003, Busl, Greer 
2010). In addition, TH has been shown to delay the release of glutamate, an excitotoxic 
amino acid (Nakashima, Todd 1996), downregulate glutamate induced increase in nitric 
oxide production (Polderman 2009) and inhibits phosphorylation of NMDA receptors 
(Mueller-Burke, Koehler et al. 2008). These changes translate into prevention of a 
detrimental acidic environment, which otherwise exacerbates neuronal cell death 
(Kuffler 2012).  
Figure 1-4 Schema showing beneficial effects of TH on minimising hypoxic brain injury 
 
In the subacute phase (hours to days) after the initial insult, the brain parenchyma can 
sustain further damage through reactive oxygen species (ROS) and nitrogen species, 
programmed cell death and generalised inflammation, leading to disruption of the BBB 
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and cerebral oedema (Yenari, Han 2012). TH has been shown to decrease hydrogen 
peroxide concentrations by 50 fold, which is an important ingredient for damage 
caused by oxidative stress (Zitta, Meybohm et al. 2010). Hypothermia also suppresses 
inflammation of the brain by downregulating astrocytes, microglial cells and pro-
inflammatory cytokines (Polderman 2009). Additionally, TH has shown some promise 
in deferring apoptosis and promoting cell repair by attenuating the expression of p53 
genes and augmenting bcl-2 expression (Zhang, Xu et al. 2010). More importantly, TH 
was found to play a vital role in maintaining the integrity of the BBB by deactivating 
metalloproteinases (Yenari, Han 2012), that degrade extracellular matrix and 
suppressing membrane permeability by reducing endothelial nitric oxide availability 
(Polderman 2009).  
In the chronic phase (weeks to months), the role of TH is less well understood. There 
have been isolated reports of some evidence of neurogenesis in animal models with 
longer duration of hypothermia treatment (4-24hrs) (Silasi, Colbourne 2011). However, 
this effect has not been reproducible. Overall, the current evidence of the therapeutic 
benefit of hypothermia in the context of hypoxic brain injury is led by its role in reducing 
cerebral metabolic rate, oxygen demand, minimising reperfusion injury, attenuating 
apoptosis and maintaining the integrity of the blood brain barrier (Polderman 2009).       
 
1.1.6.3. TH – historic use in medicine 
Historic evidence of hypothermia being used as a therapeutic agent goes back about 
5000 years as documented in an ancient Egyptian treatise on medicine and surgery  
(Wang, Olivero et al. 2006). In the late 1700s, Dr James Currie, a Scottish physician, 
was credited for using cold water (hydrotherapy) as a treatment in several clinical 
disorders and documenting changes in human body temperature in health and illness 
(Wang, Olivero et al. 2006). The Russians also used TH in the form of snow to 
resuscitate patients back in 1803 (Varon, Acosta 2008).  
In the 1940s, Dr Temple Fay, a neurosurgeon from Seattle, USA, pioneered the role of 
hypothermia as a therapeutic agent for pain control and preventing disease 
progression in cancer patients (Fay 1959). Although he did not see much benefit of 
hypothermia in preventing cancer progression, the patients tolerated the treatment 
without much adverse events and reported significant reductions in pain perceptions 
(Fay 1959). He then went on to develop the first cooling blanket and successfully 
implanted a metal capsule intra-cranially to deliver localised cooling to the brain (Wang, 
Olivero et al. 2006). His research was however prematurely stopped by the Nazis 
during World War II due to negative associations with Nazi experiments. Following a 
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period of dormancy, hypothermia was successfully applied in animal models, including 
dogs, monkeys and groundhogs for neuro-protection during cardiac surgery (Bigelow, 
Mcbirinie 1953). In human cardiac surgery, moderate hypothermia (28-32°C) was 
investigated in closed environments by surgeons to provide neuro-protection, but 
deeper hypothermia (20-28°C) was required to perform longer open heart surgery 
under compromised conditions (Baffes 1958). However, deeper hypothermia came at a 
cost of inducing terminal fibrillation and coagulopathy (Tveita, Mortensen et al. 1994), 
which led to the development of cardiopulmonary bypass machine, to allow more 
complex open heart surgery without deep hypothermia. At this stage, whilst some 
argued that hypothermia would become an unnecessary intervention in cardiac 
surgery, many continued to use it as they believed that the benefit of neuro-protection 
with controlled hypothermia outweigh any risks associated with this treatment (Baffes 
1958).      
1.1.6.4. Early evidence of TH in cardiac arrest 
In 1958, the first clinical trial of hypothermia in humans following cardiac arrest was 
published (Williams, Spencer 1958). In this early study, the authors reported on 4 
cases of cardiac arrest outside the operating room, suffering severe neurological injury. 
They were cooled to 30-34°C and maintained for up to 72hrs.  All patients survived, 3 
patients in this study made complete recovery whilst the 4th patient exhibited moderate 
residual neurological deficit. The authors concluded that the observation in this study 
was due to hypothermia induced reduction in brain swelling. In 1959, a small controlled 
study involving 19 patients resuscitated from cardiac arrest was published (Benson, 
Williams et al. 1959). In this study, 12 patients were cooled to 30-32°C for variable 
duration depending on clinical condition, whereas 7 patients did not receive 
hypothermia (control). In this study, 50% of the patients in the hypothermia group 
survived compared to 14% in the control group. Although it is difficult to draw 
conclusions from these small non-randomised studies, Dr Peter Safar felt that there 
was enough reasoning to incorporate hypothermia in the heart-lung resuscitation 
algorithm in patients with ROSC after cardiac arrest within 30 minutes (Safar 1964).  
After a further period of dormancy in the 1960s and 1970s due to concerns regarding 
deeper hypothermia induced ventricular fibrillation, infection and bleeding 
complications, there was resurgence in hypothermia research activity in the 1980s and 
1990s, mostly involving animals. Safar et al (Leonov, Sterz et al. 1990) demonstrated 
that mild hypothermia (34-36°C) administered during cardiac arrest was associated 
with good neurological recovery in a group of dogs without inducing any adverse 
events that were observed with deeper or moderate hypothermia (<30°C). Another 
group of researchers (Dietrich, Busto et al. 1993) demonstrated that post-ischaemic 
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hypothermia offered greater neuro-protection in rat forebrain in the short term (3 day 
follow up) compared to normothermia (maintained at 37°C throughout ischaemia and 
recirculation). This observed advantage was lost at 2 months follow up. More 
importantly, intra-ischaemic hypothermia demonstrated even greater neuro-protection 
compared to post-ischaemic hypothermia at longer term (2 month) follow up. 
Subsequent animal studies focused on reduced ischaemia time, minimising delay in 
initiating hypothermia and longer duration of hypothermia treatment to show greatest 
neuro-protection after cardiac arrest (Kuboyama, Safar et al. 1993, Noguchi, 
Matsumoto et al. 2011).    
 
 
 
 
1.1.6.5. Landmark clinical trials in humans in 2002 
The promising results from animal studies prompted researchers to re-investigate the 
role of hypothermia in human survivors of cardiac arrest in the late 1990s. Earlier 
challenges faced by previous researchers warranted assessment of the feasibility of 
instituting hypothermia in the setting of cardiac arrest and several researchers 
concluded that this intervention was safe whilst also reporting some clinical advantage 
of using this therapy over historical controls (Felberg, Krieger et al. 2001, Zeiner, 
Holzer et al. 2000). On the basis of these safety reports, 2 significant randomised 
controlled trials (RCTs) were conducted in Europe (Hypothermia after Cardiac 2002) 
and Australia (Bernard, Gray et al. 2002), the experiences of which are discussed 
below: 
1.1.6.5.1. Hypothermia after cardiac arrest study 2002 
Hypothermia after cardiac arrest (HACA) was set up as a prospective multi-centre RCT 
involving 275 adult patients who suffered out of hospital cardiac arrest. Half the 
patients (n=137) were randomly assigned to mild TH after ROSC and the other half 
(n=138) received standard care without temperature management. Patients in the 
hypothermia group were cooled to 32-34°C within 4hrs using surface cooling blankets 
and maintained for 24hrs before passive rewarming was allowed.  
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Figure 1-5 Bladder temperature in normothermia and hypothermia groups  
Please note that patients in the normothermia group did not have any temperature 
management and therefore, mean temperature in this group reached above 37°C 
during the study period. Adapted from (Hypothermia after Cardiac 2002) 
 
 
 
 
The follow up of these patients at 6 months showed that, 55% of the patients in the 
hypothermia group made a statistically significant favourable neurological recovery 
compared to 39% in the standard care group (risk ratio 1.40: 95% confidence interval 
of 1.08 to 1.81). The mortality rates were also significantly lower in the hypothermia 
group compared with standard care group (41% v 55% respectively; risk ratio 0.74, 
95% confidence interval 0.58-0.95). Whilst infection was more prevalent in the 
hypothermia group, the numbers did not reach statistical significance and the authors 
concluded that the benefit of the treatment outweighed any adverse events due to 
hypothermia institution. One of the limitations of this study was the inability to blind 
attending physicians from the mode of intervention. However, the authors claimed that 
the research team was unaware of the treatment modality at the time of 6 month 
assessment. Also, the restrictions on the selection criteria of the study meant that only 
8% of screened patients were enrolled into the study. Therefore, the authors concluded 
that wider application of TH in cardiac arrest warranted further research in this area.  
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1.1.6.5.2. The Australian study 2002 
This study was conducted across 4 hospitals in Australia as a prospective RCT 
involving 77 cardiac arrest survivors, out of whom 43 patients were randomly assigned 
to treatment with TH and 34 patients were allocated to standard post resuscitation 
treatment with temperature maintained at 37°C (control group). Patients in the 
hypothermia group were cooled to 33°C using surface ice packs and maintained for 
12hours following hospital admission after which, they were actively rewarmed using 
warm blankets. The authors in this study concluded that 49% patients in the 
intervention group had a statistically significant improvement in neurological status and  
survival rate at hospital discharge in comparison to 26% in the control group (p=0.046). 
After adjustment of baseline characteristics, the odd ratio of a good outcome with 
hypothermia was 5.25 compared to the control group (95% confidence interval 1.47-
18.76). The authors observed that hypothermia was associated with lower cardiac 
index and greater systemic vascular resistance, although these measures did not reach 
statistical significance. Similar to the HACA trial, it was difficult to establish blinding 
during treatment due to the nature of the intervention. However, the authors pointed out 
that due to strict adherence to the study protocol and the final assessment being 
carried out by an independent rehabilitation physician, any potential bias would have 
been minimised.     
Despite the promising role TH shown in the context of cardiac arrest in these landmark 
trials in 2002, some researchers questioned whether any observed beneficial effect of 
TH was attributable to targeted temperature management (TTM) or fever prevention. In 
2013, a group of researchers published a study that was aimed at answering some of 
these very important questions (Nielsen, Wetterslev et al. 2013). 
 
 
1.1.6.6. TTM study 2013 
This was by far the largest RCT in this field involving 36 intensive care units (ICUs) in 
Europe and Australia. Adult unconscious patients (>18yrs age) with at least 20 minutes 
of circulation after successful resuscitation from cardiac arrest were screened for 
enrolment. A total of 1431 patients were screened for eligibility, out of which 950 
patients (66%) were enrolled into the study.  Patients were then randomly assigned in a 
1:1 manner into TTM at 33°C or 36°C for 28hrs from the time of randomisation and 
maintained below 37.5°C for 72hrs in total.  
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Figure 1-6 Bladder temperature during intervention period, shown as mean ± 2SD  
Please note that patient in both groups had active temperature management during 
intervention and therefore, mean temperature never rose above 36°C in either group of 
patients.  Adapted from (Nielsen, Wetterslev et al. 2013)  
 
 
 
TH at different hospital sites were induced and maintained with application of ice 
packs, ice cold fluids and intravascular or surface temperature management devices. 
Although blinding was not possible during active temperature management, physicians 
carrying out neurological prognostication and research team carrying out follow up 
were unaware of trial intervention. Patients were followed up for 6 months or death, 
whichever happened first. At the end of the trial period, it was found that, 50% patients 
died in the 33°C group compared with 48% in the 36°C group (hazard ratio in 33°C 
group 1.06; 95% confidence interval 0.89-1.28). Also, at 6-month follow up, 54% 
patients in 33°C group had died or had poor neurological outcome compared to 52% in 
the 36°C group. (risk ratio 1.02; 95% confidence interval 0.88-1.16). The authors 
concluded that there was no significant difference in clinical outcome of patients with 
TTM at 33°C vs. 36°C in this group of patients.  
Subsequently, the design of TTM trial has been critically appraised and it highlighted 
potential pitfalls in trial design that may have contributed to the equivocal outcome of 
the 2 study arms (Polderman, Varon 2015). There was a long delay of up to 4 hours 
(mean time to initiation 130 minutes) before cooling was initiated and a further 8 hours 
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before target temperature was reached, which translates into approximately 10 hours 
before target temperature of 33°C was reached from the time of ROSC. Any potential 
benefit offered to patients maintained at 33°C would be lost due to this prolonged delay 
in reaching target temperature, as a lot of irreversible damage may have already taken 
place. In addition, the TTM trial does not comment on temperature fluctuations during 
patient movement between various hospital departments. Portable cooling equipment 
was not readily available at all centres, which could result in rebound hyperthermia 
during patient movement and this may itself contribute to poor outcomes (Polderman 
2008). 
 
1.1.6.7. Meta-analysis and consensus guidelines 
Several meta-analyses have been carried out at various time points with evolving 
research in this field of TH in cardiac arrest. The earliest was conducted in 2005 
(Holzer, Bernard et al. 2005) which demonstrated that adult survivors of cardiac arrest 
who received TH within 6 hours of hospital admission were more likely to leave hospital 
with good neurological recovery than patients who were offered standard care (risk 
ratio 1.68; 95% confidence interval 1.29-2.07). The number needed to treat to allow 
one additional patient to leave hospital with good neurological recovery was 6 (95% 
confidence interval of 4-13). The 6-month survival data available from 1 study 
(Hypothermia after Cardiac 2002) also translated to better survival rate with favourable 
neurological recovery in patients treated with hypothermia (risk ratio 1.44; 95% 
confidence interval 1.11-1.76). The publication of this meta-analysis and historic 
evidence of the beneficial role of TH in cardiac arrest inspired many governing bodies 
to advocate the use of TH in patients surviving cardiac arrest (Peberdy, Callaway et al. 
2010, Nolan, Neumar et al. 2008). In more recent times, 2 further meta-analyses also 
support the use of TH in cardiac arrest (Wang, Lin et al. 2013, Schenone, Cohen et al. 
2016).  
The latest American Heart Association (AHA) guideline on TH in cardiac arrest has 
been updated in 2015 to reflect latest research findings and it says ‘all comatose adult 
patients with ROSC after cardiac arrest should have TTM, with a target temperature 
between 32°C and 36°C selected and achieved and then maintained constantly for at 
least 24 hours’ (Donnino, Andersen et al. 2015). The national institute of clinical 
excellence (NICE) also support the use of TH following cardiac arrest, however the 
guideline has not been updated since the publication of the TTM trial (NICE, National 
Institute for Clinical Excellence March 2011).     
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1.1.6.8. TH induction methods 
Earlier trials used ice packs and/or cooling blankets for TH induction and maintenance 
(Benson, Williams et al. 1959, Bernard, Gray et al. 2002, Hypothermia after Cardiac 
2002). These techniques come with innate problems in active temperature 
management as patients may need to be moved from site of cardiac arrest, often 
outside of hospital to different sites within the hospital, when these cooling devices may 
need to be switched off. This can result in unwanted temperature gain, potentially 
defeating any benefit implied by the original induction. More recently, ice cold saline 
infusion has been investigated to induce TH (Kim, Nichol et al. 2014) in patients 
surviving cardiac arrest. In this RCT, 688 patients were randomised to receiving pre-
hospital TH induction with 2 litres of 4°C intravenous saline and a further 671 patients 
received standard care. Although the intervention with cold saline resulted in lower core 
body temperature on hospital arrival and quicker time to reach target temperature, 
there was no statistical difference in survival to hospital discharge and neurological 
recovery regardless of initial presenting rhythm. Moreover, patients treated with ice-
cold saline were more likely to experience recurrence of cardiac arrest, develop 
pulmonary oedema and increased diuretic usage. A further multicentre RCT, the 
RINSE trial (Bernard, Smith et al. 2016) was conducted in 2016 with an aim to 
investigate if rapid infusion of 2 litres of intravenous cold saline resulted in better 
clinical outcomes in patients resuscitated from surviving a cardiac arrest. The RINSE 
trial did not demonstrate statistical superiority in survival to hospital discharge in 
patients treated with intravenous cold saline (10.2% in hypothermia group vs 11.4% in 
standard care). Moreover, there was a statistically significant reduction in ROSC rates 
(41.2% compared with 50.6%, p = 0.03) in patients treated with intravenous cold saline. 
Although the study closed early at 48% recruitment stage due to implementation of 
different temperature management strategies in different hospitals, the authors felt 
there was enough evidence to conclude that rapid infusion of cold saline may cause 
more harm in cardiac arrest patients with an initial shockable rhythm. In their latest 
update, the AHA recommends against using cold saline for TH induction in the pre-
hospital setting (Donnino, Andersen et al. 2015). 
Endovascular cooling has also been tested in some centres for TH induction and 
management. In one RCT (Deye, Cariou et al. 2015), 203 patients who survived OHCA 
were randomised to endovascular cooling induction and maintenance in the ICU and a 
further 197 patients received standard care. The authors found that, despite a more 
efficient arrival to target temperature and maintenance of target temperature during 
treatment, endovascular cooling did not provide statistically superior survival rate at 
hospital discharge with good neurological recovery at 28 days or 90 days, irrespective 
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of initial presenting heart rhythm after ROSC. The size and design of the endovascular 
cooling machine also limits it portability outside hospital. An effective cooling device is 
expected to have the following characteristics: 
 easy to deploy without interfering other ongoing treatment such as CPR, 
ventilation, coronary angiography 
 achieves target temperature rapidly and can maintain it 
 portable from site of cardiac arrest to hospital and in between departments 
 prevents rebound hyperthermia during patient movement 
Rhinochill® is a novel portable cooling system, which was approved by European 
Resuscitation Council for commercial use. It can induce TH by selectively cooling the 
brain through spraying an evaporative coolant via intranasal catheters with minimal 
temperature fluctuations during patient transfer. A multicentre RCT (Castren, Nordberg 
et al. 2010) involving 200 patients surviving cardiac arrest, investigated the feasibility of 
Rhinochill® application in pre-hospital setting. The authors found that, Rhinochill® was 
more efficient in reaching target temperature without compromising on patient safety. 
They observed a trend towards improved survival rate to hospital discharge and better 
neurological recovery at discharge in patients treated with Rhinochill®, but these 
observations were not statistically significant. A larger RCT is currently being 
conducted where, intra-arrest TH is being investigated to assess impact on survival 
and neurological recovery at hospital discharge (Nordberg, Taccone et al. 2013).  
1.1.6.9. Rationale for further research with TH in cardiac arrest 
The latest RCT (Nielsen, Wetterslev et al. 2013) and previous studies (Bernard, Gray 
et al. 2002, Hypothermia after Cardiac 2002) raised important questions that remain 
unanswered about the role of TH in cardiac arrest survivors. While earlier studies 
suggested lower temperatures offered better neuroprotection and survival benefit, the 
latest TTM trial showed there was no difference in clinical outcome between patients 
maintained at 2 different temperatures, although neither group were allowed to have 
febrile episodes during active temperature management, It appears that the timing of 
initiation of TH, time to reach target temperature and optimal duration of maintenance 
therapy have yielded some considerable variations in clinical outcome (Polderman, 
Varon 2015). One retrospective registry based study demonstrated that every 5 minute 
delay in TH induction increased the odd of a poor neurological outcome in hospital, at 
discharge and post discharge follow-up (Sendelbach, Hearst et al. 2012). Additionally, 
the odd of a poor neurological outcome was also increased for every 30 minute delay 
in reaching target temperature at post discharge follow up (Sendelbach, Hearst et al. 
2012). Irrespective of whether methods are employed to reduce core body temperature 
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or to prevent systemic pyrexia, the mortality rate and risk of permanent and disabling 
brain injury remains high in this patient group (Wachelder, Moulaert et al. 2009). In the 
TTM trial (Nielsen, Wetterslev et al. 2013), more than 50% patients in both treatment 
groups died or had poor neurological function at 180 day follow up. The alarming rates 
of morbidity and mortality associated with cardiac arrest provide a large incentive for 
research into novel methods of treating this important group of patients, and are the 
major driver behind the research described in Chapter 2 of this thesis. 
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1.2. Psychological wellbeing of cardiac arrest survivors 
1.2.1. Better survival rates 
Advances in technique and technology, as well as better access to the chain of survival 
(Nolan, Soar et al. 2006), have seen the number of successful resuscitations after 
cardiac arrest improve in recent times. The London Ambulance Service (LAS) reported 
a remarkable survival rate of 32% in bystander witnessed cardiac arrests with initial 
rhythm of ventricular fibrillation or ventricular tachycardia in 2011/2012 compared to 
just 5% over 10 years ago (Watson L: Virdi G, Fothergill R 2012).   
Although the overall unadjusted survival rate after cardiac arrest is still relatively low 
(Berdowski, Berg et al. 2010), an increasing number of people in public areas are being 
trained to perform cardiopulmonary resuscitation (CPR) and operate automated 
external defibrillators (AEDs). In a benchmark trial (Weaver, Hill et al. 1988), provision 
of AEDs to firefighters resulted in improved survival as compared with CPR alone (30% 
versus 19%, P<0.01). Projects like the ‘Shockingly easy campaign’ sponsored by the 
LAS facilitated more AEDs being available in public areas and consequently, more 
victims of cardiac arrest can be resuscitated sooner, even before arrival of the 
emergency medical services (EMS). In their recent report (2014/15), the LAS reported 
63.1% OHCA patients received bystander CPR compared to 55.8% in the previous 
year and 76.7% of those who had AED treatment, had ROSC at hospital arrival, with a 
remarkable survival to hospital discharge rates of 58.6% in this group of patients (Virdi 
G, Picton S, Fothergill R September 2015).  The time to ROSC is an independent 
predictor of mortality (Myerburg RJ, Castellanos A 2001) and therefore, earlier ROSC 
is expected to translate to better chances of survival. Some of the more recent trials 
investigating mortality associated with cardiac arrest reported improved short term and 
medium term survival rates (Islam, Hampton-Till et al. 2015, Castren, Nordberg et al. 
2010, Nielsen, Wetterslev et al. 2013). Historic data suggests that survivors of cardiac 
arrest have high incidence of neurological deficit, cognitive impairment and worsened 
emotional wellbeing if they survive (Moulaert, Verbunt et al. 2009), therefore posing a 
huge challenge in managing these patients. The success of resuscitation need to 
consider not only the survival rate, but also the subsequent quality of life (QoL) of the 
survivor (Beesems, Wittebrood et al. 2014). 
1.2.2. Implications of cardiac arrest 
The brain is heavily dependent on the pumping action of the heart to receive blood and 
oxygen supply that are required for its metabolism and function. During a cardiac 
arrest, the brain is completely deprived of blood supply and therefore susceptible to 
brain injury. If cardiac arrest persists for several minutes, the brain may sustain 
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irreversible damage, called hypoxic-ischaemic brain injury (Busl, Greer 2010). The 
complex molecular mechanism of brain injury was discussed in an earlier section 
(1.1.5). The hypoxic-ischaemic brain injury has the potential to affect any part of the 
brain parenchyma. Therefore the resulting neurological deficit can be quite diverse and 
can range from variable levels of consciousness, movement disorders and impairment 
of cognitive function (Khot, Tirschwell 2006). Hence, the consequence of a cardiac 
arrest is not limited to the direct pathophysiological changes in the heart and the brain 
but has significant implications on other indirect functions of the brain, which include 
emotional wellbeing and cognitive function in patients who survive this life changing 
event. In this part of the introduction, the focus will be on these indirect consequences 
of hypoxic-ischaemic brain injury and the socio-economic impact.  
1.2.3. A framework to understand the unseen consequences of cardiac 
arrest 
The World Health Organisation (WHO) model of the International Classification of 
Function (ICF), Disability and Health provides a holistic and effective framework to 
understand the indirect and unseen consequences of cardiac arrest (WHO 2001). 
Through this framework, one can anticipate impairments in function, reduced 
performance in activities of daily living and withdrawal from participation in social 
activities as consequences of cardiac arrest. 
Figure 1-7 Illustration of the ICF model 
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At a functional level, there can be impairments in cognition such as short term memory, 
executive function and emotional wellbeing such as anxiety and depression. Examples 
of activities of daily living include washing, cooking, cleaning and getting dressed, 
whilst social participation include return to work, visiting friends and family. These 
domains can also be seen to interact and influence each other through environmental 
factors, such as the presence or absence of supporting caregivers, financial situation, 
adaptation in accommodation and personal factors such as age, sex and personality.  
QoL is not incorporated in the ICF framework as it is considered to be an umbrella term 
that reflects the feelings of an individual in a given situation under the influence of the 
circumstances. The WHO defined QoL as the ‘‘individuals’ perception of their position 
in life in the context of the culture and value systems in which they live and in relation 
to their goal expectations, standards and concerns’’ (Saxena, Orley et al. 1997). 
Therefore QoL can be influenced by all the domains of the ICF model of cardiac arrest 
as described above. Indeed Moulaert et al (Moulaert, Wachelder et al. 2010) 
demonstrated via regression analysis in a retrospective cohort study that, physical QoL 
was significantly related to cognitive function, instrumental activities of daily living, post-
traumatic stress disorder (PTSD) and fatigue (p<0.001) and mental QoL was 
significantly related to cognitive function, anxiety and depression (p<0.001).      
1.2.3.1. Evidence of impaired cognitive function  
Cognitive impairment has been reported in patients surviving cardiac arrest with 
variable frequencies. Moulaert et al (Moulaert, Verbunt et al. 2009) conducted a 
systematic review on studies published between 1980 and 2006 for adult survivors of 
cardiac arrest who were followed up for a minimum of 3 months after the index event. 
Using their selection criteria, only 10% of the originally screened studies were included 
in the final evaluation (n=28). The reported frequency of cognitive function ranged 
between 6% and 100% with memory problems being reported as the most common 
form of cognitive impairment followed by impairment in attention and executive 
functioning. The hippocampus, located on the elongated ridges on the floor of each 
lateral ventricle in the brain, is the centre of emotion and memory. It is very sensitive to 
changes in cerebral perfusion (Back, Hemmen et al. 2004, Harukuni, Bhardwaj 2006) 
and could explain why memory deficit is the commonest cognitive impairment, along 
with generalised cerebral atrophy associated with hypoxic brain injury (Grubb, Fox et 
al. 2000). Three of the 28 studies included in the final analysis (Moulaert, Verbunt et al. 
2009) in the systematic review were considered to be high quality with relatively large 
number of participants (n=45, 57 and 58) and used a variety of neuropsychological 
tests (Sauve, Doolittle et al. 1996, van Alem, de Vos et al. 2004, Roine, Kajaste et al. 
1993), that were considered to be reproducible. These studies reported cognitive 
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impairments in the range of 42-50%. The variation in the reported frequencies of 
cognitive impairment could be explained by selection of the patient population, timing of 
assessment and the assessment tool itself. In addition, the impact of confounding 
factors such as age, duration of hypoxia, co-morbidities were not consistently taken 
into consideration, which makes the interpretation of reported frequencies more 
challenging. Nevertheless, the recognition of cognitive impairment as an outcome of 
cardiac arrest survival is vital as it has been shown to affect both physical and mental 
QoL (Moulaert, Wachelder et al. 2010) and therefore, should remain an important focus 
in post resuscitation care.  
1.2.3.2. Evidence of anxiety and depression 
Patients have also been known to suffer variable degrees of emotional problems as a 
consequence of suffering cardiac arrest in the form of anxiety and depression. Anxiety 
can be defined as a state of apprehension, worry or uneasiness about one’s current 
situation or an uncertain future (Torgersen, Strand et al. 2010). Depression is defined 
as a state of low mood, that results in feelings of hopelessness, disinterest and 
apathetic in any matters of life lasting for more than 2 weeks (Wilder Schaaf, Artman et 
al. 2013). Anxiety and depression often co-exist in cardiac arrest survivors and has 
been reported in frequencies of between 10-11% (Larsson, Wallin et al. 2014, 
Wachelder, Moulaert et al. 2009) to 51-52% (Bunch, White et al. 2004, Granja, Cabral 
et al. 2002, O'Reilly, Grubb et al. 2004). Larsson et al (Larsson, Wallin et al. 2014) 
found in a 6 month prospective follow up study, anxiety and depression were at their 
highest level whilst the patients were still in hospital and commented that this could 
improve over time. However, Wachelder et al (Wachelder, Moulaert et al. 2009) 
conducted a retrospective analysis and found that 38% patients still suffered anxiety 
and depression even at 3 years after cardiac arrest. In isolation, the reported frequency 
of depression has been found in the range of 16%-45% (de Vos, de Haes et al. 1999, 
Roine, Kajaste et al. 1993) and anxiety has been reported in 30%-41% patients in 
cardiac arrest survivors (Roine, Kajaste et al. 1993, O'Reilly, Grubb et al. 2004). 
Some studies claim that there is no difference in the prevalence of anxiety and 
depression between cardiac arrest survivors and the general population (Lim, Verfaellie 
et al. 2014, Saner, Borner Rodriguez et al. 2002) and one study goes further to report 
that cardiac arrest survivors do not suffer any particular anxiety or depression (Nichol, 
Guffey et al. 2015). This sort of observation has to be considered in light of factors that 
may influence the actual reported statistics. With the exception of a few studies 
(Wilson, Staniforth et al. 2014, Larsson, Wallin et al. 2014), most of the data collection 
about anxiety and depression were carried out in neurologically intact survivors of 
cardiac arrest. Inevitably, neurological recovery is a very important confounder that 
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needs to be considered when reporting frequencies as patients with compromised 
neurological status are more likely to report symptoms of anxiety and depression. The 
timing of assessment is also hugely influential, as a later assessment can show 
improvement in reported frequencies of symptoms (Saner, Borner Rodriguez et al. 
2002) because patients may have already sought and received treatment from 
specialists. In addition, the analysis tool needs to be validated and reproducible to 
provide meaningful comparison. Irrespective of the reported frequencies, anxiety and 
depression associated with cardiac arrest can significantly influence one’s QoL 
(Larsson, Wallin et al. 2014, Wilson, Staniforth et al. 2014, Wachelder, Moulaert et al. 
2009, Saner, Borner Rodriguez et al. 2002, O'Reilly, Grubb et al. 2004, Gamper, Willeit 
et al. 2004, Moulaert, Wachelder et al. 2010) and should therefore remain an important 
focus in post resuscitation care for best overall outcome.  
1.2.3.3. Post-traumatic stress disorder (PTSD) 
PTSD is described as a disorder that people may develop in response to a traumatic 
event resulting in intrusive memories, nightmares and avoidance of situations that 
remind of the offending incident (WHO 1993). Gamper et al (Gamper, Willeit et al. 
2004) carried out a prospective cohort study spanning over an 8yr period and assessed 
neurologically intact cardiac arrest survivors at a mean 45 months after the index 
event. They found that 27% patients fulfilled the criteria for experiencing PTSD at follow 
up and younger age was an independent risk factor for developing PTSD. The authors 
also found that the presence of PTSD had a significant impact on QoL perceptions 
amongst these patients. In a separate case control study, there was almost a 3 fold 
increase in incidence of PTSD (19%) in cardiac arrest survivors compared to patients 
suffering myocardial infarction (7%) (O'Reilly, Grubb et al. 2004), supporting the greater 
traumatic impact of cardiac arrest on the victim. Identification and timely management 
of PTSD in cardiac arrest survivors is likely to have significant impact on QoL 
assessment (Moulaert, Wachelder et al. 2010) and improve patient outcome.  
 
1.2.3.4. Evidence of reduced participation and return to work 
There is evidence to suggest that the vast majority of neurologically intact cardiac 
arrest survivors resume basic activities of daily living at hospital discharge (de Vos, de 
Haes et al. 1999, Hofgren, Lundgren-Nilsson et al. 2008, Wachelder, Moulaert et al. 
2009). Patients who require assistance with performing daily activities are more likely 
to be re-housed with better nursing facilities like sheltered accommodation (Hofgren, 
Lundgren-Nilsson et al. 2008). In a 1 year follow up study, it was found that about 55% 
patients still required assistance with performing more complex daily activities like 
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operating machines (Lundgren-Nilsson, Rosen et al. 2005). Interestingly, the authors 
discovered that all those who were dependent for performing activities of daily living, 
also had reduced cognitive function, supporting our ICF model of understanding the 
implications of cardiac arrest and the interconnection between the domains.   
More recently, in a retrospective follow up study it was reported that, 86% patients 
functioned independently at 1-year follow up, however, half the patients complained of 
severe fatigue (Wachelder, Moulaert et al. 2009). It was also shown in this study that a 
significant proportion of patients (74%) had lower level of participation in society 
compared to general population. The authors concluded that age and gender 
influenced patient’s QoL, participation in society and daily functioning, which has been 
reported in earlier studies (Saner, Borner Rodriguez et al. 2002, de Vos, de Haes et al. 
1999).  
The return to work rate has been found to be variable depending on the study 
population and the timing of the assessment and has been found to be in the range of 
12% to 50% (Lundgren-Nilsson, Rosen et al. 2005, Saner, Borner Rodriguez et al. 
2002, Wachelder, Moulaert et al. 2009). Other aspects of participation in society such 
as relationship with family and friends, performing in recreational activities have not 
been well documented in the context of cardiac arrest, which require further research to 
understand the true impact of the condition on wider participation. The return to work 
rate has important socioeconomic implication, which will be discussed in later section in 
discussion. 
 
1.2.4. Burden on caregivers   
The presence of a caregiver, when available, plays a huge supporting role for the 
recovery of the cardiac arrest survivor. However, studies have shown that adopting the 
role of a caregiver is associated with decline in physical and mental health, family 
relationships, employment and finances (Pearlin, Mullan et al. 1990). In practice, the 
role of the caregiver is often eclipsed by the more pressing recovery of the cardiac 
arrest survivor, until such time when caregiver may volunteer to voice their difficulty in 
coping with the situation (Kasuya, Polgar-Bailey et al. 2000). The caregiver is often a 
close family member such as a spouse or a very close friend, in whom patient can 
confidently trust with their wellbeing and assistance with performing activities of daily 
living, when necessary. It is important to recognise the role of the caregiver as it has 
been shown that patients’ psychological recovery is linked to family function (Miller, 
Wikoff 1989), compliance to risk factor modification is linked to spousal anxiety and 
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marital function (Miller, Wikoff et al. 1990) and increased mortality in older caregivers 
associated with increased strain and marital quality (Schulz, Beach 1999).  
The caregivers often make several adjustments to cope with the different physical and 
psychological needs of the cardiac arrest survivor in the immediate aftermath of the 
index event when the patient returns to usual place of residence. The recovery time is 
often prolonged and even when the physical health has made reasonable 
improvements in getting patient back to baseline function, the psychological trauma 
and participation in society can lag for years (Wachelder, Moulaert et al. 2009, 
Gamper, Willeit et al. 2004). Studies have shown that a multitude of factors, including 
the uncertainty about the prognosis of the cardiac arrest survivor, the fear of 
recurrence, the function of the implantable cardiac defibrillator (if inserted for medical 
reasons) and associated limitations in lifestyle, the unpredictable change in patients’ 
personality and the increased reliance on performing activities of daily living increased 
the strain on the caregiver (Doolittle, Sauve 1995, Pycha, Calabrese et al. 1990). 
Doolittle et al carried out a longitudinal phenomenological study over 24 weeks 
interviewing 40 cardiac arrest survivors and 30 spouses (caregivers) (Doolittle, Sauve 
1995). They found that, the reference point for the spouses for future decision making 
was the actual arrest itself, whereas the reference point for cardiac arrest survivor was 
pre-arrest lifestyle. This also explained why the spouses who witnessed the cardiac 
arrest were more protective about the patient, leading to entrapment of the patient in 
most severe situations, resulting in reduced participation in society, anger, frustration 
and turbulence in family relationship. In addition, the need to fulfil financial 
commitments like paying mortgage, adapting employment, disruption in sexual 
relationship also increases the strain on the caregiver (Steinke 2003). 
Data on prevalence of caregiver strain related to cardiac arrest is less well 
documented. In a small cross sectional follow up study, 60% spouses complained of 
psychosomatic problems and 50% felt isolated at a mean 25 month after cardiac 
rehabilitation from the index event (Pusswald, Fertl et al. 2000). In a more robust 
retrospective follow-up study at a mean 36 months after cardiac arrest, the authors 
found that 17% caregivers reported high caregiver strain, which is lower than 
previously reported (Wachelder, Moulaert et al. 2009). This could be explained by the 
longer duration of follow-up in this study. They also found that 38% of caregivers 
reported higher anxiety and depression on the Hospital Anxiety and Depression scale 
and about a quarter of the caregivers reported reductions in both physical and mental 
components of the QoL.            
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Irrespective of the prevalence of anxiety, depression and caregiver strain, it is 
important to recognise caregivers as integral participants when post resuscitation care 
is planned. Inevitably, their QoL is affected by the unexpected life changing event and 
addressing their concerns individually alongside the patients is likely to yield the best 
possible outcome for both parties in the short and long term. An effective and 
transparent communication is sometimes all that is needed to address the concern of 
the caregiver to reduce their anxiety about coping with the situation and the 
uncertainties. 
  
1.2.5. Landmark trial 2015 
Having identified the huge burden of psychological trauma and limitations in social 
participation associated with cardiac arrest for the patient and the caregiver, the 
challenge for health care providers was to devise an intervention by which both 
participants will benefit in the short term and long term. In 2015, a landmark trial was 
published in the International Journal of Cardiology, where Moulaert et al discussed a 
novel intervention which was aimed at encouraging better participation in the society 
and an improvement in QoL for cardiac arrest survivors and their caregivers (Moulaert, 
van Heugten et al. 2015).  
This was designed as a multicentre single blinded RCT where patients and caregivers 
were recruited from 5 different hospitals in the Netherlands between 2007 and 2010. All 
hospitals offered standard management of cardiac arrest patients, in line with 
international guidelines to avoid bias in treatment modalities.  Adult survivors (age 
>18yrs) of IHCA or OHCA with life expectancy of greater than 3 months were screened 
for recruitment. Caregivers, if available, were encouraged to participate but the 
absence of caregiver was not considered to be an exclusion criteria. Assessments 
were made at 2 weeks, 3 months and 12 months after index event. Participants were 
randomised in a 1:1 manner to intervention group or control group. If allocated to 
intervention, patients and caregivers were screening for cognitive and emotional 
problems, provided with verbal and written information and support, encouraged self-
management strategies and referred to specialist care if warranted from initial 
assessment.  Patients and caregivers in the control group received standard cardiac 
rehabilitation but no intervention was offered as part of the study. 
A total of 185 patients were randomised of which 97 patients were allocated to 
intervention and 88 patients were randomised to control group. In addition, 155 
caregivers participated in the study. At 12 months, 143 patients completed the trial.  
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At the analysis of the primary outcomes at 12 months, patients in the intervention group 
reported significantly better scores in role emotional, mental health and general health 
components of the SF-36 QoL questionnaire (p<0.01). In terms of secondary outcome 
measures, there was significant improvement in overall emotional state and anxiety 
levels (p<0.01) in the intervention group and the return to work rate was significantly 
higher at 3 months follow-up in the intervention arm, but this statistical superiority was 
lost at 12 month follow-up. There was no significant difference with regard to 
participation in society. Interestingly, the authors reported that there were no significant 
improvements in the caregivers’ response to either primary or secondary outcome 
measures although higher levels of anxiety, depression and PTSD were reported in 
both groups. This re-affirms earlier observation that caregivers are also a vulnerable 
group of individuals whose care needs may be different in the context of cardiac arrest 
and warrants more research to understand and address their problems with coping.    
One of the limitations discussed in the paper was that blinding was not always possible 
at home visits as participants could spontaneously disclose their group allocation to the 
research assistants, who attended follow-up and collected data. However, research 
assistants were not involved in data analysis and therefore negate any potential bias. 
The authors concluded that, the introduction of this comprehensive intervention 
resulted in significant improvements in QoL and emotional state after cardiac arrest 
and resulted in more rapid return to work and therefore, recommended regular 
implementation in routine clinical practice to improve outcome. 
The above data clearly demonstrate an on-going medium to long-term physical and 
psychological burden affecting cardiac arrest patients and their care givers. The work 
presented in Chapter 3 attempts to address this problem in a sample of patients from 
our local population. 
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1.3.  Acute Myocardial Infarction and therapeutic hypothermia 
1.3.1. Definition 
Acute myocardial infarction (AMI) or heart attack is defined as cardiomyocyte cell death 
as a direct result of severe and prolonged oxygen deprivation (often referred to as 
ischaemia). The commonest cause of AMI is the abrupt cessation of blood supply in 
one or more coronary arteries resulting in regional cardiomyocyte necrosis, delineated 
by the territory supplied by the culprit coronary artery. If left untreated or treatment is 
delayed, this may progress into life threatening arrhythmia, cardiac arrest and death in 
the acute setting (minutes to hours). Chronically (days to weeks), patient may suffer 
debilitating heart failure, secondary end organ damage, such as kidney disease and 
liver disease, the extent of which is partly determined by the size of the initial heart 
attack or myocardial area at risk (Reimer, Lowe et al. 1977) and the duration of 
ischaemia (Christian, Schwartz et al. 1992). At the molecular level, the damage 
happens in a more complex manner which will be discussed below.    
1.3.2. Incidence 
The leading cause of worldwide mortality is CVD with an estimated 17.5 million CVD 
related deaths reported in 2012, representing 31% of all deaths. Furthermore, almost 
7.4 million of these deaths were due to coronary heart disease, which refers to disease 
of the blood supply to the heart (WHO factsheet 2016 September 2016). Likewise, 
CVD is also the principal cause of mortality in the UK, accounting for 180,000 deaths in 
2010, almost half of which were attributed to coronary heart disease (Townsend, N., 
Wickramasinghe, K., Bhatnagar, P., Smolina, K., Nichols M, Leal J, R, L.-F. & Rayner, 
M. 2012). More alarmingly, 46,000 premature deaths in the UK are attributed to CVD 
and cost the UK economy an estimated £19 billion in 2009 in healthcare cost and loss 
of income (Townsend, N., Wickramasinghe, K., Bhatnagar, P., Smolina, K., Nichols M, 
Leal J, R, L.-F. & Rayner, M. 2012). In recent years however, death from coronary 
heart disease has been falling in younger age group and death rates from heart attack 
is reported to have halved since 2002 (Townsend, N., Wickramasinghe, K., Bhatnagar, 
P., Smolina, K., Nichols M, Leal J, R, L.-F. & Rayner, M. 2012).  
1.3.3. Pathophysiology of acute myocardial infarction (AMI) 
The formation of atheromatous plaques, lipid rich complexes, within the epicardial 
coronary arteries result in coronary artery disease. With time, the arterial lumen 
becomes progressively smaller contributing commonly to symptoms of chest pain or 
angina that becomes worse on exertion or can come on at rest if the luminal 
obstruction is severe. A plaque may rupture resulting in intra-coronary thrombosis 
which, may subsequently occlude the artery at the site of plaque rupture or embolise 
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and block the vessel further downstream. If this results in severe and prolonged 
deprivation of oxygen to the heart muscle then AMI ensues (Thim, Hagensen et al. 
2008). Patients will often experience severe crushing chest pain, with or without other 
symptoms such as breathlessness and clamminess and generally seek urgent medical 
help. A timely electrocardiogram (ECG) is vital in this situation, as it can often confirm 
the diagnosis of acute myocardial infarction, thus allowing emergency medical 
personnel to commence the initial management, including administering appropriate 
medications and deciding on the most appropriate destination hospital for the patient. If 
ST elevation myocardial infarction (STEMI) is present on the ECG, a complete 
occlusion of a major coronary artery is highly likely, and the priority will be to transfer 
the patient to a tertiary heart attack centre with facilities to perform emergency PPCI to 
mechanically restore coronary blood flow (Task Force on the management of ST-
segment elevation acute myocardial infarction of the European Society of Cardiology 
(ESC), Steg et al. 2012).  
 
Figure 1-8 ECG representation of STEMI 
Panel A shows normal electrocardiogram (ECG); Panel B shows STEMI on ECG 
 
  
 
In the UK alone, approximately, 100,000 people suffer from STEMI every year 
(Townsend, N., Wickramasinghe, K., Bhatnagar, P., Smolina, K., Nichols M, Leal J, R, 
L.-F. & Rayner, M. 2012). The recognition of STEMI as an indicator for myocardial 
ischaemia dates back to around 1920, when Harold Pardee described it as ‘’T wave as 
being tall and starts from a point well up on the descent of the R wave"  (Pardee H. E. 
B. 1920). The amount of damage done by STEMI is time dependent (Reimer, Lowe et 
al. 1977) as has been shown in animal model of experimental ischaemia, that spreads 
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like a ‘wave-front’ from the inner layer of heart muscle (endocardium) to the outer layer 
of the heart muscle (epicardium), thereby completing a trans-mural infarct. Any delay in 
treating in the underlying occlusion can result in acute and chronic complications as 
described earlier.  
1.3.4. Minimising injury 
At present, on recognition of a patient suffering STEMI, an early transfer to a tertiary 
heart attack centre, with facilities to perform emergency PPCI to reperfuse the 
occluded artery is the most effective recommended treatment (Task Force on the 
management of ST-segment elevation acute myocardial infarction of the European 
Society of Cardiology (ESC), Steg et al. 2012). The aim of this treatment, which 
involves a variable combination of thrombus removal, balloon dilatation of the occluded 
vessel followed by a stent insertion, is to minimise the myocardial infarct size and 
preserve left ventricular ejection fraction (Berger, Ellis et al. 1999, Lambert, Brown et 
al. 2010). In the absence of PPCI facilities, fibrinolysis can be delivered to break up and 
dissolve intra-coronary thrombus and thus re-establish blood flow (Task Force on the 
management of ST-segment elevation acute myocardial infarction of the European 
Society of Cardiology (ESC), Steg et al. 2012). However, despite the introduction of the 
PPCI and national targets such as reducing symptom to balloon time (total ischaemia 
duration), the morbidity and mortality associated with STEMI is still high. In-hospital 
mortality rates are in the range of 3-7% with regional variation, whilst 30-day mortality 
is in the region of 3-6% (Lambert, Brown et al. 2010). At 1 year, the combined risk of a 
further cardiac event, congestive cardiac failure and mortality is reported at 9-15% 
(Lambert, Brown et al. 2010). One of the major determinants of prognosis from STEMI 
is the size of the myocardial injury or infarct size (Burns, Gibbons et al. 2002, Wu, Ortiz 
et al. 2008) and it has been shown that, infarct size has a strong associated with 
development of heart failure and arrhythmias (Timmer, Breet et al. 2010, Saia, Grigioni 
et al. 2010). Therefore, these findings warrant further research into finding ways of 
minimising infarct size and improving clinical outcome, hence the research presented in 
Chapter 4.           
1.3.5. Ischemia/Reperfusion injury of the myocardium 
Emergency PPCI or thrombolysis is the mainstay of treating STEMI caused by 
thrombotic occlusion of an epicardial coronary artery to restore coronary blood flow. 
However, much like the situation in the brain following cardiac arrest described earlier 
in this chapter, the sudden restoration of circulation in a previously ischaemic 
myocardium can result in further damage, a phenomenon called reperfusion injury 
(Yellon, Hausenloy 2007). This may explain why patients still have high risk (9-15%) of 
major adverse cardiac event at 1 year after the index event. Yellon et al. demonstrated 
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in animal models that 50% of infarct size is determined by ischaemia, and the 
remaining 50% is caused by reperfusion injury (Yellon, Hausenloy 2007). Whilst in 
recent times, there have been developments including emergency revascularisation 
and anti-thrombotic pharmacotherapy to reduce ischaemic injury; there have been no 
specific developments that substantially minimise reperfusion injury.  
1.3.6. Mechanism of reperfusion injury – molecular level 
In order to understand possible therapeutic targets to minimise reperfusion injury, it is 
important to understand the mechanism of injury at the molecular level. Scientists 
demonstrated histological changes that took place in an experimental dog model of 
coronary artery occlusion and subsequent reperfusion, where necrosis was evident 
within 30-60 minutes that was similar in presentation to degree of necrosis seen in 
permanent coronary occlusion without reperfusion for 24 hours (Jennings, Sommers et 
al. 1960). These histological changes of necrosis comprised of intra-mitochondrial 
calcium phosphate deposition, disruption of the sarcolemma and contracture of 
myofibrils, which are distinct changes that are not seen in injuries sustained from 
myocardial ischaemia alone. These observations further supported the definition of 
reperfusion injury as a separate pathophysiological phenomenon that occurs on 
restoration of coronary circulation.  
Reperfusion injury can cause 4 types of cardiac dysfunction. Some of these are 
reversible, last for a short duration and can be easily managed such as myocardial 
stunning and reperfusion arrhythmia. However, other changes are irreversible including 
microvascular obstruction and lethal reperfusion injury and it is the degree of these 
irreversible damages that define infarct size and subsequent prognosis from the 
reperfusion injury.  
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Figure 1-9 Schema of reperfusion injury mechanisms  
After PPCI restores circulation, reperfusion injury can exacerbate tissue damage by 
myocardial stunning, reperfusion arrhythmias, microvascular obstruction and lethal 
reperfusion injury.   
 
 
1.3.6.1. Myocardial stunning 
Originally described in 1975 (Heyndrickx, Millard et al. 1975), this is a period of 
transient mechanical dysfunction of the cardiac myocyte contractility that can persist for 
hours to days despite restoration of the coronary circulation. It is self-limiting process 
where the myocardium is essentially ‘stunned’ from the shock of sustaining coronary 
artery occlusion but will inevitably recover completely with time. 
1.3.6.2. Reperfusion arrhythmias 
On reperfusion, patients who presented with STEMI can develop transient reperfusion 
arrhythmia (Manning, Hearse 1984) which tends to be ventricular arrhythmia in anterior 
STEMI and brady-arrhythmia in inferior STEMI patients due to the nature of 
sympathetic and parasympathetic innervation. Again, these can be self-limiting 
sequelae from reperfusion injury and expected to revert to sinus rhythm spontaneously 
or with minimal medical intervention.  
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1.3.6.3. Microvascular obstruction 
Originally described as ‘inability to reperfuse a previously ischaemic region’ in animal 
model (Krug, Du Mesnil de et al. 1966), the exact mechanism of this cardiac 
dysfunction induced by reperfusion injury is incompletely understood. It is assumed that 
a combination of intrinsic capillary damage with impaired vasodilation, extra-luminal 
compression from cardiac myocite swelling and distal embolization of the culprit 
atherosclerotic plaque, platelet and neutrophil deposition can all contribute to 
microvascular obstruction (Ito 2006). Angiographically, this may not be evident at the 
completion of PPCI but subsequent cardiac imaging with cardiac MRI can reveal 
microvascular obstruction in 30-40% patients (Bogaert, Kalantzi et al. 2007) who 
appear to have good coronary blood flow by TIMI criteria (The Thrombolysis in 
Myocardial Infarction (TIMI) trial. Phase I findings. TIMI Study Group. 1985). The 
presence of microvascular obstruction after STEMI indicates a larger infarct size, 
increased risk of impaired left ventricular ejection fraction, minimises potential for 
beneficial left ventricular remodelling and therefore, unfavourable clinical outcomes in 
the short and the long term (Bogaert, Kalantzi et al. 2007). 
1.3.6.4. Lethal reperfusion injury 
The immediate death of cardiac myocytes within minutes to hours after restoration of 
coronary circulation, which were considered viable or only reversibly injured during 
ischaemia, is termed lethal reperfusion injury (Piper, Garcia-Dorado et al. 1998). It has 
been difficult to demonstrate this process of injury directly as a distinct entity for cardiac 
dysfunction, but indirect evidence from animal studies has shown an additional 40-50% 
reduction in infarct size with therapeutic intervention at the onset of reperfusion 
suggesting that lethal reperfusion injury as an additional mechanism of further 
myocardial damage after treatment of ischaemia (Yellon, Hausenloy 2007). Lethal 
reperfusion injury comprises several complex mechanisms that can cause contractile 
dysfunction, metabolic derangement and cardiac cell death by necrosis and apoptosis 
(programmed cell death) (Piper, Garcia-Dorado et al. 1998). These mechanisms 
include generation of ROS, intracellular calcium accumulation, rapid normalisation of 
intracellular pH, a generalised inflammatory response and opening of the mitochondrial 
permeability transition pore (mPTP). 
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Figure 1-10 Schema of components of Lethal Reperfusion Injury 
 
1.3.6.4.1. Reactive oxygen species (ROS) 
Within a few minutes of restoration of coronary blood flow, when molecular oxygen is 
reintroduced into previously ischaemic myocardium, it undergoes sequential reduction 
leading to ROS formation such as superoxide anion (O2-), hydroxyl radical (OH) and 
perioxynitrite (ONOO-) (Bolli, Jeroudi et al. 1989). These ROS damages the vascular 
endothelium, activates adhesion molecules attracting polymorphonucleotides (Serrano, 
Mikhail et al. 1996), disrupts phospholipid bilayer membrane resulting in calcium influx 
within the cells (Steinberg 2013), damages sarcoplasmic reticulum leading to 
contractile dysfunction (Rowe, Manson et al. 1983), induces derangement of several 
metabolic pathways including glycolysis and act as chemo attractants to neutrophils 
and other inflammatory cells, which contribute to microvascular obstruction (Zimmet, 
Hare 2006). Moreover, ROS stimulates the opening of mPTP (Zorov, Juhaszova et al. 
2009), which promotes necrotic cell death. ROS has also been found to interfere with 
the bioavailability of cardio protective endogenous nitric oxide, the lack of which 
contributes to larger infarct size (Johnson, Tsao et al. 1991, Jones, Girod et al. 1999). 
1.3.6.4.2. Intracellular calcium accumulation 
In ischaemic state, the reduction in high energy ATP levels results in inhibition of 
energy dependent sarcolemmal Na+/K+ ATPase transporter, increased activity of 
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Na+/H+ exchanger and reverses the activity of the Na+/Ca2+ exchanger (Inserte, 
Garcia-Dorado et al. 2005), which increases intra-cellular calcium levels. At 
reperfusion, there is further influx of calcium intro intracellular space as ROS degrades 
membrane integrity, as described above. Consequently, there is increased risk of 
arrhythmias due to electrolyte imbalance, hyper-contracture of the cardio-myocytes 
resulting in cell death. In addition, there is desensitisation of the cardiac contractile 
apparatus causing impairment of the myofibril function (Piper, Garcia-Dorado et al. 
1998), which can then lead to impaired left ventricular function.  
1.3.6.4.3. Normalisation of intracellular pH 
During ischaemia, an acidic environment prevents lethal tissue injury by preventing 
hyper-contracture (Ladilov, Siegmund et al. 1995), calpain activation, Na+/H+ 
exchanger and opening of the mPTP (Piper, Abdallah et al. 2004, Kim, Jin et al. 2006). 
However, the sudden restoration of coronary blood flow results in rapid normalisation of 
intracellular pH by activating the Na+/H+ exchanger and washing out the lactic acid 
and is termed the pH paradox (Lemasters, Bond et al. 1996) and therefore, promotes 
all the processes described above that contribute to cardiac dysfunction.  
1.3.6.4.4. Inflammatory response 
An active inflammatory process already takes place during the ischaemic phase, which 
is part of the innate immune system response (Entman, Smith 1994). At reperfusion, 
the inflammatory response is more adaptive, which involves activation of the 
complement system; cytokine release and ROS secretion from endothelial cells attract 
neutrophils into the myocardium. Neutrophil accumulation contribute to further 
reperfusion injury by influencing further pro-inflammatory cascade, including: 
endothelial ROS release (Albertine, Weyrich et al. 1994); release of elastase and 
collagenase (Weiss 1989), distal embolization into microcirculation resulting in 
secondary ischaemia (Mehta, Nichols et al. 1988), further damage to coronary 
endothelium by recruiting more neutrophils through adhesion molecules (Jordan, Zhao 
et al. 1999), severe vasoconstriction through release of lipoxygenase products 
(Nichols, Mehta et al. 1988), platelet activation (Alloatti, Montrucchio et al. 1992) and 
further enhancing apoptosis towards the late reperfusion (Zhao, Velez et al. 2001). 
Neutrophil accumulation is followed by monocyte and lymphocyte infiltration which 
contribute to the reperfusion injury cascade (Wan, LeClerc et al. 1997, Yang, Day et al. 
2006, Chen, Crispin et al. 2009).  
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1.3.6.4.5. Opening mitochondrial permeability transition pore 
(mPTP) 
It has been increasingly recognised that opening of the mPTP, a latent non-specific 
pore within the inner mitochondrial membrane, plays a significant role in programmed 
cell death during early reperfusion (Crompton, Costi et al. 1987). Indeed, mPTP remain 
closed during ischaemia (Griffiths, Halestrap 1995) and under normal physiological 
conditions, but opens in response to rising ROS, increased intracellular calcium and 
rapid restoration of physiological pH at the onset of reperfusion (Griffiths, Halestrap 
1993, Lapidus, Sokolove 1994). Consequently, it has been demonstrated that mPTP 
inhibitors, cyclosporine A, NIM811 or sanglifehrin A offer some degree of cardio 
protection during early reperfusion (Griffiths, Halestrap 1995, Griffiths, Halestrap 1993, 
Hausenloy, Duchen et al. 2003).  
  
 
 
1.3.7. Hypothermia in STEMI 
The knowledge of molecular level of ischaemia/reperfusion injury of the myocardium 
during AMI enabled a better understanding and appreciation of the potential 
therapeutic targets in minimising infarct size. Hypothermia is one such intervention 
which has been investigated extensively in animal models and more recently, in 
humans with an attempt to reduce infarct size related morbidity and mortality. One of 
the very first animal studies conducted the early 1990s showed a linear relationship 
between hypothermia and infarct size, demonstrating an 8% reduction in infarcted 
region for every 1°C drop in temperature from 42°C to 35°C (Chien, Wolff et al. 1994). 
Importantly, it has been demonstrated in experimental models that, pre-ischaemic 
hypothermia reduces infarct size by 100%, while peri-ischaemic hypothermia can 
reduce infarct size by up to 80% and the therapeutic benefit of hypothermia is 
negligible if instituted after reperfusion (Maeng, Mortensen et al. 2006, Gotberg, 
Olivecrona et al. 2008b, Erlinge 2011). In practice, pre-ischaemic cooling is however 
not applicable to humans as patients only present to hospital after the onset of STEMI. 
Hence, most of the research has been centred on the feasibility of hypothermia prior to 
reperfusion and its translation into clinical outcomes.   
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1.3.8. Role of Hypothermia in reperfusion injury from STEMI 
The precise mechanism of hypothermia related cardio-protection in STEMI is less well 
understood, although some potential therapeutic targets at the molecular level have 
been proposed and investigated. Hypothermia has been shown to protect against 
myocardial stunning in rabbit model, where segment length shortening, used as a 
surrogate for cardiac contractility, was significantly increased in rabbit heart (Tissier, 
Couvreur et al. 2009), suggesting a reduction in myocardial stunning in those treated 
with hypothermia. 
In another experimental model of coronary artery occlusion, hypothermia (32°C) 
initiated late during ischaemia but continued for 2 hours afters reperfusion was 
associated with significant reductions in necrotic zone and no-reflow zones (Hale, Dae 
et al. 2003) compared to control group maintained at 37°C, suggesting a therapeutic 
benefit in the microvascular circulation. This observation was reinforced by a separate 
observational animal study (Gotberg, Olivecrona et al. 2008a), where hypothermia 
before reperfusion was associated with significant reduction in infarct size and 
complete disappearance of microvascular obstruction. 
Hypothermia has been shown to play a beneficial role in several pathways that form 
the hallmark of lethal reperfusion injury. At lower temperatures, ATP consumption was 
lower in experimental animal models of coronary artery occlusion (Simkhovich, Hale et 
al. 2004) resulting in reduced lactic acid production. This is expected to have protective 
effect on ATP dependent membrane ion channels, involved in maintaining intracellular 
calcium levels and pH homeostasis, which was confirmed on a further observational 
study (Inoue, Ando et al. 2003). More importantly, hypothermia has also been shown to 
maintain the integrity of myocardial cell membranes and myocardial mitochondrial 
function, which is integral in preserving cell function, ATP synthesis and reducing 
apoptosis (Ning, Xu et al. 1998, Ning, Chi et al. 2007, Huang, Chen et al. 2009). 
Additionally, hypothermia significantly reduced ROS, one of the key mediators of lethal 
reperfusion injury and showed preservation of mitochondrial function in animal models 
of ischaemia (Tissier, Chenoune et al. 2013). At macrovascular level, hypothermia has 
been shown to decrease post-ischaemic reactive hyperaemia at the onset of 
reperfusion (Olivecrona, Gotberg et al. 2007), which can be hugely beneficial in 
minimising reperfusion injury and preserving contractile function of the heart (Bopassa, 
Vandroux et al. 2006). 
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1.3.9. Methods of hypothermia induction in experimental STEMI 
Whilst earlier animal studies used methods such as ice-pack surface cooling (Hale, 
Kloner 1997), infusing cold fluid directly into the pericardium (Dave, Hale et al. 1998) 
and cold fluid infusions into the epicardial coronary arteries (Otake, Shite et al. 2007), 
these techniques are innately complex and carry a high risk of complication, in addition 
to potentially interfering with PPCI. The introduction of endovascular cooling has been 
a revelation in this field, having been experimented in human size porcine models of 
coronary artery occlusion (Dae, Gao et al. 2002) and found to be feasible. The authors 
also demonstrated that hypothermia at 34°C induced by endovascular cooling in the 
inferior vena cava, resulted a significant reduction in infarct size in relation to area at 
risk (9% vs. 45%; p<0.001).  
1.3.10. Early Hypothermia trials in the setting of STEMI in humans 
The first prospective RCT was carried out with STEMI patients where 21 patients were 
randomised to endovascular cooling and 21 patients received standard PPCI with no 
temperature management (Dixon, Whitbourn et al. 2002). The authors reported that 
95% patients in the hypothermia group reached the target temperature of 33°C and the 
mean temperature at reperfusion was 34.7°C. There were no major cardiovascular 
events (MACE) reported in the hypothermia group and a non-significant trend towards 
reduction in infarct size (2% vs. 8%; p=0.80) was observed on single-photon emission 
computed tomography (SPECT) scan. The authors concluded that hypothermia 
intervention was feasible in the setting of STEMI and that larger studies were required 
to verify the potential reduction in infarct size that was noted here. There were 2 further 
small sized cohort studies carried out to assess feasibility of hypothermia induction in 
the setting of STEMI. The LOWTEMP study (Kandzari, Chu et al. 2004) and the 
NICAMI study (Ly, Denault et al. 2005) reported that institution of hypothermia is 
feasible in patients undergoing PPCI for STEMI, although the surface cooling employed 
in the NICAMI study required a mean of 79 minutes to reach target temperature, which 
for the purposes of hypothermia induction is very slow prior to reperfusion with PPCI.  
Two further relatively larger prospective RCTs were conducted with endovascular 
cooling and presented at the Transcatheter Cardiovascular Therapeutics conferences 
in Washington DC. The COOL-MI trial (O'Neill 2004) included 357 patients who were 
randomised to PPCI alone (n=180) or endovascular cooling for 3hrs + PPCI (n=177). 
There were no significant differences in infarct size measured by SPECT scan at 
30days (p=0.45). A post hoc analysis of the study showed that patient presenting with 
anterior STEMI who reached 35°C or less prior to reperfusion, showed a 49% trend 
towards reduction in infarct size. The study group reported that the mean door to 
balloon time was extended by 18 minutes, but there was no significant difference in 
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MACE or death rates between the 2 groups. The ICE-IT trial (Grines CL 2004) 
recruited 228 STEMI patients and randomised them to PPCI (n=114) or endovascular 
cooling for 6 hours + PPCI (n=114). Again, there was no significant reduction in infarct 
size reported on SPECT scan at 30 days (p=0.14), although a post hoc analysis of 
patients presenting with anterior STEMI who reached a target temperature of <35°C 
prior to reperfusion, a more promising trend of 43% reduction in infarct size was 
observed (p=0.09). The mean door to balloon time was increased by about 10 minutes 
in patients receiving hypothermia, but there was no significant difference between 
MACE and death rates between the groups.  
1.3.11. Timing, speed and duration of hypothermia 
The findings of the COOL-MI and ICE-IT trials attenuated interest in hypothermia 
treatment in the setting of STEMI. The discovery of a potential beneficial impact of 
hypothermia in patients who reached target temperature of <35°C before reperfusion in 
reducing infarct size raised important questions about devising a more efficient system 
of inducing hypothermia. Indeed, only a small proportion of patients (about 30%) in the 
COOL-MI and ICE-IT trials reached a temperature of <35°C before reperfusion and 
earlier studies had already confirmed that hypothermia after reperfusion generates little 
or no impact on infarct size (Maeng, Mortensen et al. 2006, Gotberg, Olivecrona et al. 
2008a, Erlinge 2011). Gotberg et al (Gotberg, Olivecrona et al. 2008a) showed that the 
combination of induction with 1 litre of cold saline followed by endovascular cooling 
was able to achieve target temperature of <35°C within 5 minutes and more 
importantly, it was associated with 43% reduction in infarct size compared to post-
reperfusion hypothermia. In a further experiment, it was shown that 5 minutes of 
hypothermia prior to reperfusion, at the end of 40 minutes of normothermic ischaemia, 
delivered with a combination of intravenous cold fluid and endovascular cooling was 
associated with 18% reduction in infarct size in relation to area at risk (Gotberg, van 
der Pals et al. 2011). Furthermore, extending post-reperfusion hypothermia duration by 
an extra 45 minutes was not associated with additional reduction in infarct size, 
suggesting that hypothermia treatment can be withdrawn soon after reperfusion. This 
observation has important implications in clinical practice as it may potentially avoid 
extra resources that may otherwise need to be employed to look after patients 
undergoing hypothermia treatment. This study suggests that the hypothermic 
intervention could potentially be completed within the cardiac catheter laboratory with 
the patient transferred directly to coronary care unit without any additional invasive 
hypothermia management.  
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1.3.12. Contemporary TH clinical research in STEMI 
The RAPID MI-ICE trial (Gotberg, Olivecrona et al. 2010) was designed as a pilot study 
to investigate the feasibility and effect of combination cooling (cold saline and 
endovascular cooling) on infarct size. Twenty STEMI patients were randomised to 
hypothermia + PPCI or standard PPCI alone. All patients in the hypothermia group 
achieved a temperature of <35°C with a mean 3 minute delay in door to balloon time 
(p=0.12). Despite similar ischaemia duration, the authors found that hypothermia was 
associated with significant 38% reduction in infarct size in relation to area at risk 
measured by cardiac MRI scan (p=0.041). Interestingly, the authors observed that 
there was also a trend towards less heart failure in the hypothermia group.  
On the back of this strong performance, the CHILL MI study (Erlinge, Götberg et al. 
2014) was designed as a multi-centre prospective RCT where 120 STEMI patients 
were randomised to hypothermia with cold fluid and endovascular cooling or standard 
PPCI. Unlike previous trials, the cooling duration after reperfusion was reduced to 1hr. 
The authors reported that the trial was feasible with a mean 9 minute increase in door 
to balloon time due to hypothermia intervention and 76% patients reached temperature 
<35°C prior to reperfusion. In the overall group, the primary end point of median infarct 
size relative to myocardium at risk was not significantly reduced. However, sub-group 
analysis showed that there was a significant 33% reduction in infarct size when 
patients presenting with anterior STEMI within 4 hours were cooled. The incidence of 
heart failure was significantly reduced in the hypothermia group at a mean 45 day 
follow-up (3% vs. 14%; p <0.05).    
The pooled analysis of the ICE-IT and RAPID MI-ICE (Erlinge, Gotberg et al. 2013) 
showed a 24% reduction in infarct size as a percentage of the left ventricular 
myocardium (p<0.049) and for patients achieving <35°C prior to reperfusion, there was 
a significant similar reduction in infarct size for both anterior (33%, p = 0.03) and 
inferior STEMI (42%, p = 0.04). The combined analysis of the RAPID MI-ICE and 
CHILL MI study (Erlinge, Gotberg et al. 2015) showed that hypothermia resulted in 
15% relative reduction in infarct size normalised to myocardium at risk (p=0.046). 
Patients with larger area of myocardium at risk (>30% of left ventricular volume) 
showed the most reductions in infarct size when treated with hypothermia (p=0.03). 
In recent times, a different way of hypothermia induction using peritoneal lavage has 
been investigated (Nichol, Strickland et al. 2015). Despite demonstrating feasibility and 
the median temperature reached at perfusion being 34.7°C, there was no significant 
reduction in infarct size reported. Moreover, this study showed a higher incidence of 
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MACE in the hypothermia group primarily driven by a higher rate of stent thrombosis 
(11% vs. 0%).  
1.3.13. Shivering and side-effects of hypothermia 
One of the most challenging aspects of hypothermia induction and maintenance in the 
setting of STEMI is shivering in the conscious patients. The thermoregulatory centre in 
the brain has an involuntary reflex to systemic cooling and responds by reducing skin 
circulation and inducing shivering to raise core temperature. Shivering seems to most 
prominent between 35°C and 36°C, below which shivering becomes less prominent. 
The most important patient factors that determine shiver response to treatment are age 
and weight. Elderly and lean patients are easier to cool, whereas the shiver response 
seems to be more vigorous in young and overweight patients. One effective way of 
managing shivering is by applying surface counter-warming on the skin with warm 
blankets and hot air blankets such as Bair Hugger, as it has been shown that a 1°C  
drop in core temperature can be compensated for by a 4°C rise in skin temperature 
(Cheng, Matsukawa et al. 1995). In addition, pharmacological agents such as oral 
buspirone in combination with intravenous meperidine have been shown to act 
synergistically to suppress shivering without causing respiratory depression 
(Mokhtarani, Mahgoub et al. 2001). The combination of pharmacological agents and 
skin counter-rewarming has been used successfully in the vast majority of reported 
hypothermia STEMI trials involving conscious patients, with no studies reporting early 
termination due to cold intolerance or shivering (Dixon, Whitbourn et al. 2002, O'Neill 
2004, Gotberg, Olivecrona et al. 2010, Nichol, Strickland et al. 2015).  
Deeper hypothermia (<30°C) has been associated with QT interval prolongation, 
widening QRS complexes, ventricular fibrillation and reduced cardiac function 
(Polderman 2009, Tveita, Mortensen et al. 1994). However, mild hypothermia (up to 
32°C ) is not associated with electrical disturbance of heart rhythm (Grines CL 2004, 
Kandzari, Chu et al. 2004, Ly, Denault et al. 2005, Gotberg, Olivecrona et al. 2010, 
Testori, Sterz et al. 2013, Erlinge, Götberg et al. 2014, Blatt, Elbaz-Greener et al. 2015, 
Nichol, Strickland et al. 2015). Cardiac output has also been shown to drop by 30-40% 
during mild hypothermia, but this is compensated by a greater drop in metabolic rate by 
50-65%, resulting in net improvement in demand and supply (Polderman 2009). In 
addition, hypothermia has been associated with reduced immune response, resulting in 
slightly higher risk of pneumonia (Polderman 2009) and therefore, shorter duration of 
hypothermia treatment is preferable. 
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The original research that is presented in this thesis concentrates on the three main 
areas that have been covered in the above introduction. The introduction summarises 
the following key areas which form the core of this thesis: 
 The historical role and the current consensus on the use of TH in cardiac arrest 
in minimising hypoxic brain injury are discussed. 
 The enormous psychological burden experienced by cardiac arrest survivors 
and their caregivers is highlighted and recent research suggesting that simple 
interventions could improve the QoL and its cost effectiveness is underlined. 
 The role of TH in AMI as an adjunct to PPCI in minimising reperfusion injury of 
the myocardium and its potential role in future clinical practice is discussed.        
 
 
1.4.  Hypothesis of the study 
 
The research within this thesis was conducted with to investigate the following 
hypotheses: 
 
1. Rhinochill®, a trans-nasal cooling device is more efficient in inducing TH in patients 
successfully resuscitated from cardiac arrest than conventional Blanketrol.  
 
2. Simple psychological interventions improve QoL and cognitive function in cardiac 
arrest survivors and their caregivers and can be delivered in a Tertiary Heart Attack 
Centre (HAC). 
 
3. Simultaneous induction and maintenance of TH in conscious patients presenting 
with STEMI using an endovascular cooling device is feasible and safe and can be 
delivered with minimal delay in the delivery of PPCI. 
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2. Chapter 2: COOLCATH  
 
Early targeted brain COOLing in the cardiac CATHeterisation laboratory 
following cardiac arrest (COOLCATH) 
 
2.1. Introduction 
Temperature management has been shown to improve clinical outcomes in patients 
suffering OHCA (Bernard, Gray et al. 2002, Hypothermia after Cardiac 2002). 
Retrospective registry data demonstrated that delays in TH induction increases 
mortality (Mooney, Unger et al. 2011, Sendelbach, Hearst et al. 2012). More recent 
data from a large randomized trial has shown no difference in outcomes when 
comparing targeted temperature management (TTM) at 36°C or 33°C, suggesting the 
possibility that, prevention of fever following cardiac arrest could be an important 
mechanism by which neurological injury can be prevented (Nielsen, Wetterslev et al. 
2013). However, in this latest study, delays in initiation of cooling (mean 130 minutes) 
and time to reach 34°C (mean 5 hours) could have offset any potential benefit that TTM 
at 33°C could offer in comparison to 36°C (Nielsen, Wetterslev et al. 2013, Polderman, 
Varon 2015).  
Irrespective of whether methods are employed to reduce core body temperature or to 
prevent systemic pyrexia, the mortality rate and risk of permanent and disabling brain 
injury remains high in this patient group. In the TTM trial (Nielsen, Wetterslev et al. 
2013), more than 50% patients in both treatment groups died or had poor neurological 
function at 180 day follow-up. The alarming rates of morbidity and mortality associated 
with cardiac arrest provide a large incentive for research into novel methods of treating 
this important group of patients. 
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Figure 2-1 An Illustration of the Rhinochill
®
 device and its components 
 
 
In practice, several modalities of hypothermia induction exist including cold saline 
infusion (Kim, Nichol et al. 2014), surface blankets (Don, Longstreth et al. 2009) and 
endovascular cooling (Gillies, Pratt et al. 2010). Earlier studies indicated that targeted 
brain cooling is more important in cerebral protection than whole body cooling (Busto, 
Dietrich et al. 1989) and associated with lesser side effects (Harris, Muh et al. 2009). 
Rhinochill® is a portable, intranasal cooling system that is capable of rapid targeted 
brain cooling (Figure 2.1), as demonstrated in jugular venous temperature recordings in 
animal models (Yu, Barbut et al. 2010). Thus, it may be able to reduce the risk of 
neurological injury associated with cardiac arrest (Castren, Nordberg et al. 2010, 
Sendelbach, Hearst et al. 2012, Busto, Dietrich et al. 1989). In addition to its innovative 
mode of action, its portability allows it to be applied to patients in confined spaces and 
to be used whilst transferring patients either from the field to the hospital, or between 
different departments within the hospital.  
Coronary artery disease is the most common cause of cardiac arrest (Reichenbach, 
Moss et al. 1977, Davies 1992) and it is becoming increasingly common for these 
patients to be brought directly to HAC with cardiac catheter laboratory facilities for 
emergency PPCI. Although, ECG remains a key diagnostic tool by the bedside and 
provide invaluable information in any patient suspected of suffering a myocardial 
infarction as well as cardiac arrest setting, the clinical translation of a normal or non-
ischaemic ECG does not always equate to unobstructed coronary artery in the setting 
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of a cardiac arrest and even myocardial infarction (Spaulding, Joly et al. 1997). 
Therefore if the clinical suspicion is high for a coronary event and transfer of patient to 
a HAC is not considered futile by the attending EMS for reasons such as poor 
prognosis, prolonged hypoxia, severe academia, then resuscitated patients should be 
considered for emergency revascularization. In a relatively small observational study, 
Sunde et al demonstrated that an aggressive post resuscitation protocol aimed at 
supporting vital organs by a combination of TH, PPCI, control of haemodynamics, 
blood glucose, ventilation and seizures resulted in 56% survival to hospital discharge 
with favourable neurological recovery compared to 26% in historical control group, who 
received standard care (Sunde, Pytte et al. 2007).  Similar findings with improved 
survival to hospital discharge (64% v 39%, p<0.05) and favourable neurological 
outcomes (57% v 29%, p<0.05) have also been reported by combining TH and early 
coronary angiography by Stub et al (Stub, Hengel et al. 2011). The Parisian Region 
Out of Hospital Cardiac Arrest (PROCAT) registry demonstrated that 96% patients with 
STEMI and 58% patients without STEMI had at least one significant coronary artery 
lesion and early PCI was associated with significantly improved survival to hospital 
discharge (Cronier, Vignon et al. 2011, Dumas, Cariou et al. 2010). Hence, the 
European Society of Cardiology revised their guideline to recommend early PPCI for 
survivors of cardiac arrest, irrespective of their initial post-arrest ECG if no obvious 
non-coronary cause of arrhythmia is present (Noc, Fajadet et al. 2014, Authors/Task 
Force members, Windecker et al. 2014).  
Whilst there is evidence to suggest temperature management in combination with PPCI 
result in better clinical outcomes for survivors of cardiac arrest, the primary survey to 
ensure adequate airway protection, ongoing monitoring of ventilation by expert 
anesthetist, correction of any simple reversible causes, such as electrolyte imbalance 
should also be done simultaneously to ensure a safety for the patient at all times. 
Therefore, it goes without saying that the treatment of the cardiac arrest survivor is in 
the hands of a multi-disciplinary team with different specialist skillset who work together 
as a team and communicate effectively.     
In this randomized study, we test the hypothesis that Rhinochill® device is more 
efficient in TH induction than surface cooling Blanketrol® for cardiac arrest patients 
presenting to a HAC, in whom an underlying coronary etiology is suspected. The safety 
of Rhinochill® application is also closely monitored as it is an additional procedure that 
is implemented in a busy cardiac catheter laboratory environment.   
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2.2. Methods 
2.2.1. Study design 
Early targeted brain cooling in the cardiac catheterisation laboratory following cardiac 
arrest (COOLCATH) was designed as a single centre, prospective, open labelled, 
randomised controlled clinical trial to compare the efficiency of Rhinochill® intranasal 
cooling device (BeneChill International AG ) in TH induction to our standard surface-
cooling protocol with the Blanketrol® III device (Cincinnati Sub-Zero Products ). The 
study received ethical approval from the National Research Ethics Service (Ref: 
12/EE/0472). An independent data and safety monitoring committee reviewed the data 
and performed a comprehensive interim analysis. An independent data monitor 
performed regular data checks to ensure accuracy and completeness of data collection 
and strict adherence to the study protocol. 
2.2.2. Patients 
74 adult patients suffering cardiac arrest, irrespective of any specific initial presenting 
heart rhythm with ROSC after resuscitation were enrolled between January 2013 and 
November 2014. The main exclusion criteria were cardiac arrest caused by trauma, 
head injury, massive haemorrhage, patients without a definitive airway and patients 
who were already hypothermic on arrival (< 34°C). The full list of inclusion and 
exclusion criteria can be found in Appendix 1.1. As eligible patients were unconscious 
on admission, initial written informed consent was obtained from a legal surrogate in 
accordance with the Helsinki declaration (The Helsinki Declaration of the World 
Medical Association (WMA). Ethical principles of medical research involving human 
subjects. 2014). However, if the patient made sufficient neurological recovery and 
demonstrated mental capacity, a further informed consent was obtained from the 
patient.  
2.2.3. Randomisation 
Patients were admitted directly to the HAC by the ambulance crew, bypassing the local 
emergency department for emergency catheter laboratory based diagnostics and 
therapies. Patients fulfilling the selection criteria were enrolled and randomised (by 
allocation of a random sealed envelope) in the cardiac catheter laboratory to receive 
TH induction by either Rhinochill® or Blanketrol® III cooling blanket in a 1:1 manner. 
Randomisation was pre-performed by the local research and development office using 
a computer generated assignment sequence dictating envelope allocation. 
2.2.4. Trial intervention 
Baseline tympanic temperatures were recorded immediately after randomisation as a 
surrogate for brain temperature and an oesophageal temperature probe inserted 
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simultaneously to measure core body temperature in both treatment arms. The 
oesophageal temperature recordings were taken as a surrogate for core body 
temperature. Both tympanic and oesophageal temperatures were measured during TH 
induction every 10 minutes up to 5 hours. It was not in our study protocol to administer 
any additional TH inducing agent and therefore, no cold intravenous saline was given 
to patients in either group.  
Rhinochill® (BeneChill International AG ) 
The RhinoChill® is the only CE marked intranasal evaporative cooling system (National 
Institute of Clinical Excellence February 2014)  that is capable of inducing TH in cardiac 
arrest patients. In patients randomised to the Rhinochill® group, TH was initiated in the 
cardiac catheter laboratory by advancing the intranasal cannulae into each nostril, and 
switching on the Rhinochill® device to deliver cold vapour into the nasal cavity. The 
cooling continued throughout the initial induction period, during PCI if performed, and 
patient transfer to the intensive care unit (ICU), where maintenance cooling by 
conventional Blanketrol® III could be commenced and Rhinochill® discontinued when 
the core temperature reached ≤ 34°C. As mentioned earlier, the portability of the 
Rhinochill® allowed for continuous delivery of TH during transfer between hospital 
departments and minimised temperature fluctuations.   
Blanketrol® cooling system (Cincinnati Sub-Zero Products ) 
Patients allocated to Blanketrol® arm received TH induction in the catheter laboratory 
by application of surface cooling blankets covering the whole body but sparing a small 
area in the femoral region to allow arterial access if needed for coronary intervention. 
Unlike the Rhinochill® device, the Blanketrol® cooling machine needed to be switched 
off during patient transfer from the catheter laboratory to the ICU. 
2.2.5. General patient management 
Patients in both intervention arms were maintained at <34°C for 24 hours with active 
sedation and protected airway management. The trust protocol for active sedation 
(Propofol infusion at 0.3 to 4.0 mg/kg/hr, Morphine Sulphate infusion at 1-2mg/hr) and 
shiver prevention (Atracurium at 5mg/hr) was followed for all enrolled patients. After the 
maintenance phase (24hrs), patients were gradually rewarmed to 36°C in hourly 
increments of 0.25–0.5°C and sedation weaned to allow the patients to regain 
consciousness. If patients were in cardiogenic shock, intra-aortic balloon pumps were 
inserted at the discretion of the treating physician in the cardiac catheter laboratory and 
inotropes infusion was administered in the ICU (Table 2.1). The patient’s next of kin 
was kept informed about the progress at all times and members of the research team 
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explained the treatment received by the patient, including participation in the research, 
at a time that was convenient for the family or close friend. This was also an 
opportunity to address any concerns and answer questions about any uncertainties 
raised by the next of kin.  
 
2.2.6. Outcome measures 
Primary outcomes 
Primary outcome measures were time to reach tympanic ≤34°C from randomisation as 
a surrogate for brain temperature and oesophageal ≤34°C from randomisation as a 
measurement of core body temperature.  
Secondary outcomes 
Secondary outcomes included rate of cooling in the first hour, length of stay in ICU, 
hospital stay, neurological recovery and all-cause mortality at hospital discharge. The 
neurological assessment was made using the cerebral performance category (CPC) 
scale (Jennett, Bond 1975). The CPC scale ranges from 1 to 5, with 1 indicating an 
excellent recovery and 5 signifying brain death (Appendix 1.2). 
Adverse events were reported and documented as either related to the study 
intervention or related to the presenting medical condition by the safety monitoring 
committee. All significant events were reported to the trial sponsor and a written report 
sent to the responsible ethics committee for acknowledgement. Decisions relating to 
patient care, other than the method of TH induction, such as withdrawal of active 
treatment, were taken at the discretion of the treating physician, who was blinded to the 
trial intervention. Initial temperature data collection and progress of patients’ health 
were monitored daily by the research team, who were not blinded due to the nature of 
the study intervention. If patients were discharged from hospital within 30 days, then a 
telephone call was made to ascertain the patient’s physical health status. 
 
2.2.7. Statistics 
Statistical analysis was conducted in a modified intention to treat population, defined as 
all randomly assigned patients excluding those withdrawn from the study due to a 
delayed diagnosis or meeting one of the exclusion criteria. Descriptive statistics are 
presented for continuous, as well as categorical variables as mean (standard deviation) 
and tabulated by treatment. Analyses were performed using the computer program R 
(Gentleman Robert 2013). The time taken to reach target temperature (≤34°C), 
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duration of ventilation hours, ICU stay and hospital stay were expected to have a non-
normal distribution and so the means for the two groups were compared using a two-
sample permutation t-test with bootstrap 95% confidence limits for the difference 
between the means. The CPC between the 2 groups were described in a contingency 
table and compared using Fisher’s exact test. For statistical significance, a p-value of 
0.05 was adopted. The analysis was performed by an independent statistician. 
2.3. Results 
2.3.1. Patients 
A total of 120 cardiac arrest patients were screened for enrolment, out of which 46 
patients were excluded for not meeting selection criteria. All 74 eligible patients were 
enrolled, of which 37 were allocated to Blanketrol® and 37 were allocated to Rhinochill® 
therapy.  
Exclusions after enrolment: There were 4 exclusions from patients enrolled: 2 patients 
in the Blanketrol® arm and 1 patient in the Rhinochill® arm were found to have sub-
arachnoid haemorrhage on subsequent CT scan following randomisation and 1 patient 
in the Rhinochill® arm was already hypothermic (≤34°C ) at randomisation (Figure 2.2). 
Figure 2-2 Flow of participants from recruitment to analysis 
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Coronary angiography: Although, all patients were received and enrolled in the cardiac 
catheter laboratory, 4 patients allocated to Rhinochill® did not undergo coronary 
angiography at the physician’s discretion (2 patients had pre-existing 3 vessel coronary 
artery disease, not amenable for PCI and 2 patients were haemodynamically very 
unstable for catheter laboratory admission). One patient randomised to Blanketrol 
therapy did not undergo coronary angiography as the admitting physician reported that 
there was no clear ST elevation on ECG. This is in contrast to latest recommendation 
by the ESC as discussed in the introduction (Authors/Task Force members, Windecker 
et al. 2014). However, the revision on the ESC guideline was published after our trial 
initiation.   
2.3.2. Adverse Events 
There were no trial related adverse events or serious adverse events in patients 
randomised to Blanketrol®. One patient allocated to Blanketrol® TH induction was 
withdrawn prematurely due to development of retroperitoneal bleed, unrelated to trial 
intervention and required surgical intervention equating to 97% success rate of TH 
device application in this group.  
There were 4 trial related adverse events in patients treated with Rhinochill® – 2 
patients (5.7%) experienced epistaxis and 2 patients (5.7%) experienced white nose 
tip. These adverse events recovered without any further intervention upon termination 
of Rhinochill® induction phase. Four patients randomised to Rhinochill® therapy 
required early termination of trial intervention and crossed over to Blanketrol® for TH 
induction and maintenance equating to a success rate of 89% for device employment 
within the catheter laboratory in this group. Only 1 of these incidents was trial related: 
epistaxis (n=1) and the others were unrelated events: acute respiratory distress 
(pulmonary oedema and peri-arrest gastric aspiration; n=2) and technical difficulties 
with the device as it ran out of coolant (n=1).  
There were no exclusions due to withdrawal of consent. All enrolled patients were 
followed up according to trial protocol. The two groups had similar baseline 
characteristics prior to randomisation including the mean first temperature recordings 
(Table 2.1).  
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Table 2-1 Baseline Characteristics of patients in Blanketrol and Rhinochill
®
 group.  
Values are presented as mean (standard deviation) and n (%); p>0.05 for all comparisons 
 
  Blanketrol Rhinochill® 
Age - mean (SD) 62.1 (12.5) 63.5 (12.3) 
Male sex – n (%) 26 (74.3) 30 (85.7) 
Body Surface Area - mean (SD) in m2 1.93 (0.29) 2.03 (0.22) 
Cardiac History - n (%) 9 (25.7) 16 (45.7) 
Bystander CPR - n (%) 22 (62.9) 24 (68.6) 
Ventricular fibrillation - n (%) 33 (94.3) 32 (91.4) 
Time of untreated cardiac arrest - mean 
(SD) in mins 
5.06 (11.7) 2.83 (4.7) 
Recurrence of cardiac arrest - n (%) 13 (37.1) 16 (45.7) 
Shocks - mean (SD) 2.89 (2.23) 3.88 (4.56) 
Median Time to ROSC from cardiac arrest 
in mins (IQR) 
21 (15-35) 20 (10-36) 
Percutaneous intervention - n (%) 24 (68.6) 19 (54.3) 
Inotropes - n (%) 12 (34.3) 10 (28.6) 
Intra-Aortic Balloon Pump - n (%) 12 (34.3) 12 (34.3) 
Mean 1st Tympanic temperature (⁰C) 35.3 (0.80) 35.3 (1.0) 
Mean 1st Oesophageal temperature (⁰C) 35.3 (0.70) 35.1 (1.0) 
 
 
2.3.3. Primary Outcomes: TH induction 
From randomisation, the mean time-to-target tympanic temperature (≤34°C) as a 
surrogate for brain temperature was 75 minutes (median 45; range: 0-240) in the 
Rhinochill® arm in comparison to 107 minutes in the Blanketrol® arm (median 70; 
range: 0-366) (p=0.101).   
The mean time to oesophageal temperature (≤34°C) was 85 minutes (median 50; 
range 0-270) in the Rhinochill® arm compared to 115 minutes (median 80; range 10-
366) in the Blanketrol® arm from randomisation (p=0.151).  
 
The results are summarised in Table 2.2 and shown in graphical form in figure 2.3. 
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Table 2-2 Temperature data of the two groups:  
Comparison of group means using two-sample permutation t-tests and bootstrap 95% 
confidence limits 
 
  Blanketrol Rhinochill
®
 
Residual standard 
deviation 
P value   Mean mean 
Outcome measure     
Time to tympanic temp ≤34⁰C 
from randomisation 
107.2 75.2 
78.4 0.101 
(n = 32) (n = 33) 
Time to oesophageal ≤34⁰C 
from randomisation 
114.9 84.7 
83.4 0.151 
(n = 33) (n = 32) 
Tympanic temperature drop 
(⁰C in first hr) 
0.935 1.75 
0.897 < 0.001 
(n = 31) (n = 30) 
Oesophageal temperature 
drop (⁰C in first hr) 
0.904 1.148 
0.573 0.152 
(n = 24) (n = 23) 
Tympanic temperature slope 
(⁰C in first hr) 
-0.808 -1.615 
0.867 < 0.001 
(n = 35) (n = 35) 
Oesophageal temperature 
slope (⁰C in first hr) 
-0.823 -1.21 
0.829 0.054 
(n = 35) (n = 32) 
 
 
2.3.4. Secondary outcomes 
In the first hour of cooling, the tympanic temperature dropped significantly more quickly 
in the Rhinochill® arm than the Blanketrol® arm (1.75°C vs. 0.94°C; p<0.001) (Table 
2.2). There were no significant differences between length of ventilation hours, stay in 
ICU, duration of hospital stay, and CPC 1-2 outcomes between the 2 groups (Table 2.3 
and Table 2.4). 
There were no significant differences in survival to hospital discharge between patients 
treated with Rhinochill® and Blanketrol® therapy (65.7% vs 68.6% respectively, Table 
2.5). This equates to a combined survival to hospital discharge of 67.1%.  
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Figure 2-3 Efficiency of Blanketrol and Rhinochill
®
 in reaching target temperature 
Medians and ranges of outcome measures for patients in Blanketrol and Rhinochill
®
 arm 
 
2.4. Discussion 
Rhinochill® did not achieve statistical superiority in achieving target temperature 
(≤34°C) from randomisation, although there is trend towards faster cooling with 
Rhinochill® therapy in both tympanic and oesophageal temperature recordings as 
surrogate for brain temperature and core body temperature respectively. Rhinochill® 
induction achieved statistically significant tympanic temperature reductions compared 
to Blanketrol® during the first hour of cooling suggesting more rapid and focused brain 
cooling (Table 2.2).  
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Table 2-3 Length of ventilation hours, duration of stay in ICU and hospital: comparison of group 
means using permutation t-tests and bootstrap 95% confidence intervals 
  Blanketrol Rhinochill® Residual 
standard 
deviation 
Difference: P 
value   mean mean Rhinochill® – 
Blanketrol 
Outcome measure     (95% 
confidence 
limits) 
Length of ventilation 
(hours) 
100.7 218 280.9 117.2 0.079 
(n = 35) (n = 35) (-12.3, 254.2) 
Length of ICU stay 
(hours) 
145.6 210.5 169.3 64.9 0.122 
(n = 34) (n = 34) (-14.5, 142.1) 
Length of hospital stay 
(hours) 
447.9 508.9 656.9 61 0.709 
(n = 35) (n = 35) (-239.9, 381.9) 
 
  
Table 2-4 Cerebral performance category (CPC): comparison of percentages using Fisher’s 
Exact Test 
  Blanketrol Rhinochill® Difference: P value 
Outcome category Rhinochill® – 
Blanketrol 
  (95% confidence 
limits) 
CPC (1-2) at ICU discharge 51.40% 45.70% -5.7 0.811 
(18/35) (16/35) (-27.5, 16.9) 
CPC (1-2) at hospital 
discharge 
57.10% 54.30% -2.9 1 
(20/35) (19/35) (-24.8, 19.5) 
 
 
Table 2-5 Comparison of survival to hospital discharge between 2 groups 
  Blanketrol Rhinochill® Overall 
Survival to hospital discharge 68.60% 65.70% 67.10% 
(24/35) 23/35 (47/70) 
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The cooling times in both groups in this trial are impressive when one compares to 
other trials carried out in this field (Hypothermia after Cardiac 2002, Kim, Nichol et al. 
2014, Nielsen, Wetterslev et al. 2013). While we have shown that an aggressive 
cooling strategy in the catheter laboratory can result in a mean time-to-target tympanic 
temperature (≤34°C) of 75 minutes and 85 minutes with Rhinochill® and Blanketrol® 
respectively, there is still a 1-2 hour period in the field and during transfer to the HAC 
where no brain cooling is initiated.  It may be that even earlier and even more 
aggressive targeted brain cooling is required to show a significant survival and 
neurological improvement as compared to TTM. The PRINCESS trial that is currently 
recruiting in Europe will help to answer this question, as to whether pre-ROSC targeted 
brain cooling can improve cardiac arrest outcomes (Nordberg, Taccone et al. 2013) 
and if successful, a future large scale randomised controlled study can be designed to 
compare intra-arrest cooling and TTM protocol at 36°C. 
Irrespective of the study intervention, COOLCATH demonstrates a combined survival 
rate of over 67.1% at hospital discharge in both groups, which is better than previously 
reported trials with similar study designs (Table 2.5) (Castren, Nordberg et al. 2010, 
Mooney, Unger et al. 2011, Bernard, Gray et al. 2002). Sub-group analysis of patients 
presenting with initial shockable rhythm demonstrates a combined survival rate was 
75.3% which is favourable to previously reported data (Kim, Nichol et al. 2014, Don, 
Longstreth et al. 2009). This could be partly explained by simultaneous coronary 
intervention and early TH induction in the catheter laboratory, providing maximal 
myocardial salvage and neuro-protection in these patients. TH has been shown to have 
beneficial effects on left ventricular myocardial salvage in animal models of coronary 
artery occlusion and reperfusion (Dae, Gao et al. 2002, Gotberg, Olivecrona et al. 
2008a, Erlinge 2011). Studies of TH in humans presenting with STEMI have so far not 
established significant clinical benefit (Erlinge, Götberg et al. 2014, Erlinge, Gotberg et 
al. 2013, Dixon, Whitbourn et al. 2002). However, a recent multi-centre RCT (Erlinge, 
Götberg et al. 2014) demonstrated a 33% reduction in infarct size if TH was 
administered within 4 hours of symptom onset in patients with anterior STEMI, and also 
a reduction in incidence of heart failure was noted in this group. Although, some basic 
information was collected about initial myocardial damage, including measurement of 
troponin enzyme and an assessment of the left ventricular function is routinely 
measured by transthoracic echocardiogram; our study was not designed to answer 
questions regarding myocardial salvage with different TH induction methods.  
Our trial has limitations. In retrospect, the sample size was not sufficient to detect a 
difference in the primary outcome measure. A post hoc calculation would suggest that 
a minimum of 192 patients would be required to have 80% power to detect a 
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statistically significant difference in the time to reach ≤34°C from randomisation. 
Secondly, TH was only initiated when the patients were admitted to hospital but ROSC 
was usually achieved at the site of cardiac arrest. Therefore, valuable time is lost 
during patient transfer, when no TH is offered to patients, and neurological damage is 
inflicted. Thirdly, tympanic temperature recordings were taken as a surrogate marker of 
brain temperature. Whilst earlier studies reported a close correlation between tympanic 
temperature recordings and brain temperature (Mariak, Lewko et al. 1994), other 
studies have challenged this concept (Kirk, Rainey et al. 2009). Magnetic resonance 
spectroscopy (Corbett, Laptook et al. 1997) and other novel methods of measuring 
brain temperature can be explored in future trials. Fourthly, the nature of the 
intervention used meant that the trial was unblinded to some of the treating medical 
team, which may introduce some bias. Finally, patients were followed up to hospital 
discharge, which may not give us adequate information regarding neurological 
recovery and mortality following a cardiac arrest.  
2.5. Conclusions 
Rhinochill® can be applied safely in the cardiac catheter laboratory for the vast majority 
of patients undergoing emergency PCI following cardiac arrest and during transfer to 
ICU. Its portability, ease of use and non-intrusive nature make it user friendly for 
cardiac catheter laboratory use. The combination of aggressive catheter laboratory 
cooling and urgent coronary revascularisation in a specialist cardiac unit resulted in a 
mean overall trial survival rate to hospital discharge of 67.1%. In this study population, 
Rhinochill® did not achieve better efficiency in TH induction compared to Blanketrol® 
surface cooling and there were no differences in clinical outcomes between the 2 
groups. There is, however, a non-significant trend in favour of Rhinochill® that 
potentially warrants further investigation with a larger trial. If such a trial was to show a 
statistically significant advantage, then future research would be required to determine 
whether earlier and more rapid targeted brain hypothermia induction improves 
neurological outcome and mortality in patients presenting with cardiac arrest.  
Declaration of interest 
Rhinochill® equipment and monitoring support were provided by Benechill GmbH.  
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3. Chapter 3: CARE 
 
CARE: Care after Resuscitation – An observational study to assess the impact of 
simple psychological intervention on the quality of life and cognitive function of 
cardiac arrest survivors and caregivers 
 
3.1. Introduction 
 
In the UK, the incidence of cardiac arrest is approximately 30,000 per year (Berdowski, 
Berg et al. 2010). Better access to early chain of survival and aggressive treatment of 
underlying cause has translated to better cardiac arrest survival rates (10-32%) 
(Watson L: Virdi G, Fothergill R 2012). Recent studies have shown that, survivors are 
living with the psychological consequences of cardiac arrest event even months after 
the index presentation (Saner, Borner Rodriguez et al. 2002, Moulaert, Verbunt et al. 
2009). A large proportion of these survivors, between 25 to 50%, experience cognitive 
impairment, emotional problems, fatigue, difficulty in performing daily activities and 
perceive a poor quality of life (Moulaert, Verbunt et al. 2009, Wachelder, Moulaert et al. 
2009). These experiences can have direct negative implications on their ability to 
reintegrate into society including relationship within family and return to work if 
appropriate. Caregivers of cardiac arrest survivors may experience both physical and 
psychological strain through witnessing the cardiac arrest itself and adapting to life with 
the cardiac arrest survivor (Pusswald, Fertl et al. 2000, Wachelder, Moulaert et al. 
2009).   
At Essex CTC, a retrospective overview of current practice demonstrated that the 
conventional psychological support arrangements for cardiac arrest survivors and their 
caregivers were inadequate. A recently conducted RCT at the CTC suggested overall 
survival to hospital discharge rates of 67.1% amongst patients presenting after cardiac 
arrest (Islam, Hampton-Till et al. 2015). Of the 750 PPCI performed annually at the 
CTC, approximately 100 admissions are accounted by OHCA patients. Therefore, a 
significant proportion of these patients are expected to survive and live with the unseen 
consequences of the cardiac arrest.   
Recently, a large RCT conducted in the Netherlands, have shown significantly 
improved quality of life in cardiac arrest survivors receiving psychological support from 
health care professionals (Moulaert, van Heugten et al. 2015). It has also shown better 
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socio-economic benefit on patients receiving intervention compared to control groups 
(Moulaert, Goossens et al. 2016).  
On the basis of this strong evidence, care after resuscitation (CARE) study was 
designed to document the burden of psychological problems in cardiac arrest survivors 
and caregivers and to investigate if simple psychological intervention can improve their 
QoL and cognitive function in the short term.  
 
 
3.2. Study design and methods 
 
CARE was set up as a single centre non-randomised placebo controlled trial, 
investigating early psychological support for cardiac arrest survivor and caregivers. The 
study was registered with the institution of clinical trials (NCT02275234) and ethics 
approval was obtained from National Research and Ethics Service (14/EE/1019). The 
study was carried out in 2 phases using 2 groups of participants. The focus of the first 
group was to establish the residual psychological burden at a mean of 6 months after 
cardiac arrest, who received standard care. In the second group, simple psychological 
interventions were introduced from the outset to see if they made an impact on 
psychological wellbeing and cognitive function of the participants. 
 
3.2.1. Setup  
 
The CTC is the regional tertiary cardiac centre, serving a large population in the east of 
Essex with approximately 100 emergency admissions with out-of-hospital cardiac 
arrest. A recent study has confirmed that, the short term survival rate of patients 
admitted with cardiac arrest are in the region of 67.1% in this centre (Islam, Hampton-
Till et al. 2015) and therefore, any potential benefit of the CARE study would be 
available to a significant proportion of cardiac arrest survivors and their caregivers in 
this region.  
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3.2.2. Participants and study materials 
 
Consecutive patients were recruited from hospital registry of cardiac arrest admissions. 
Inclusion criteria for the study were English speaking; cardiac arrest survivors aged 18 
years or older, with good neurological recovery - CPC of 1-2 (Jennett, Bond 1975) and 
their caregivers. Exclusion criteria were cardiac arrest survivors with poor neurological 
recovery (CPC 3-5) with a poor prognosis (assessed by the clinical team) (Appendix 
1.2). In this study, caregiver was defined as a family member or a close friend, who had 
the most connection with the patient during the initial presentation and recovery. There 
were no additional selection criteria for caregivers. It was not obligatory for a survivor to 
assign a caregiver to be included in the study.  
The study assessment team consisted of a research fellow, a cardiologist, a clinical 
psychiatrist, a senior intensive care nurse with specialist interest in cardiac 
rehabilitation. Psychological wellbeing, including quality of life, was assessed by RAND 
SF36 questionnaire (RAND as part of the Medical Outcomes Study ) and cognitive 
function was assessed by MOCA (Julayanont, Tangwongchai et al. 2015) and 
COGFAIL questionnaires (Broadbent, Cooper et al. 1982) (Appendix 1.3). The same 
assessment tools were used for both groups of patients and caregivers. 
 
3.2.3. Group 1 (assessment of standard care) 
 
20 cardiac arrest survivors and their caregivers were invited to attend a one-off cardiac 
arrest clinic at an average of 6 months after the index event. They received standard 
treatment and follow-up after cardiac arrest. The study objectives were explained and 
an informed consent obtained. An assessment of their psychological wellbeing and 
cognitive function were made. Patients and/or caregivers exhibiting signs or symptoms 
of severe depression or post-traumatic stress were referred to our team psychiatrist for 
further management. This additional follow-up was beyond the remit of the study 
protocol and the impact of this specialist service was not evaluated.     
 
3.2.4. Group 2 (intervention group) 
 
A further 20 cardiac arrest survivors and their caregivers were identified during index 
admission to the cardiac catheter laboratory at the CTC. If they met the selection 
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criteria, patients and their caregivers were approached to discuss the study objectives 
and informed consent obtained. Baseline assessments of quality of life and cognitive 
function made. They were then offered simple psychological interventions as follows:  
1. Detailed information leaflet for patient and caregivers, explaining the 
mechanism and consequences of cardiac arrest, how to adapt with challenging 
circumstances and when to seek help (Appendix 1.4).   
2. Immediate referral to a clinical psychiatrist on recognition of moderate to severe 
depression or signs of post-traumatic stress disorder 
3. Dedicated telephone helpline on discharge for patients and caregivers to get 
direct access to a health care professional to discuss any clinical or 
psychological challenges during recovery. 
4. Attendance at a focused cardiac arrest clinic with health care professionals, 
where a physical health check and psychological wellbeing was evaluated and 
managed appropriately 
At 6 months after the index event, patients and caregivers were then re-invited to 
attend an outpatient clinic, where a re-assessment of quality of life and cognitive 
function was made using the same assessment tool to see the impact of the 
aforementioned interventions. 
 
3.2.5. Outcomes 
The primary outcome of this study was to establish if simple psychological interventions 
improved quality of life perceptions in patients and caregivers in the short term. The 
secondary outcome measures were to assess impact of simple psychological 
intervention on cognitive function of cardiac arrest survivors and caregivers. During 
consultations, the psychiatrist identified participants with moderate to severe 
depression, PTSD and offered them further appointments. These additional data about 
prevalence of depression, PTSD, psychiatry follow up and return to work were also 
documented but not measured as an outcome for this study. 
 
3.2.6. Statistical analysis 
Baseline characteristics between Group 1 and Group 2 (Table 3.1) are compared using 
descriptive statistics. The baseline and 6 month data in Group 2 (intervention group) 
were compared using the total scores from the three questionnaires (SF36, MOCA, 
and Cognitive Failures) using a paired sample t-test, at a 5% significance level and 
95% confidence limits were obtained for the change in means of the scores using a 
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bootstrap approach. Group 2 (intervention) assessments at 6 months  was then 
compared with assessments of Group 1 patients (standard care) using unpaired t-test 
at a 5% significance level and 95% confidence limits were obtained for the difference 
between the means of the scores using a bootstrap approach. The computer software 
SPSS (IBM SPSS Statistics for Windows, Version 20.0. Armonk, NY: IBM Corp.) was 
used to analyse the data. 
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3.3. Results 
3.3.1. Patient flow 
The flow of patients in Group 1 and Group 2 are shown in Figure 3.1 and Figure 3.2 
respectively. As demonstrated, 50% patients in Group 1 were still suffering from 
moderate to severe depression and 20% suffered from PTSD, out of which 15% 
warranted referral to our team psychiatrist. Of the caregivers in Group 1, 29% suffered 
moderate depression but none required referral to psychiatry services.   
 
Figure 3-1: Group 1 patient and caregiver flow chart 
 
Two patients in Group 2 were withdrawn from the study due to mortality (unrelated to 
participation in the study) and 1 caregiver was lost to follow up at 6 months. In Group 2 
patients, 26% suffered moderate to severe depression, 16% experienced PTSD and 
26% required referral to psychiatry. Of the caregivers, 33% suffered moderate to 
severe depression, 16% experienced PTSD and 33% required psychiatry referral. The 
unemployment rates at 6 month follow-up were similar in both groups for patients and 
caregivers.  
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Figure 3-2: Group 2 patient and caregiver flow chart 
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3.3.2. Baseline demographic data 
The baseline demographic data for patients in Group 1 and Group 2 are shown in 
Table 3.1. Despite being a non-randomised controlled trial, there was no notable 
difference between the 2 groups of patients from descriptive statistics. 
 
Table 3-1: Baseline demographics of patients in Group 1 and Group 2;  
CV = cardiovascular, PCI = percutaneous intervention, CABG: coronary artery bypass grafting 
 
     Group 1 (n=20) Group 2 (n=19) 
 
n(%) or mean (SD) n(%) or mean (SD) 
Age 59.15 (9.85) 61.68 (13.98) 
Male 16 (80%) 16 (84%) 
Marital status 
  Married/partner 13 (65%) 15 (79%) 
Single/Divorced/Widowed 7 (35%) 4 (21%) 
Education 
  Basic 16 (80%) 14 (74%) 
Higher 4 (20%) 5 (26%) 
Employment 
  Paid job 10 (50%) 9 (47%) 
Unemployed/Retired 10 (50%) 10 (53%) 
Medical history 
  No CV history 15 (75%) 15 (79%) 
CV risk factors 5 (25%) 4 (21%) 
Medical outcome 
  PCI 20 (100%) 16 (84%) 
CABG 0 (0%) 3 (15%) 
Heart failure 2 (10%) 1 (1%) 
Location of discharge 
  Home 20 (100%) 19 (100%) 
Rehab/Nursing home 0 (0%) 0 (0%) 
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3.3.3. Primary outcome  
Quality of life assessment: Patients 
The analysis of the impact of simple psychological interventions showed that there was 
significant improvement in all domains of SF36 except general health when patients 
within Group 2 were reassessed at 6 months follow up (Table 3.2).  
 
Table 3-2 Comparison of baseline and 6 month quality of life assessment for patients within 
Group 2 by RAND SF36 
SF36 Domains Baseline 
Mean (SD) 
6 month 
Mean (SD) 
Mean 
change 
SEM p value Lower 
(95% CI) 
Upper 
(95% CI) 
Physical 
functioning 
35.79 
(30.15) 
66.84 
(24.70) 
31.05 7.95 0.001 -47.76 -14.35 
Social 
functioning 
23.03 
(23.67) 
71.71 
(33.03) 
48.68 8.05 <0.001 -65.59 -31.77 
Role Physical 10.53 
(24.03) 
55.26 
(49.71) 
44.73 11.72 0.001 -69.36 -20.11 
Role Emotional 40.35 
(46.59) 
77.19 
(36.95) 
36.84 11.08 0.004 -60.11 -13.55 
Vitality 31.84 
(23.23) 
58.16 
(21.55) 
26.32 6.40 0.001 -39.75 -12.88 
Mental Health 64.00 
(24.15) 
78.11 
(17.04) 
14.11 4.15 0.003 -22.83 -5.38 
Bodily Pain 40.66 
(28.90) 
77.89 
(23.29) 
37.23 8.19 <0.001 -54.45 -20.02 
General Health 52.63 
(19.10) 
63.95 
(25.69) 
11.32 6.16 0.083 -24.26 1.63 
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When patients in Group 1 (standard care) were compared with patients in Group 2 
(intervention) at 6-month follow-up, there was some improvement in perceptions of 
mental health, general health, bodily pain and role limitations due to physical health. 
However, these improvements did not reach statistical significance between the 2 
groups (Table3.3). 
Table 3-3: Comparison of quality of life assessment for patients between Group 1 and Group 2 
by RAND SF36 
 SF36 Domains Group 1 (6m) 
Mean (SD) 
Group 2 (6m) 
Mean (SD) 
Mean 
Difference 
SEM p value Lower 
(95% CI) 
Upper 
(95% 
CI) 
Physical 
functioning 
70.25 (23.98) 66.84 (27.4) -3.41 8.23 0.681 -13.27 20.08 
Social 
functioning 
79.38 (21.94) 71.71 (33.03) -7.67 8.94 0.397 -10.44 25.77 
Role physical 45 (41.83) 55.26 (49.71) 10.26 14.68 0.489 -40.01 19.49 
Role Emotional 78.33 (36.32) 77.19 (36.95) -1.14 11.73 0.923 -22.63 24.91 
Vitality 58.75 (19.59) 58.16 (21.55) -0.59 6.59 0.929 -12.76 13.94 
Mental Health 75.6 (20.88) 78.11 (17.04) 2.51 6.12 0.685 -14.91 9.9 
Bodily Pain 72.13 (23.23) 77.89 (23.29) 5.76 7.45 0.444 -20.87 9.32 
General Health 62.5 (21.3) 63.95 (25.69) 1.45 7.54 0.849 -16.72 13.83 
 
 
 
 
 
 
 
 
Quality of life assessment: Caregivers 
When caregivers within Group 2 were reassessed at 6 months, there was improvement 
in all domains of SF36, except physical functioning, bodily pain and general health 
perception. However, these changes were not statistically significant (Table 3.4).  
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Table 3-4: Comparison of baseline and 6 month quality of life assessment for caregivers within 
Group 2 by RAND SF36 
 SF36 Domains Baseline  
Mean (SD) 
6 month 
Mean (SD) 
Mean 
change 
SEM p 
value 
Lower 
(95% 
CI) 
Upper 
(95% CI) 
Physical 
functioning 
84.67 
(23.02) 
83.00 
(20.16) 
-1.67 3.44 0.64 -5.71 9.04 
Social functioning 42.19 
(34.33) 
57.50 
(33.67) 
15.31 13.25 0.36 -40.92 15.92 
Role physical 54.69 
(46.93) 
71.66 
(37.64) 
16.97 10.02 0.21 -34.82 8.16 
Role Emotional 43.74 
(46.80) 
71.11 
(45.19) 
27.37 14.72 0.12 -56.02 7.11 
Vitality 37.81 
(25.83) 
45.33 
(22.08) 
7.52 8.00 0.38 -24.49 9.83 
Mental Health 50.50 
(23.15) 
58.40 
(22.87) 
7.90 8.29 0.38 -25.24 10.31 
Bodily Pain 70.49 
(30.82) 
70.33 
(30.12) 
-0.16 8.30 0.69 -14.48 21.15 
General Health 63.44 
(20.83) 
55.67 
(19.26) 
-7.77 5.14 0.14 -3.02 19.02 
 
 
When caregivers in Group 1 (standard care) were compared with caregivers in Group 2 
(intervention) at 6-month follow-up, there was no statistically significant difference in 
any domain of the SF36 questionnaire (Table 3.5). 
Table 3-5: Comparison of quality of life assessment for caregivers between Group 1 and Group 
2 by RAND SF36 
 SF36 Domains Group 1 (6m) 
Mean (SD) 
Group 2 (6m) 
Mean (SD) 
Mean 
difference 
SEM p 
value 
Lower 
(95% 
CI) 
Upper 
(95% CI) 
Physical 
functioning 
84.54 (26.44) 83.00 (20.16) -1.54 8.40 0.86 -15.62 18.70 
Social functioning 72.50 (29.39) 57.50 (33.67) -15.00 11.15 0.19 -7.76 37.76 
Role physical 75.00 (43.30) 71.66 (37.64) -3.34 14.44 0.82 -26.15 32.82 
Role emotional 76.47 (40.24) 71.11 (45.19) -5.36 15.13 0.73 -25.55 36.26 
Vitality 54.90 (20.08) 45.33 (22.07) -9.57 7.45 0.21 -5.65 24.79 
Mental Health 68.47 (19.89) 58.40 (22.87) -10.07 7.56 0.19 -5.36 25.50 
Bodily Pain 79.26 (26.06) 70.33 (30.12) -8.93 9.93 0.38 -11.35 29.21 
General Health 67.06 (23.85) 55.67 (19.26) -11.39 7.73 0.15 -4.40 27.19 
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3.3.4. Secondary Outcome 
Cognitive function: Patients 
The analysis of the impact of simple psychological interventions showed that there was 
statistically significant improvement in cognitive function assessed by MOCA but not 
with Cogfail, when patients within Group 2 were reassessed at 6 months follow-up 
(Table 3.6). 
 
Table 3-6: Comparison of cognitive function assessments by Cogfail and MOCA in patients 
within Group 2 
 Baseline 
Mean (SD) 
6 month 
Mean (SD) 
Mean 
change 
SEM p 
value 
Lower 
(95% 
CI) 
Upper 
(95% CI) 
Cogfail 27.95 (12.50) 26.95 (16.97) -1.00 4.67 0.833 -8.81 10.81 
MOCA 24.53 (2.91) 27.26 (2.18) 2.73 0.83 0.004 -4.47 -1.00 
 
 
When patients in Group 1 (standard care) were compared with patients in Group 2 
(intervention) at 6-month follow-up, there was no difference in cognitive function 
between the 2 groups (Table 3.7). 
Table 3-7: Comparison of cognitive function between Group 1 and Group 2 by Cogfail and 
MOCA 
  Group 1 (6m) 
Mean (SD) 
Group 2 (6m) 
Mean (SD) 
Mean 
difference 
SEM p value Lower 
(95% CI) 
Upper 
(95% 
CI) 
Cogfail 30.15 (14.33) 26.95 (16.97) -3.2 5.02 0.527 -6.97 13.37 
MOCA 27.5 (1.76) 27.26 (2.18) -0.24 0.63 0.711 -1.05 1.52 
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Cognitive function: Caregivers 
When caregivers within Group 2 (intervention) were reassessed at 6 months, there was 
non-significant improvement in cognitive function assessed by both Cogfail and MOCA 
(Table 3.8).  
Table 3-8: Comparison of cognitive function for caregivers within Group 2 by Cogfail and MOCA 
 Baseline 
Mean (SD) 
6 month 
Mean (SD) 
Mean 
change 
SEM p value Lower 
(95% CI) 
Upper 
(95% 
CI) 
Cogfail 31.13 (15.51) 36.67 (14.24) 5.54 5.83 0.36 -18.03 6.97 
MOCA 27.00 (3.59) 27.67 (2.09) 0.67 0.66 0.21 -2.28 0.55 
 
 
When caregivers in Group 1 (standard care) were compared with caregivers in Group 2 
(intervention) at 6-month follow-up, there was non-significant improvement in cognitive 
function assessed by both Cogfail and MOCA (Table 3.9). 
Table 3-9: Comparison of cognitive function for caregivers between Group 1 and Group 2 by 
Cogfail and MOCA 
  Group 1 (6m) 
Mean (SD) 
Group 2 (6m) 
Mean (SD) 
Mean 
difference 
SEM p value Lower 
(95% CI) 
Upper 
(95% 
CI) 
Cogfail 30.18 (18.98) 36.67 (14.24) 6.49 6.00 0.29 -18.74 5.76 
MOCA 26.31 (2.68) 27.67 (2.09) 1.36 0.87 0.13 -3.12 0.42 
 
 
 
3.4. Discussion 
The CARE study demonstrates that patients and caregivers experience enormous 
emotional burden of surviving a cardiac arrest even months after the index event. The 
assessment of QoL perceptions in Group 1 and Group 2 is comparable to the Medical 
Outcomes study, where 2471 patients with chronic health conditions completed the 
SF36 survey (Tarlov, Ware et al. 1989). The recognition of this finding, along with 
evidence from the Dutch study (Moulaert, van Heugten et al. 2015) warrants further 
research and investment in this very important area of post resuscitation care.  
Our study demonstrated that, there is statistically significant improvement in all 
domains of the SF36 except general health in patients who were offered simple 
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psychological intervention at 6-month follow-up, consistent with the finding of the Dutch 
study (Moulaert, van Heugten et al. 2015). Although there was a trend in improvement 
for QoL measures in caregivers at 6 months, these did not reach statistical 
significance. This finding was also consistent with the Dutch study, where caregivers in 
the intervention arm did not report a statistically significant improvement in QoL 
(Moulaert, van Heugten et al. 2015). This observation reaffirms the point that 
caregivers may sustain the effects of the cardiac arrest in a worse manner as a 
consequence of witnessing the event and adapting to enforced changes to their 
lifestyle (Zimmerli, Tisljar et al. 2014). Therefore, more needs to be done to identify the 
individual care needs of the caregivers and address them appropriately for better 
participation in the society.   
In comparison to patients in group 1, patients and caregivers in group 2 did not score 
highly on any domain of QoL assessments at 6 months follow up, suggesting that there 
are more factors influencing QoL perceptions than the simple psychological 
interventions offered in this study. Indeed, some of the patients recruited in group 2 
were physically quite unwell and had residual problems with heart failure and other 
chronic illnesses requiring multiple hospital admissions. These factors can indeed add 
further strain on patients and the caregivers and influence their perception of QoL. 
Other factors such as finances, redundancies, worries about uncertain futures also 
played an important role in determining QoL of the individuals.  
Patients within Group 2 demonstrated superior cognitive function by MOCA 
assessments at 6 months. However, caregivers within Group 2 did not show such 
improvement in cognition.  Neither patients nor caregivers in Group 2 showed superior 
cognition in comparison to participants in Group 1, an observation that was also 
consistent with the Dutch study (Moulaert, van Heugten et al. 2015). This mirrors the 
QoL assessments between the 2 groups, suggesting that there is a close relationship 
between QoL and cognitive function, as previously documented (Andersson, Rosen et 
al. 2015). Cardiac arrest can lead to transient or more long lasting cognitive impairment 
through hypoxic brain injury, which may explain the time dependent recovery in 
cognitive function in group 2 patients at 6 month follow up. Although, it is difficult to 
draw conclusions from this relatively small study, the absence of hypoxic brain injury 
could explain the unchanged cognitive function in caregivers.      
Our study had limitations and therefore, the findings have to be considered in light of 
these factors. Firstly, it was a small non-randomised placebo controlled trial aimed at 
reinforcing the findings of the Dutch study in a UK healthcare setting. However, the fact 
that there is so much resemblance in our findings with the benchmark RCT (Moulaert, 
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van Heugten et al. 2015) suggest that, this is a realistic reflection of the problems faced 
by cardiac arrest survivors and caregivers. Secondly, limitations in resources and 
research timeframe meant that we did not have access to a clinical psychologist, who 
could provide a more focussed therapy to those in need of treatment. And finally, the 
nature of the trial meant that, blinding could not be achieved during stages of 
recruitment, provision of psychological intervention and reassessment. However, as the 
assessment tools were scored independently by the research participants, the risk of 
bias was minimised.    
NICE recommends follow up critically ill patients (discharged from ICU) with a face to 
face consultation within 2-3 months after hospital discharge with an emphasis to 
recognise the residual physical and emotional needs of the patients and referral to 
appropriate services as indicated (CG83). The CARE study has reaffirmed that cardiac 
arrest survivors and caregivers live with the invisible negative emotional consequences 
even months after the index event. Our attempt at offering the simple psychological 
interventions is just a small step towards addressing the much bigger problems faced 
by these very important group of individuals. It will require much more resource 
allocation, individualised care support for both patient and caregiver to enable them to 
reintegrate into society and there is an anticipated health economic benefit attached to 
this approach. Indeed, a post-hoc analysis of the data has shown significant economic 
benefit of psychological intervention in this important group of patients (Moulaert, 
Goossens et al. 2016).  
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4. Chapter 4: COOLAMI 
 
Setting up an efficient TH (TH) team in conscious ST Elevation Myocardial 
Infarction (STEMI) patients  
A UK Heart Attack Centre Experience 
 
4.1. Introduction 
The primary therapeutic aim of treating patients presenting with STEMI is to restore 
blood flow in any occluded coronary artery at the earliest opportunity to reduce infarct 
size and any associated complications. However, restoring blood flow can itself lead to 
further myocardial damage by complex molecular mechanisms leading to reperfusion 
injury (Kloner 1993). Therefore recent research has focused on ways of minimising 
reperfusion injury.  
TH has been shown to have beneficial effects on left ventricular myocardial salvage in 
animal models of coronary artery occlusion and reperfusion (Dae, Gao et al. 2002, 
Gotberg, Olivecrona et al. 2008a, Erlinge 2011). The exact mechanism of this benefit 
remains unclear, although it has been suggested that at lower core body temperatures, 
there is significant reduction in reactive hyperaemia (Olivecrona, Gotberg et al. 2007) 
and also complex molecular regulation including suppression of destructive enzymes, 
free radicals, protection of the cellular phospholipid bilayer membrane and reduction of 
intracellular acidosis resulting in reduced reperfusion injury (Chopp, Knight et al. 1989, 
Dempsey, Combs et al. 1987). There seems to be a strong relationship between the 
timing of hypothermic temperature achievement and reduction in infarct size - with 
100% reduction in infarct size demonstrated, if TH is achieved before onset of 
ischaemia although of course this is not realistically possible in practice (Gotberg, 
Olivecrona et al. 2008a, Erlinge, Gotberg et al. 2013, Dixon, Whitbourn et al. 2002). 
There is no reduction in infarct size if TH is initiated after reperfusion. However, some 
report up to 80% reduction in infarct size can be achieved if TH can be initiated at the 
earliest recognition of onset of ischaemia and TH achieved before reperfusion 
(Gotberg, Olivecrona et al. 2008a, Erlinge, Gotberg et al. 2013, Dixon, Whitbourn et al. 
2002). Therefore, it can be postulated that, an efficient transfer of patient suffering 
STEMI and initiating TH simultaneously early in the catheter lab before reperfusion, is 
likely to offer most potential therapeutic benefit of this treatment.  
Studies of TH in humans presenting with STEMI have so far not demonstrated 
significant clinical benefit (Erlinge, Götberg et al. 2014, Erlinge, Gotberg et al. 2013, 
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Dixon, Whitbourn et al. 2002).  In the latest multi-centre RCT (Erlinge, Götberg et al. 
2014), it was shown that TH administered simultaneously at the time of PPCI did not 
reduce the infarct size significantly. However, exploratory analysis demonstrated that 
there was a significant 33% reduction in infarct size if TH was administered within 4 
hours of symptom onset in patients with anterior STEMI, and also a significant 
reduction in incidence of heart failure was noted in this group. Future studies on TH will 
focus on early presenting anterior STEMI, using more powerful TH devices enabling a 
more rapid cooling profile, and to achieve a lower temperature before reperfusion 
specifically in these larger infarcts. Some investigators are also looking at 
commencement of TH at an earlier stage including during ambulance transfer. (Testori 
2014) It has been learnt that an important aspect of future potential success in this area 
is efficiency of the clinical team in administering TH simultaneously with PPCI. The time 
of coronary intervention following symptom onset is vital in dictating prognosis and 
therefore, any delay following hospital admission should be minimised. There is a 
nationally agreed consensus to target door to balloon time of < 60 mins in HAC offering 
PPCI service (Authors/Task Force members, Windecker et al. 2014). The introduction 
of TH intervention in the setting of STEMI can potentially prolong door to balloon time 
and therefore, it is vitally important to look at the framework that exist to ensure safety 
and efficacy of any intervention that might affect current practice. In this paper, we 
focus our discussion on our experience of running a TH interventional research trial in 
the setting of patients presenting with STEMI. 
 
4.2. Methods 
The Essex CTC is a tertiary HAC serving a population of 1.7 million in the county. 
Every year the centre carries out approximately 750 PPCIs. It is the first UK centre that 
received ethical approval to conduct a feasibility study of TH in patients presenting with 
STEMI, sponsored by ZOLL Circulation (USA).  
The purpose of the study is to: 
A. Investigate the feasibility of administering TH simultaneously with PPCI and before 
reperfusion. 
B. Organise an efficient team to minimise time delays to TH without compromising 
patient care.  
C. Controlling shivering in conscious patients who are actively cooled with an 
intravenous cooling device. 
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Recruitment model 
Preparation  
All 24/7 heart attack centres are well trained and efficient in the assessment and 
treatment of the STEMI patient. Teamwork in this potentially stressful clinical arena is 
vital, and currently the roles and responsibilities of all PPCI team members are well 
described and understood.  Implementing a TH service in the setting of STEMI clinical 
trial adds further complexity.  To ensure efficient enrolment and cooling, it is paramount 
that these extra tasks are defined and delegated.  
 
The day is started by briefing all members of the cardiac catheter lab and research 
team that if a suitable patient with STEMI is admitted, he/she will be approached to 
participate in the study. Members of the team are given clear instructions about their 
roles during various stages of the recruitment. All medications, including Buspirone, 
Pethidine, and cold intra-venous saline are checked to ensure adequate supply.  The 
Essex CTC is notified in advance by ambulance crew when a patient suffering STEMI 
is identified and boarded for transfer with an expected arrival time. The ZOLL 
Thermoguard (TG) cooling machine is pre-cooled to ensure immediate availability at 
the optimum temperature. A typical patient flow diagram is illustrated in figure 4.1.  
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Figure 4-1: Flow diagram of COOL AMI EU patient flow with time for completing each part of 
study protocol. 
 
 
 
Stage 1: Holding Bay / Consent  
On arrival, the patient is taken to the holding bay outside the catheter lab for initial 
assessment by the study team. If haemodynamically stable, the patient is screened 
against the inclusion / exclusion criteria of the ZOLL COOL AMI EU Study. An informed 
consent is obtained if patient decides to take part in the study and baseline data is 
collected. Two intravenous access sites are secured, and the patient is then transferred 
to the catheter laboratory for urgent TH and coronary intervention. We aim for the 
consenting and IV access step to be completed within 10 minutes where possible. 
Stage 2: Catheter Lab 
Once included into the trial the focus is on delivering the maximum “dose” of cooling 
prior to early reperfusion therapy.  A bair-hugger is already placed on the catheter lab 
table in anticipation for the patient’s arrival and it is set at 43°C.  Using warming 
blankets on the skin, while cooling within the vena cava with a cooling catheter is a 
recognised strategy for preventing shivering.  For successful and rapid reduction in 
patient core temperature shivering must be prevented. Once shivering occurs core 
76 
 
temperature will reduce no further and may in-fact increase until the shivering is 
suppressed. The anti-shiver regimen includes 60mg Buspirone orally; with the 
oesophageal temperature probe inserted simultaneously, as it is easier to pass the 
tube when the patient is swallowing which minimises the gag reflex. A bolus of 
pethidine is then administered at a dose of 1mg/kg, followed by intravenous cold saline 
to initiate TH. The patient is then wrapped up in blankets to provide surface warming.  
We aim to have the patient on the catheter lab table, consented, anti-shiver regimen 
delivered, intravenous iced saline commenced and patient ready for cooling catheter 
insertion within 15 minutes from arrival. The layout of the cardiac catheter laboratory 
during PPCI and simultaneous application endovascular TH is shown in figure 4.2.   
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Figure 4-2: An illustration of the catheter laboratory layout during PPCI and simultaneous 
administration of endovascular therapeutic hypothermia 
 
The volume of cold saline administered is dependent on the suspected area of 
myocardial infarction. In inferior myocardial infarction, up to 2 litres of cold saline is 
administered compared to 1 litre in anterior myocardial infarction. The rationale for this 
is related to the territory of the myocardium supplied by the coronary arteries. The right 
coronary artery (inferior STEMI) supplies predominantly the right ventricle and 
consequently the left ventricle is more susceptible to volume depletion due to reduced 
right ventricular contractility (Cohen, Guyon et al. 1995), whereas the left anterior 
descending artery supplies the bulk of the left ventricle and it is more susceptible to 
volume overload following a myocardial infarction (Opie, Commerford et al. 2006).   
Following routine sterilisation procedures, the consultant cardiologist secures right 
femoral vein access to pass the cooling catheter (ZOLL Quattro catheter). The optimal 
catheter position in the inferior vena cava is confirmed under x-ray guidance. The 
catheter is then connected to the TG cooling device to initiate cooling with a set point 
temperature of 32°C. The oesophageal temperature probe is connected to the TG 
cooling device which then displays core body temperature changes. Peripheral 
tympanic temperatures are also obtained at regular intervals according to the study 
protocol and this allows checking for any discrepancy in temperature measurement. 
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We aim for the cooling catheter to be inserted and cooling commenced within 20 
minutes of hospital arrival.   
Arterial access is then obtained preferably via the right radial artery as there is a lower 
bleeding risk for the procedure and it is easier to manage the radial sheath on the ward 
and monitor arterial blood gases if required. Baseline bloods are taken and sent off to 
the laboratory for analysis. Coronary angiogram images are obtained and the occluded 
artery is identified. Following 18 minutes of cooling via TG cooling device, the 
consultant cardiologist proceeds to appropriate coronary intervention. We aim for a 
door to balloon time in this trial of between 35-40 minutes, with 18 minutes of cooling 
prior to reperfusion.  
According to the study shiver management protocol, a pethidine infusion is set up that 
can be titrated between 24mg/hr to 32mg/hr depending on the level of shivering and 
respiratory drive and administered 15 minutes after the initial loading dose. The patient 
is closely monitored during this active cooling phase to ensure haemodynamic stability, 
adequate shiver management, and end tidal CO2 is monitored via a sensor within the 
oxygen mask to ensure the patient has adequate ventilation.  
Stage 3: Transfer from catheter laboratory to ward 
At the end of the coronary intervention, the patient is prepared for transfer to the ward. 
This phase of the cooling maintenance is vital. The TG cooling device currently needs 
to be turned off for transfer, and as a result patients can increase in temperature about 
0.5oC within 5 minutes. We have developed an iced cold saline protocol, where during 
transfer the patient is given a bolus 250ml of ice cold saline to cover the transfer time. 
We have learnt from our experience that this intervention minimises any rebound 
temperature gain during the transfer from the catheter lab to the ward. The Essex CTC 
is well designed for a quick and efficient transfer between lab and the coronary care 
unit and the average journey time is 3 minutes or less.  
Stage 4: Ward 
On arrival to the ward, the TG cooling device and the Bair Hugger machine are both 
switched on immediately to continue the active cooling therapy to a target temperature 
of 32±1°C. The pethidine infusion rate is tailored to patient’s clinical condition. The 
radial sheath is kept in situ to monitor arterial blood pressures and blood gas on the 
ward. The right femoral vein site is inspected on regular intervals for any vascular 
complications. After 3 hrs of active cooling, the patient is re-warmed passively. The TG 
cooling is turned off, but the oesophageal temperature probe is still kept in situ until 
core temperature warms to above 35.5°C, defined as normothermia. A cooling curve of 
a typical patient is shown in figure 4.3. The femoral catheter is then removed in a sterile 
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fashion, and manual pressure is applied for 10-15 minutes. At this point, usual post PCI 
care is resumed by the ward team. All steps of research participation are documented 
in the medical notes and formally handed over to the clinical team for continuation of 
care. 
Figure 4-3: Cooling curve of a typical patient recruited to COOL AMI trial  
Please note mild temperature rise during ward transfer; DTC = Door to consent; DTBPS = Door 
to Buspirone, Pethidine, ice-cold Saline; DTIVTM = Door to IVTM; DTB = Door to Balloon 
 
 
4.3. Results and Discussion 
It is feasible to deliver efficient TH within the setting of a clinical trial to patients 
presenting with STEMI in a tertiary PPCI centre. The average door to balloon (DTB) 
time for the first 11 patients recruited into the trial was 38 minutes with an average of 
16.5 minutes of intra-venous catheter cooling before reperfusion. This compares with a 
DTB mean of 37 minutes for all patients presenting with STEMI without administration 
of TH at the Essex CTC during 2014. This observed 1 minute delay is favourable to the 
mean 9 minute delay observed in the CHILL MI trial, although their sample size was 
much larger across multiple sites (Erlinge, Götberg et al. 2014, Canadian 
Cardiovascular Society, American Academy of Family Physicians et al. 2008). More 
importantly, this minor delay is well within the 60 minute door to balloon time target that 
PPCI centres are expected to meet (Authors/Task Force members, Windecker et al. 
2014).  
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Figure 4-4: An illustration of the DTB achieved through our case series at CTC 
 
 
Evidence from external monitors suggest that our performance improved significantly 
over time in terms of achieving minimal delay in door to balloon time and shiver 
management. This can be attributed to a combination of factors including strict 
adherence to protocol, co-ordination of team and clearly defined roles. Following the 
enrolment of each patient, we conduct a debrief session where we discuss different 
aspects of the patient treatment and areas for improvement. We, as a team got better 
in speed, efficiency by practising our roles meticulously over the duration of the study. 
There has been no compromise to the safety of the patients and there has been no trial 
related serious adverse events.  
The prevention of shivering is the key to successfully administering TH in these 
patients. The anti-shivering regimen provided by the sponsor is a useful guide to 
ensuring that safe doses of anti-shivering medications are administered and in the 
correct order. Early signs of shivering can be identified from the ECG monitors, where 
the isoelectric line may demonstrate signs of micro-shivering. This then allows the 
clinical team to administer bolus doses of pethidine if clinically indicated. However, the 
patient’s clinical condition and safety takes priority over shiver control. Therefore, it is 
essential to monitor patient’s clinical condition before any pethidine bolus is 
administered.  The application of multiple layers of blanket ensures maximum surface 
warming, as the skin is the largest organ for heat exchange, and if the skin perceives 
warmth, then it appears that shivering is minimised.  
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The efficient transfer of patient from the catheter lab to the ward is another key element 
to success as this is a time when active cooling needs to be turned off and therefore 
allows the potential for rebound hyperthermia. We introduced the administration of a 
250ml of cold saline into our transfer regime to minimise temperature rebound. In 
addition, the CCU is pre-notified before transfer to ensure all equipment including Bair 
Hugger and TG cooling device can be re-started instantly on patient’s arrival. The 
continuous presence of a clinician throughout the course of the patient monitoring 
during active cooling and passive rewarming adds to the safety of this trial; however 
this may be a challenge in a centre with limited resources.   
With a well-trained team within this feasibility trial, it is possible to deliver 18 minutes of 
TH to STEMI patients prior to PPCI reperfusion without a significant prolongation of 
door to balloon times. This work paves the way for a larger RCT, where important 
clinical outcomes including left ventricular infarct size and function, patient safety, and 
mortality can be measured against standard PPCI care.  
In summary, reperfusion injury is associated with an increase in morbidity and 
mortality. TH has shown promise particularly in patients presenting early with anterior 
STEMI. The delivery of TH in the conscious patient is challenging, and previous trials 
have been criticised by delaying reperfusion to allow for delivery of TH, the benefits of 
which may be cancelled out by the adverse effects of lengthening the symptom to 
reperfusion time. This review outlines our experience at a busy Heart Attack Centre, in 
delivery of TH in conscious STEMI without delaying reperfusion, albeit in the setting of 
a clinical trial. We hope that this review will help other centres deliver similar results, 
thus giving TH the best chance of succeeding in reducing the adverse of effects of 
reperfusion injury in STEMI. 
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5. Chapter 5: Discussion 
 
5.1. COOLCATH 
5.1.1. Key findings  
Early targeted brain cooling in the cardiac catheterisation laboratory following cardiac 
arrest (COOLCATH) was designed as single centre RCT to investigate the efficacy of a 
novel intra-nasal cooling device, Rhinochill® over conventional surface cooling using 
Blanketrol for TH induction and also, its impact on clinical outcomes including hospital 
length of stay, neurological recovery and all-cause mortality at hospital discharge. 
Rhinochill® TH induction was associated with quicker time to reach target temperature 
of ≤34°C from randomisation for both modalities of tympanic and oesophageal 
measurements, although these times were not statistically significant. It was however 
noted that the rate of drop in tympanic temperature in the first hour was significantly 
quicker with Rhinochill® induction, suggesting more rapid and focussed brain cooling. 
These observations did not translate to superior clinical outcomes in patients receiving 
Rhinochill® induction including neurological recovery and survival to hospital discharge. 
Remarkably, the combined survival to hospital discharge was a remarkable 67.1%, 
which is better than previously reported (Bernard, Gray et al. 2002, Mooney, Unger et 
al. 2011, Castren, Nordberg et al. 2010)  
Two landmark RCTs published in the New England Journal of Medicine in 2002 
(Bernard, Gray et al. 2002, Hypothermia after Cardiac 2002) showed significant 
mortality and morbidity benefit in cardiac arrest patients treated with mild TH over 
control groups. Other retrospective studies also supported the positive outcomes of 
these studies and reinforced the fact that, delays in initiating TH was associated with 
worse clinical outcomes in this group of patients. (Sendelbach, Hearst et al. 2012, 
Mooney, Unger et al. 2011). The TTM trial published in 2013 raised some important 
questions about the therapeutic role of hypothermia in cardiac arrest patients (Nielsen, 
Wetterslev et al. 2013). In this large RCT, there was no significant difference in 
neurological recovery or mortality reported between patients managed at 33°C and 
36°C. However, closer inspection of the study design suggested that the mean delay in 
initiation of cooling was 130 minutes and the mean time to reach target temperature of 
34°C was 5 hours (Polderman, Varon 2015), which was quite substantial for TH 
induction and could offset any potential benefit that can be offered by hypothermia. 
Another possible explanation for the equivocal results in this study is that both groups 
(33°C and 36°C) had active temperature management unlike previous trial, where 
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temperature in the control group was not actively maintained (Hypothermia after 
Cardiac 2002) resulting higher temperatures.  
The rationale for further research in this area derives from high incidence of mortality 
and morbidity associated with cardiac arrest, whether methods are employed to reduce 
core temperature or to prevent systemic pyrexia. In the TTM trial alone, more than 50% 
of the patients died or had poor neurological recovery at 6-month follow-up (Nielsen, 
Wetterslev et al. 2013). To the best of our knowledge, COOLCATH was the first 
reported RCT, where TH induction using Rhinochill® was investigated in cardiac 
catheter laboratory in the setting of cardiac arrest.  
In the COOLCATH study, 74 adult cardiac arrest patients with ROSC were randomly 
allocated to induction with Rhinochill® or Blanketrol irrespective of their initial pre-arrest 
rhythm. Initial consent was obtained from a legal surrogate in accordance with the 
Helsinki declaration (The Helsinki Declaration of the World Medical Association (WMA). 
Ethical principles of medical research involving human subjects. 2014). Simultaneous 
temperature recordings were made from tympanic and oesophageal probes. Patients 
randomised to Rhinochill® induction received uninterrupted cooling from randomisation 
throughout coronary intervention and transfer to ICU and were transferred to Blanketrol 
maintenance cooling once target temperature of 34°C was achieved. Patients allocated 
to Blanketrol induction were also cooled from randomisation and throughout coronary 
intervention but interrupted during patient transfer from cardiac catheter laboratory to 
ICU as the machine only operates from mains electricity supply. Both groups of 
patients were maintained at <34°C for 24 hours, using standard sedation protocol as 
per trust guideline, before active rewarming was conducted at hourly increments of 
0.25-0.5°C and sedation withdrawn. There were no differences in baseline 
characteristics between the 2 groups including pre-arrest rhythms, mean time of 
untreated cardiac arrest and median time to ROSC. Day-to-day clinical decisions 
including prognosis and withdrawal of treatment were taken by treating medical team, 
who were unaware of the trial intervention for TH induction. The follow up duration was 
till hospital discharge. 
Despite efficient cooling profile in both Rhinochill® and Blanketrol induction, a 
substantial amount of time (1-2 hours) had elapsed between ROSC and initiation of 
cooling, during which considerable brain damage may already have occurred. This 
could partially explain the findings of the COOLCATH study although the sample size 
was not sufficiently powered to detect a significant difference in primary and secondary 
outcomes. An ongoing trial, PRINCESS (Nordberg, Taccone et al. 2013) is being 
conducted to investigate pre-ROSC targeted brain cooling in cardiac arrest patients 
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and is anticipated to address some vital questions regarding the optimal time for 
initiation of cooling to provide greater neuro-protection.                
 
5.1.2. Latest guidelines on TH in cardiac arrest 
Having assessed the safety and feasibility of mild hypothermia in human survivors of 
cardiac arrest, landmark RCTs conducted in Europe (Hypothermia after Cardiac 2002) 
and Australia (Bernard, Gray et al. 2002) showed morbidity and mortality benefit of TH 
in cardiac arrest survivors. Following the publication of these studies, several other 
studies and meta-analyses were conducted (Holzer, Bernard et al. 2005, Hachimi-
Idrissi, Corne et al. 2001) which resulted in many governing bodies advocating the 
routine use of hypothermia in cardiac arrest survivors (Peberdy, Callaway et al. 2010, 
Nolan, Neumar et al. 2008, NICE, National Institute for Clinical Excellence March 
2011). The TTM trial (Nielsen, Wetterslev et al. 2013) was conducted to establish 
whether beneficial effects of hypothermia observed in previous studies is attributable to 
targeted temperature management or fever prevention and it did not show any 
superiority of patients being maintained at 33°C compared to patients maintained at 
36°C. The limitations of this study were discussed earlier. The latest AHA guideline has 
been updated to reflect the current body of evidence on the institution of hypothermia in 
the setting of cardiac arrest and it recommends that ‘all comatose adult patients with 
ROSC after cardiac arrest should have TTM, with target temperature between 32°C 
and 36°C selected and achieved and then maintained for at least 24hours’ (Donnino, 
Andersen et al. 2015).    
5.1.3. Other important considerations about TH in cardiac arrest 
5.1.3.1. Downtime, cooling the right patient and target temperature 
Epidemiological data suggests majority of OHCA occur at home and only a fraction in 
public areas (Nicholas P, Virdi G, Fothergill R September 2013). Only about 1 in 5 
patients are found to be in shockable rhythm (Nicholas P, Virdi G, Fothergill R 
September 2013). In the UK, EMS attempted to resuscitate an estimated 28,000 OHCA 
in 2013 (NHS England 2013) but the actual number of calls were much higher where 
resuscitation attempts were not made due to medical reasons, including presence of a 
valid do-not-attempt resuscitation form, already deceased before EMS arrival and other 
situations where resuscitation attempts would be considered futile (NHS England 
2013).  There are regional variations in success of attempted CPR and LAS claim to be 
one of the better performing emergency services both in terms of successful ROSC to 
hospital arrival and survival to hospital discharge in their latest report (Virdi G, Picton S, 
Fothergill R September 2015). In London, only 49.2% of all OHCA were witnessed by 
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bystanders and despite improved education and training, about 63.1% of patients 
received bystander CPR, which is an improvement compared to previous year (Virdi G, 
Picton S, Fothergill R September 2015). Therefore, a significant proportion of OHCA is 
unattended at the time of the cardiac arrest and does not receive CPR. Prolonged 
downtime (cardiac arrest without ROSC) results in increased duration of anoxia, which 
is inherently related to poor clinical outcome (Oddo, Ribordy et al. 2008).  
Majority of the success of hypothermia in cardiac arrest both in terms of neurological 
recovery and mortality is derived from patients who had minimal downtime, received 
effective bystander CPR and had initial shockable rhythm (Hypothermia after Cardiac 
2002, Castren, Nordberg et al. 2010, Bernard, Gray et al. 2002). However, if 
hypothermia is considered to be beneficial in the context of cardiac arrest, then wider 
application in patients with poorer prognosis also needs to be verified. One of the latest 
meta-analysis (Schenone, Cohen et al. 2016) used very generous selection criteria to 
include all comatose survivors of witnessed or unwitnessed cardiac arrest irrespective 
of pre-arrest rhythm, with or without shock and more lenient downtimes. The only 
notable exclusion criteria were those who did not reach target temperature during 
hypothermia treatment.   
In this meta-analysis, the authors reported that there was no statistically significant 
heterogeneity between the groups and concluded that TH reduced mortality (odds ratio 
0.51; 95% confidence interval 0.41-0.64) and improved odds of neurological recovery 
(odds ratio 2.48; 95% confidence interval 1.91-3.22), regardless of pre-arrest rhythm, 
length of downtime and bystander CPR. Based on these findings, the authors 
advocated wider application of TH in cardiac arrest. However, in practice, the clinical 
judgement of the physician should take precedence in deciding institution of TH as it is 
an additional resource consuming intervention and some patients may be at high risk of 
sustaining adverse events due to pre-morbid functional status.  
Unlike other meta-analysis, the authors decided to analyse a further 3 studies 
separately that compared different targeted temperature management in cardiac arrest 
(Schenone, Cohen et al. 2016). Kim et al (Kim, Yang et al. 2011) compared outcomes 
at 32°C, 33°C and 34°C in comatose patients surviving cardiac arrest and found no 
difference in clinical outcome. It is important to note that, two thirds of the patients in 
this study had non-shockable rhythm on presentation and half of the patients had 
cardiac arrests from non-cardiac origin. A smaller pilot RCT (Lopez-de-Sa, Rey et al. 
2012) investigated outcomes in patients managed at 32°C and 34°C for 24hrs followed 
by controlled rewarming for a further 24 hours. The authors found better 6 months 
survival rate in patients managed at 32°C (p=0.03) and better neurological recovery in 
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patients with initial shockable rhythm managed at 32°C (p=0.029). And finally, TTM 
study (Nielsen, Wetterslev et al. 2013) was also included in this section of the analysis, 
which was discussed earlier. Additionally, a pooled analysis of 34 hypothermia arms 
grouped by cooling temperature did not show any statistically significant morbidity or 
mortality benefit and therefore, this analysis did not support the superiority of one 
temperature over another.  
5.1.3.2. Optimal initiation of cooling and duration of cooling 
One of the major limitations in hypothermia intervention is the timing of initiation of 
therapy as the vast majority of cardiac arrests occur out of hospital, where the priority 
of the EMS is to restore circulation and transfer the patient to a place of safety to treat 
the underlying cause. Aside from Rhinochill® and institution of cold fluid, no other 
available cooling equipment is portable and therefore the feasibility of TH induction in 
public areas is very challenging. The equivocal results in the TTM trial can be 
explained by the notable delay in initiating hypothermia (mean 130 minutes) and mean 
time to reach target temperature of 34°C of 5 hours (Nielsen, Wetterslev et al. 2013). 
On the basis of our understanding of molecular mechanism of hypoxic brain injury, one 
could hypothesise that a substantial amount of damage already occurred and 
hypothermia could not exert any additional neuro-protection. Registry based data has 
shown that delay in initiating hypothermia is associated with poorer outcomes 
(Sendelbach, Hearst et al. 2012, Mooney, Unger et al. 2011).  
A recently published Cochrane review investigated the current body of evidence to see 
if pre-hospital cooling is more beneficial than in-hospital cooling (Arrich, Holzer et al. 
2016) . Seven RCTs met the selection criteria for inclusion in this analysis (Bernard, 
Smith et al. 2012, Bernard, Smith et al. 2010, Castren, Nordberg et al. 2010, Debaty, 
Maignan et al. 2014, Kim, Nichol et al. 2014, Kim, Olsufka et al. 2007, Kamarainen, 
Virkkunen et al. 2009). The findings of the studies were investigated individually 
because of the methodological differences and the risk of bias due to variation in 
cooling strategies. High level of inconsistency and low precision resulted in very lowly 
scores for the quality of evidence.  The authors declared that the beneficial or harmful 
effect of pre-hospital cooling over in-hospital cooling remain inconclusive with current 
low quality evidence and therefore, warrants further robust research in this field to 
establish reproducible facts.  
There is very limited data investigating different duration of targeted temperature 
management on mortality and neurological recovery (Donnino, Andersen et al. 2016). 
One retrospective registry based observational study compared temperature 
management at 33°C for 24hrs with 32°C for 72hrs in comatose asphyxial cardiac 
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arrest survivors and found no difference in neurological recovery or mortality at 30 day 
follow up (Lee, Lee et al. 2014). In the absence of robust data to establish optimal 
duration of temperature management, The AHA currently suggests active temperature 
management for 24hrs based on 2 largest RCTs in this field (Nielsen, Wetterslev et al. 
2013, Hypothermia after Cardiac 2002).  
   
5.1.3.3. Consenting the unconscious patient – ethical challenge 
Obtaining consent for participation in research is one of the biggest challenges in 
unconscious patients in the setting of cardiac arrest. The national research ethics 
committee has made special exception in this situation for an interim consent to be 
obtained from a legal surrogate in accordance with declaration of the Helsinki (The 
Helsinki Declaration of the World Medical Association (WMA). Ethical principles of 
medical research involving human subjects. 2014) but advises to obtain a further 
prospective consent from the patient if and when patient makes sufficient neurological 
recovery.  
The whole experience of the cardiac arrest is very traumatic for any immediate family 
or friend without any reasonable doubt, who attend with the patient and consenting for 
an unproven intervention require a very thoughtful and compassionate conversation 
between the clinician and the next of kin. Evidence from trial data suggest that the vast 
majority of legal surrogates consent to the patient participation if sufficient information 
is provided about the rationale for research. Supplementary appendix from one of the 
largest multi-centre trial in this field, TTM (Nielsen, Wetterslev et al. 2013) showed only 
4 patients out of the 950 (0.4%) randomised were withdrawn due to withdrawal consent 
either by the legal surrogate or the patients themselves on regaining consciousness. 
However, it also reports that 160 participants of the original 1242 (12.8%) eligible were 
not included for randomisation because consent could not be obtained in a timely 
manner. This highlights the extremely challenging circumstances under which consent 
is obtained, which can also be at unsocial hours when the patient is admitted to 
hospital.      
5.1.3.4. Measuring brain temperature more accurately 
The direct measurement of brain temperature in targeted brain cooling would be ideal 
for research purposes to accurately assess the impact of TH but it poses real life 
challenges. First of all, the anatomical location of the brain means that an invasive 
approach needs to be adopted to obtain direct measurement of the brain temperature 
but it can only be done in unconscious patients. Furthermore, the brain temperature 
may have variations depending on site of measurement and especially in the context of 
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cooling when areas of hot and cold gradients become more prominent (Karaszewski, 
Wardlaw et al. 2006, Laptook, Shalak et al. 2001).  
The correlation of core temperature as a surrogate for brain temperature has been 
subject to controversy. It has been reported that there is a difference in the range of 
0.3°C to 2.1°C between rectal temperature and frontal lobe recordings (Rumana, 
Gopinath et al. 1998) and 0.7°C to 2.3°C between pulmonary artery and ventricular 
temperature recordings (Rossi, Zanier et al. 2001). Infrared tympanic temperature was 
used as a surrogate for brain temperature in our RCT (Islam, Hampton-Till et al. 2015). 
Whilst some studies supported this as a close surrogate (Mariak, Lewko et al. 1994), 
others have challenged its validity (Kirk, Rainey et al. 2009, Moran, Peter et al. 2007).  
The simultaneous measurement of oesophageal temperature as a surrogate for core 
body temperature was also made in our RCT to better understand the overall 
temperature changes with treatment. Although targeted brain cooling preferentially 
cools the cerebral hemispheres, venous blood returning from the cooled brain is likely 
to reduce core body temperature as well (Harris BA 2005). Thus if oesophageal 
temperature was reduced with Rhinochill® during TH induction, one can speculate that 
the intracranial temperature has also been reduced. 
In future trials, the direct non-invasive measurements of brain temperature by more 
complex techniques such as MRI spectroscopy, microwave radiometry and infrared 
spectroscopy can be explored in trials involving TH in cardiac arrest (Covaciu, Weis et 
al. 2011, Bakhsheshi, Lee 2014, Stauffer, Snow et al. 2014). Whilst these measures 
are more resource intensive, it will be worth investigating the practicality of application 
of these measuring tools in the setting of cardiac arrest to get a better understanding of 
the temperature fluctuations during targeted temperature management.            
5.1.3.5. Neurological prognostication 
Following a period of 24 hours of temperature management with active sedation as per 
AHA recommendation (Donnino, Andersen et al. 2016), routine practice is to actively 
rewarm patients in increments of 0.5°C per hour whilst simultaneously weaning off 
sedation to allow patients to regain consciousness. In the TTM trial (Nielsen, 
Wetterslev et al. 2013), active temperature management with an aim to keep 
temperature below 37.5°C continued for a total of 72hrs to prevent pyrexia. The patient 
is assessed by the treating physicians for signs of recovery and expertise from a 
neurologist is sought to assess and prognosticate in patients who remain in comatose.  
Although hypothermia in cardiac arrest has been instituted for many decades and even 
found its place in historic algorithms and most recent ones (Safar 1964, Donnino, 
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Andersen et al. 2016), there remains scepticism on its wider application due to lack of 
robust and convincing evidence and in some cases, it may not be appropriate where 
patients are considered to be too high risk due to pre-morbid function. Hence, the vast 
majority of historic guidelines on prognostication are documented without taking 
hypothermia into consideration. In 1985, Levy et al produced a model of 
prognostication based on neurological examination of 210 patients who survived 
cerebral hypoxia-ischaemia (Levy, Caronna et al. 1985). They reported that indicators 
of poor outcome include absent pupillary reflexes on admission and lack of flexor or 
extensor motor responses and absent spontaneous eye movements that were neither 
orientating nor roving conjugate. A comprehensive set of guideline was published by 
the American Academy of Neurology in 2006 (Wijdicks, Hijdra et al. 2006), that 
incorporated the body of evidence published in the previous decade and expanded on 
recommendations from Levy et al (Levy, Caronna et al. 1985) on prognostication after 
cardiac arrest. In this guideline, the authors concluded that absence of pupillary light 
response, corneal reflexes, motor reflexes to painful stimuli and the presence of 
myoclonus status epilepticus; raised biochemical marker serum neuron-specific 
enolase and somatosensory evoked potential studies can reliably assist in predicting 
neurological recovery after cardiac arrest (Wijdicks, Hijdra et al. 2006). The role of 
neuroimaging to guide prognostication was less established in this guideline. 
Neurological prognostication is more challenging in patients who have been treated 
with hypothermia as it affects drug metabolism and also induces physiological changes 
and therefore, patients may not exhibit true neurological recovery at the time of 
assessment (Perman, Kirkpatrick et al. 2012).  
5.1.3.5.1. Neurological examination 
A neurological examination to assess pupillary and corneal reflexes and motor 
responses to painful stimuli can predict prognosis if performed within 1-3 days after 
cardiac arrest according to the American Academy of Neurology (AAN) guidelines 
published in 2006 (Wijdicks, Hijdra et al. 2006). However, neurological examination 
performed during active hypothermia institution may not reliably provide accurate 
assessment of neurological recovery as hypothermia induces many physiological 
changes that include delayed in drug metabolism at temperatures below 35°C 
(Polderman 2004) and therefore, the effects of sedation may mask the examination. 
One prospective trial seem to suggest that there are no differences in time to regaining 
consciousness between patients treated with hypothermia and those without (Fugate, 
Wijdicks et al. 2011) and found that the median time to awakening was 2 days in both 
groups. However, other researchers seem to suggest that an assessment at 72 hours 
may not provide an accurate assessment in any modalities of neurological examination 
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in patients treated with hypothermia (Rossetti, Oddo et al. 2010). The variations in 
these findings suggest that either a delayed assessment or addition of other tools may 
provide more realistic reflection of neurological prognostication in patients treated with 
hypothermia.  
5.1.3.5.2. Neuroimaging 
The AAN guideline published in 2006 suggested that neuroimaging has limited role in 
neurological prognostication in cardiac arrest survivors (Wijdicks, Hijdra et al. 2006). 
However, more recent developments especially in magnetic resonance imaging (MRI) 
with diffusion weighted imaging (DWI) have shown that poorer outcomes are 
associated with size, number and location of lesions performed within 3-5 days after 
index event in patients treated with hypothermia (Jarnum, Knutsson et al. 2009, Lang, 
Welte et al. 2002). The relative lack of data suggests that neuroimaging alone cannot 
provide sufficient information to prognosticate but can be used in conjunction with other 
assessments to support the diagnosis.  
5.1.3.5.3. Electrophysiological studies 
According to the AAN guideline (Wijdicks, Hijdra et al. 2006), the absence of N20 
component of the somatosensory evoked potentials (SSEPs) on stimulation of the 
median nerve can predict poor outcome between 24-72 hours after the index event. 
Hypothermia has been shown to affect the altitude and the latency of the SSEPs (Lang, 
Welte et al. 2002). There is limited evidence on the validity of performing SSEPs in the 
setting of hypothermia to predict outcome and although considered to be a useful tool, 
it is resource intensive and may not be feasible to perform in the ICU. The presence of 
burst-suppression or generalised epileptiform activity on electroencephalograms (EEG) 
has also been associated with poor outcome according to the AAN guideline (Wijdicks, 
Hijdra et al. 2006). In the setting of hypothermia, one small prospective study revealed 
that patients with poor outcomes showed non-reactive or discontinuous burst-
suppression activity on continuous EEG monitoring (Rossetti, Urbano et al. 2010). 
Again, the relative lack of data means that EEG alone cannot be used to prognosticate 
in cardiac arrest patients treated with hypothermia but can provide valuable information 
that can be used as an additional tool to guide patient management. 
5.1.3.5.4. Status epilepticus 
The presence of myoclonus status epilepticus within 24hrs of cardiac arrest indicates 
poor prognosis (Wijdicks, Hijdra et al. 2006). However, in the context of hypothermia, 
there have been isolated reports of favourable prognosis despite clinical manifestation 
of myoclonic seizures (Rossetti, Oddo et al. 2009). Other studies supported the poor 
prognosis associated with seizures even in patients treated with hypothermia (Al 
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Thenayan, Savard et al. 2008). As most patients remain under active sedation whilst 
receiving TH, seizure activity may be difficult to witness clinically but EEG can aid early 
recognition and further research is warranted to establish the usefulness of EEG in this 
setting.  
5.1.3.5.5. Biomarkers 
Neuron-specific enolase (NSE) is an enzyme released by neurons in response to 
hypoxic injury (Rundgren, Karlsson et al. 2009) and a level >33µg/L between 24-72 
hours after cardiac arrest has been associated with poor outcome (Wijdicks, Hijdra et 
al. 2006). However, the threshold for poor prognosis in patients treated with 
hypothermia has been debated (Daubin, Quentin et al. 2011) perhaps related to the 
timing of sampling and therefore, although high levels of NSE can give some indication 
on prognosis, it cannot be used in isolation based on current body of evidence. 
5.1.4. Future directions and conclusions 
Despite all recent controversies regarding hypothermia institution in cardiac arrest, 
epidemiological studies repeatedly confirmed the high incidence of morbidity and 
mortality associated with this life changing event in the presence or absence of 
hypothermia (Mozaffarian, Benjamin et al. 2015). In the latest consensus paper, the 
unadjusted survival to hospital discharge rate still stands at a meagre 8.6% (NHS 
England 2013). The relative lack of robust data in temperature management means 
that definite conclusions cannot be easily drawn from the current body of evidence. The 
observation from the TTM trial, the largest in this field (Nielsen, Wetterslev et al. 2013) 
was included in the latest meta-analysis published in 2016 (Schenone, Cohen et al. 
2016) and it showed that, there is no difference in clinical outcome between various 
levels of active temperature management in the range of 33°C and 36°C. More 
importantly, this meta-analysis concluded that TH offers greater neuro-protection and 
mortality benefit compared to no temperature management.  
The latest AHA guideline has been amended to reflect this observation (Donnino, 
Andersen et al. 2016). In this review the authors asked some very important questions 
and scrutinised the current body of evidence to provide meaningful answers. In 
response to question regarding mild hypothermia compared to no TTM in comatose 
survivors of OHCA, the authors recommend using TTM in patients with initial shockable 
rhythm (strong recommendation, low-quality evidence). The recommendation is weaker 
in comatose survivors of OHCA whose pre-arrest rhythm was non-shockable and for 
IHCA with any pre-arrest rhythm due to lack of robust data. The authors commented 
that the current data was indirectly obtained through extrapolation from studies focused 
on OHCA with shockable rhythm. Therefore, more research is warranted in this sub-
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group of patients to establish if there is true reproducible therapeutic benefit of TH. Also 
in qualification of TTM between 32°C and 36°C, the authors outline that whether 
certain subgroup of patients would benefit from lower or higher temperature 
management remain unknown. For instance, the latest meta-analysis (Schenone, 
Cohen et al. 2016) suggested that there may be a potential beneficial role of lower TTM 
in non-shockable rhythm, but recommends verification with more robust research.  
In response to question regarding early (pre-hospital) institution of TTM, the authors 
recommended against using large volume of cold saline to induce TH as it was 
associated with increased risk of pulmonary oedema and recurrence of cardiac arrest 
in one of the larger RCTs (Kim, Nichol et al. 2014). There is inadequate data 
investigating other modalities and strategies of TH induction in the pre-hospital setting 
and the authors have suggested that further research is required in this field. Indeed, 
one can speculate that it will be a noteworthy project to investigate an efficient and safe 
pre-hospital TH induction at 33°C with TTM at 36°C in the hospital setting on clinical 
outcome. For this to be feasible, the TH induction equipment need to be portable, least 
resource intensive and above all safe for application without incurring side effects as 
observed with cold fluids (Kim, Nichol et al. 2014).  
And finally, the authors responded to the optimal duration TTM. In the absence of 
robust data, the authors recommended pursuing with 24hrs of active TTM based on the 
2 largest RCTs in this field (Nielsen, Wetterslev et al. 2013, Hypothermia after Cardiac 
2002). Again, there is knowledge gap in this aspect of temperature management and 
require further research to establish reliable and reproducible facts.  
Authors from the TTM trial (Nielsen, Wetterslev et al. 2013) are embarking on a new 
and larger multicentre superiority trial, TTM2 (NCT02908308) in an attempt to answer 
some key questions that were raised from their original study. Highlights of these 
questions include whether faster and earlier cooling at 33°C improves clinical outcome 
and whether prevention of fever, without lowering core body temperature, provides 
adequate neuroprotection in cardiac arrest survivors.  
The TTM2 is set up to investigate TTM at 33°C compared to normothermia with early 
treatment of fever (≥37.8°C). Outcome assessors and prognosticators will be blinded to 
the intervention; however healthcare providers will be unblinded at the time of 
application of intervention due to nature of the study. Patients allocated to 33°C will be 
cooled for 28hrs followed by 12hrs of controlled rewarming. In the normothermia (fever 
prevention group), pharmacological measures and physical cooling will be deployed at 
the recognition of temperature ≥37.8°C. Neurological recovery will be assessed in line 
with European Resuscitation Council’s recommendations on neurological 
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prognostication. This trial will follow up patients up to 24months after inclusion in the 
study, although interim results will be reported at 6 months.  
In theory, TTM2 trial is a major attempt to respond to key unanswered questions. 
However, one key observation from the study design is that, the deployment of TH at 
33°C will still be started after hospital admission despite ROSC being achieved in the 
out of hospital setting. From TTM-1 (Nielsen, Wetterslev et al. 2013) it has been noted 
that considerable time is lost in patient transfer and initiation of intervention, during 
which substantial brain damage can occur. In other words, the true neuro-protective 
beneficial effect of TH at 33°C may still not be observed. The other observation is that, 
the authors mentioned TH induction method will include infusion of cold fluids despite 
current recommendations advocating against this due to risk of pulmonary oedema and 
recurrence of cardiac arrest (Kim, Nichol et al. 2014). Nonetheless, the outcome of this 
study is expected to influence wider adoption of TH in clinical practice and governing 
bodies will be reading the outcome of this study with a lot of interest.         
In conclusion, TH has been around for many decades in the context of cardiac arrest 
and went through peaks and troughs in reporting success and failures over time. It will 
be far too naïve to deter from further research with hypothermia in cardiac arrest as 
there is still so many unknown, yet very important factors associated with this field of 
treatment. The extremely high incidence of morbidity and mortality associated with this 
condition provides an enormous impetus in its own merit to conduct further 
comprehensive and robust research within this field and perhaps, we can get more 
meaningful answers to the questions. 
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5.2. CARE 
5.2.1. Key findings 
Care after resuscitation (CARE) was set up as a non-randomised placebo controlled 
trial to investigate the impact of early psychological support for cardiac arrest survivors 
and their caregivers. The study was carried out in 2 phases using 2 groups of 
participants in a single tertiary centre. The focus of the first group was to establish the 
residual burden of emotional trauma, QoL and cognitive impairment at a mean 6 month 
after cardiac arrest who received standard rehabilitation care. In the second group, a 
comprehensive psychological support intervention was introduced from the outset to 
see if it made an impact on the wellbeing and cognitive function of the participants in a 
6-month follow-up timescale. A recent study confirmed that short term unadjusted 
survival to hospital discharge of patients admitted with cardiac arrest was in the region 
of 67.1% and neurologically intact survival to hospital discharge was in the region of 
55.7% (Islam, Hampton-Till et al. 2015) and therefore, any potential benefit of the 
CARE study would be available to the vast majority of cardiac arrest survivors and their 
caregivers.  
Consecutive adult survivors of cardiac arrest with good neurological recovery defined 
by CPC grade 1-2 (Jennett, Bond 1975) and their caregivers were included in the 
study. Participants in group 1 were recruited using the hospital registry for cardiac 
arrest and Group 2 participants were recruited prospectively on hospital admission if 
they met the selection criteria. The latter group received detailed information leaflet, 
immediate referral to on-site psychiatrist, if appropriate, dedicated phone line to provide 
information regarding cardiac arrest on discharge and attendance at a focused cardiac 
arrest clinic, where physical health and psychological well-being were assessed and 
managed. Validated questionnaires were used to document assessments of QoL and 
cognitive function at defined time points. 
Comparisons were made between Group 1 and Group 2 participants at 6-month follow-
up and also a further comparison was made within Group 2 to compare baseline data 
with 6-month follow-up. Patients within Group 2 showed significant improvements in all 
domains of QoL assessment at 6 months except general health; however such 
improvement were not statistically significant when patients in Group 1 were compared 
with Group 2 patients. Caregivers within Group 2 also showed improvements in most 
domains of QoL assessment at 6-month follow-up without reaching statistical 
significance. No such trend was observed when caregivers in Group 1 were compared 
with caregivers in Group 2. 
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In terms of cognitive function, patients within Group 2 showed significant improvement 
when re-assessed at 6 months in one of the validated assessment tools but no 
difference was observed when Group 2 patients were compared with Group 1. 
Although the differences did not reach statistical significance, there was a trend 
towards improvement in cognitive function when caregivers within Group 2 were re-
assessed at 6 months and similar comparison made with caregivers from Group 1.  
In summary, the CARE study re-affirms presence of enormous emotional burden 
amongst cardiac arrest survivors and caregivers. Within the limitations of our small 
study, we were unable to demonstrate a benefit of the simple psychological 
intervention in cardiac arrest survivors and caregivers compared to those who received 
standard rehabilitation. However, our experience of looking after these participants has 
given us greater insight into understanding some of the very individual problems that 
they face. And clearly, there is a need more greater investment to address the 
concerns of this very important group of patients and their caregivers.      
5.2.2. Relevant research in this field 
The LAS reported a remarkable 32% survival to hospital discharge of witnessed OHCA 
with initial shockable rhythm compared to 5% over 10 years ago (Watson L: Virdi G, 
Fothergill R 2012). Better access to chain of survival is likely to result in improvement in 
cardiac arrest survival to hospital discharge rates and therefore, more people are 
expected to live with the unseen consequences of cardiac arrest. Beyond the physical 
health impacts, it has been reported that 50% patients suffer cognitive impairment, 
50% develop fatigue, 35% live with emotional problems and 25% experience a reduced 
QoL (Moulaert, Verbunt et al. 2009, Wachelder, Moulaert et al. 2009).  
The landmark trial in this field was carried out in Netherlands by Moulaert et al 
(Moulaert, van Heugten et al. 2015) where 185 patients were randomised to receiving 
intervention or standard care with an aim to better participation in society and improve 
QoL. They successfully reported that patients in the intervention group reported 
significant improvements in role emotional, mental health and general health 
components of the SF-36 and overall emotional state and anxiety levels at 12-month 
follow-up. Return to work rate was significantly better at 3-month follow-up but the 
difference in improvement could not hold at 12 months. Caregivers did not report 
improvement in QoL or emotional wellbeing at 12-month follow-up, which is similar to 
the finding in the CARE study described above.  
Two further studies previously successfully investigated impact of psychological 
interventions in cardiac arrest survivors. Cowan et al conducted a prospective RCT 
investigating the impact of focused psychosocial therapy on cardiovascular mortality in 
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cardiac arrest survivors and found a significant reduction in mortality in patients 
receiving the intervention over a 2 year period (Cowan, Pike et al. 2001). Dougherty et 
al carried out a prospective RCT investigating the impact of 8 week educational 
telephone intervention aimed at improving the psychological wellbeing of cardiac arrest 
survivors who received ICD as part of their treatment (Dougherty, Thompson et al. 
2005). They found that there was sustained improvement on patient concerns, reduced 
anxiety levels and better self-efficacy at 12-month follow-up in the intervention group. 
However, these groups did not carry out a cost-effectiveness analysis to see if this 
intervention should be incorporated into routine clinical practice.   
 
5.2.3. Cost effectiveness of neurologically focussed follow up 
The success of implementing a simple comprehensive intervention in improving the 
emotional state and QoL of cardiac arrest survivors (Moulaert, van Heugten et al. 2015) 
prompted authors to evaluate its cost effectiveness to help advocate routine 
incorporation into clinical practice. The findings were published recently in the journal of 
Resuscitation (Moulaert, Goossens et al. 2016). In addition to standard rehabilitation, 
patients and caregivers in the intervention group received between 1-6 face-to-face 
consultations with a trained nurse at patients’ homes or at an outpatient clinic, 
depending on individual circumstances of the patient and caregiver. During these 
consultations, an assessment of the cognitive function and emotional wellbeing was 
made using validated questionnaires, verbal and written information on cardiac arrest 
and neurological consequences provided, self-management promoted and referred to a 
specialist if clinically warranted. Follow-up meetings were carried out by research 
assistants at 2 weeks, 3 months and 1 year to evaluate effectiveness of the 
intervention over the control group.  
A comprehensive cost analysis was carried out to include intervention costs, direct 
costs such as healthcare costs, patient and family costs and indirect costs such as 
productivity losses using monthly cost diaries. In the economic evaluation, 136 patients 
were included for whom all cost data was available (Intervention n=72; Control n=64). 
The economic evaluation consisted of a cost-utility analysis and a cost effectiveness 
analysis. 
The direct medical costs were significantly lower in the intervention group for many 
routine hospital visits but the cost of out-patient rehabilitation and admission in a 
psychiatry hospital was higher. The mean cost of providing the intervention in the year 
was €127. There were no significant differences in the overall costs between the 2 
groups. The incremental cost effectiveness ratio supported the cost effectiveness of the 
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intervention and the probability of the intervention being cost effective was in excess of 
54%. The authors concluded that, the results were robust and it demonstrated positive 
societal economic effects and is cost effective. Based on these findings, the authors 
recommend incorporation of this intervention into routine medical practice.    
5.2.4. Conclusion and Future direction 
The National Institute of Clinical Excellence (NICE) recommend routine review of 
patients discharged from critical care units within 2-3 months by means of a face-to-
face consultation by an appropriately skilled health care professional, to carry out a 
functional assessment (NICE, National Institute for Clinical Excellence 2013). The 
recommendation extends to advocate referral to specialist services if there is concern 
regarding rate of recovery or development of unanticipated physical or non-physical 
comorbidity. Elaboration of the symptoms of non-physical comorbidity includes 
development of anxiety, depression, cognitive impairment and PTSD. Therefore, based 
on this guideline and the evidence presented in earlier sections, a business case can 
be put forward to implement simple psychological intervention to improve QoL and 
emotional wellbeing of cardiac arrest survivors. Although it is likely to be more resource 
intensive, it will be worth including patients whose neurological recovery remain 
compromised at CPC level 3 (Jennett, Bond 1975) as these are the group who are 
most likely to benefit from any proven psychological intervention along with their 
caregivers.    
At the Essex CTC, since the conclusion of the CARE study, a regular CARE clinic is 
being held whereby cardiac arrest survivors and their caregivers are offered 
comprehensive support and information regarding coping strategies. Patients and any 
caregivers identified to be at risk of or suffering from psychological trauma such as 
PTSD, are now offered formal consultation with a clinical psychologist who offer 
specialist support for this important group of individuals. Going forward, we want to 
expand the services to include patients with poorer neurological recovery (CPC 3-5) 
and their caregivers to be offered the professional psychological support. Inevitably, 
this will be challenging as it is likely that these group of individuals may have restricted 
mobility and impaired cognitive function. The caregivers of these cardiac arrest 
survivors are likely to suffer prolonged and protracted period of psychological trauma in 
the form of depression, anxiety and PTSD and there is every reason to offer them a 
helping hand to enable them to re-integrate them into society. Their care needs may be 
unique and specific to the environment that they live in. Hence, any support being 
offered may need to be individualised for their needs.  
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In the long term, we hope to form a focus group in collaboration with the resuscitation 
council such that the CARE model can be expanded across the nation and the 
beneficial effects of our ground work can reach far and wide. Needless to say, the 
expansion of the services will require more financial and human resources; but as 
shown in the latest analysis by Moulaert et al (Moulaert, Goossens et al. 2016), 
attempts to help survivors of cardiac arrest and their caregivers reintegrate into society 
are cost effective.     
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5.3. COOLAMI 
5.3.1. Key findings 
The COOLAMI case series was carried out as a prospective study to evaluate the 
feasibility of simultaneously administering TH in patients presenting with STEMI in a 
tertiary UK heart attack centre, specifically looking at team dynamics, reducing door to 
balloon time and recording any adverse incidents related to trial intervention. The trial 
was found to be feasible as evidenced by a similar average door to balloon times for 
the first 11 patients recruited to this study being 38 minutes in comparison to a mean of 
37 minutes for all patients presenting with STEMI at the Essex CTC in 2014. In the 
CHILL MI trial the door to balloon time was delayed by an average of 9 minutes 
(Erlinge, Gotberg et al. 2014).  
Independent monitoring of our data suggested that the door to balloon time and 
general team efficiency improved with time. There has been no trial related adverse 
event and no compromise to patient care as a result of participation in this study. One 
of the major challenges of conducting this study was shiver management in conscious 
patients, which was discussed in introduction. Through strict adherence to trial protocol 
regarding shiver management, early recognition from ECG changes, we were able to 
deliver a cooling regimen to our patients effectively without any early termination due to 
shivering.    
 
5.3.2. Conclusion and future direction 
Animal studies have shown that TH can reduce left ventricular infarct size by up to 80% 
if instituted early before reperfusion in the setting coronary artery occlusion (Dixon, 
Whitbourn et al. 2002, Gotberg, Olivecrona et al. 2008a, Erlinge 2011). Human trials to 
date have not been so promising to date. The CHILL MI was the latest RCT conducted 
by Erlinge et al (Erlinge, Gotberg et al. 2014) and found no significant difference in 
overall infarct size in patients treated with TH. However, subgroup analysis of patients 
presenting with anterior STEMI within 4 hours, showed that TH reduced infarct size by 
33% and a significant reduction in incidence of heart failure was also reported.  
 
A structured literature review was recently published looking at the feasibility, safety 
and efficacy of TH in the setting of STEMI (Saunderson, Chowdhary et al. 2016). The 
authors commented that with exception of one trial (Nichol, Strickland et al. 2015) 
where they used peritoneal lavage, all other studies were considered feasible. The 
higher MACE rate in the VELOCITY trial (Nichol, Strickland et al. 2015) was driven by 
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higher rate of stent thrombosis but it was interesting to note that a third of the patients 
in this trial were administered clopidogrel which has been reported to have worse anti-
platelet function in the context of hypothermia (Bednar, Kroupa et al. 2016). The 
authors also pointed out the lack of overall success for TH in STEMI can be explained 
by delayed presentation from symptom onset and only about 75% patients reaching 
target temperature of ≤35°C prior to reperfusion in the larger trials (Erlinge, Gotberg et 
al. 2014).  Therefore future trials should aim to establish if more rapid and efficient TH 
to ensure target temperature of ≤35°C is reached before reperfusion without causing 
delay in PPCI can translate into reduction in infarct size and sustained improvement in 
left ventricular ejection fraction. 
The recently conducted COOL AMI EU pilot trial using Zoll Proteus intravascular 
temperature management (IVTM) system demonstrated rapid and safe cooling of 
patients presenting with anterior STEMI to 33.6°C prior to reperfusion and this was 
associated with a non-significant, yet notable 7.1% absolute and 30% relative reduction 
in infarct size (Noc, Erlinge et al. 2017). This pilot trial was not powered to show 
difference in clinical outcome.  
The COOL AMI EU pivotal trial (NCT03173313) is a larger statistically powered trial 
designed to investigate whether simultaneous TH with PPCI results in reduction in 
infarct size. In this multicentre trial, 468 patients presenting with anterior and inferior 
STEMI will be randomly allocated in a 1:1 manner to PPCI plus simultaneous 
endovascular cooling with Zoll Proteus IVTM device and the results will be compared 
with standard treatment with PPCI alone. Infarct size will be measured with cardiac 
MRI scan 4-6 weeks after initial presentation. The results of this trial will be eagerly 
awaited as it is expected to generate important insight into the future role of TH in 
STEMI.  
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Appendix 1.1 COOLCATH Selection Criteria 
 
Patient Inclusion Criteria 
1) ≥ 18 years old 
2) Post cardiac arrest with ROSC 
3) Planning to receive therapeutic hypothermia as part of post- cardiac arrest 
care 
 
Patient Exclusion Criteria 
1) Cardiac arrest caused by trauma, head injury, massive haemorrhage, drug overdose, 
cerebrovascular accident, drowning, electric shock or hanging. 
2) Already hypothermic (<34°C) 
3) Nasal obstruction preventing the insertion of a nasal catheter 
4) Patients without established definitive airway 
5) Do Not Attempt to Resuscitate (DNAR) orders 
6) Known terminal illness (eg. malignancy in the end stages) 
7) Known or obvious pregnancy 
8) Known coagulation disorder (except those induced by medication eg. thrombolytics) 
9) Known O2- dependency 
 
Appendix 1.2 CPC Scale  
 
CPC Scale Interpretation 
1 Good cerebral performance or minor disability 
2 Moderate disability 
3 Severe disability 
4 Coma or vegetative state 
5 Brain Death 
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Appendix 1.3: CARE Questionnaires 
 
SF-36 Questionnaire adopted from RAND  
1. In general, would you say 
your health is: 
Excellent 1 
Very good  2 
Good 3 
Fair 4 
Poor 5 
 
 
2. Compared to one year ago, 
how would you rate your health in general now? 
Much better now than one year ago 1 
Somewhat better now than one year ago 2 
About the same 3 
Somewhat worse now than one year ago 4 
Much worse now than one year ago 5 
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The following items are about activities you might do during a typical day. Does your health 
now limit you in these activities? If so, how much? 
(Circle One Number on Each Line) 
 Yes, 
Limited a 
Lot  
Yes, Limited 
a Little  
No, Not 
limited at All  
3. Vigorous activities, such as running, lifting heavy 
objects, participating in strenuous sports 
[1]  [2]  [3]  
4. Moderate activities, such as moving a table, 
pushing a vacuum cleaner, bowling, or playing golf 
[1]  [2]  [3]  
5. Lifting or carrying groceries [1]  [2]  [3]  
6. Climbing several flights of stairs [1]  [2]  [3]  
7. Climbing one flight of stairs [1] [2] [3] 
8. Bending, kneeling, or stooping [1] [2] [3] 
9. Walking more than a mile [1]  [2]  [3]  
10. Walking several blocks  [1]  [2]  [3]  
11. Walking one block [1] [2] [3]  
12. Bathing or dressing yourself [1] [2] [3] 
During the past 4 weeks, have you had any of the following problems with your work or other 
regular daily activities as a result of your physical health? 
(Circle One Number on Each Line) 
 Yes  No  
13. Cut down the amount of time you spent on work or other activities 1  2  
14. Accomplished less than you would like 1  2  
15. Were limited in the kind of work or other activities  1  2  
16. Had difficulty performing the work or other activities (for example, it took extra 
effort)  
1  2  
104 
 
During the past 4 weeks, have you had any of the following problems with your work or other 
regular daily activities as a result of any emotional problems (such as feeling depressed or 
anxious)? 
(Circle One Number on Each Line) 
 Yes No 
17. Cut down the amount of time you spent on work or other activities 1  2  
18. Accomplished less than you would like 1  2  
19. Didn't do work or other activities as carefully as usual 1  2  
 
20. During the past 4 weeks, to what extent has your physical health or emotional problems 
interfered with your normal social activities with family, friends, neighbors, or groups? 
(Circle One Number) 
Not at all 1 
Slightly 2 
Moderately 3 
Quite a bit 4 
Extremely 5 
 
21. How much bodily pain have you had during the past 4 weeks? 
(Circle One Number) 
None 1 
Very mild 2 
Mild 3 
Moderate 4 
Severe 5 
Very severe 6 
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22. During the past 4 weeks, how much did pain interfere with your normal work (including 
both work outside the home and housework)? 
(Circle One Number) 
Not at all 1 
A little bit 2 
Moderately 3 
Quite a bit 4 
Extremely 5 
 
These questions are about how you feel and how things have been with you during the past 4 
weeks. For each question, please give the one answer that comes closest to the way you have 
been feeling. How much of the time during the past 4 weeks . . . 
(Circle One Number on Each Line) 
 All of 
the 
Time 
Most of 
the 
Time 
A Good Bit 
of the 
Time 
Some of 
the Time 
A Little 
of the 
Time 
None of 
the Time 
23. Did you feel full of pep? 1  2  3  4  5  6  
24. Have you been a very 
nervous person? 
1  2  3  4  5  6  
25. Have you felt so down in 
the dumps that nothing could 
cheer you up? 
1  2  3  4  5  6  
26. Have you felt calm and 
peaceful? 
1  2  3  4  5  6  
27. Did you have a lot of 
energy? 
1  2  3  4  5  6  
28. Have you felt downhearted 
and blue? 
1  2  3  4  5  6  
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29. Did you feel worn out? 1  2  3  4  5  6  
30. Have you been a happy 
person? 
1  2  3  4  5  6  
31. Did you feel tired?  1  2  3  4  5  6  
 
32. During the past 4 weeks, how much of the time has your physical health or emotional 
problems interfered with your social activities (like visiting with friends, relatives, etc.)? 
(Circle One Number) 
All of the time 1 
Most of the time 2 
Some of the time 3 
A little of the time 4 
None of the time 5 
 
How TRUE or FALSE is each of the following statements for you. 
(Circle One Number on Each Line) 
 Definitely 
True 
Mostly 
True  
Don't 
Know  
Mostly 
False  
Definitely 
False  
33. I seem to get sick a little easier 
than other people  
1  2  3  4  5  
34. I am as healthy as anybody I 
know  
1  2  3  4  5  
35. I expect my health to get 
worse  
1  2  3  4  5  
36. My health is excellent  1  2  3  4  5  
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The Cognitive Failures Questionnaire (Broadbent et al 1982) 
The following questions are about minor mistakes which everyone makes from time to 
time, but some of which happen more often than others. We want to know how often 
these things have happened to you in the past 6 months.  Please circle the appropriate 
number. 
  Very 
often 
Quite often Occasion
-   ally 
 
Very  
rarely 
Never 
1. Do you read something and find 
you haven’t been thinking about it 
and must read it again? 
    4     3     2     1     0 
2. Do you find you forget why you 
went from one part of the house 
to the other? 
    4     3     2     1     0 
3. Do you fail to notice signposts on 
the road? 
    4     3     2     1     0 
4. Do you find you confuse right and 
left when giving directions? 
    4     3     2     1     0 
5.   Do you bump into people?     4     3     2     1     0 
6. Do you find you forget whether 
you’ve turned off a light or a fire 
or locked the door? 
    4     3     2     1     0 
7. Do you fail to listen to people’s 
names when you are meeting 
them? 
    4     3     2     1     0 
8. Do you say something and 
realize afterwards that it might be 
taken as insulting? 
    4     3     2     1     0 
9. Do you fail to hear people 
speaking to you when you are 
doing something else? 
    4     3     2     1     0 
10. Do you lose your temper and 
regret it? 
    4     3     2     1     0 
11. Do you leave important letters 
unanswered for days? 
    4     3     2     1     0 
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  Very 
often 
Quite often Occasion
-   ally 
 
Very  
rarely 
Never 
 
12. Do you find you forget which way 
to turn on a road you know well 
but rarely use? 
    4     3     2     1     0 
13. Do you fail to see what you want 
in a supermarket (although it’s 
there)? 
    4     3     2     1     0 
14. Do you find yourself suddenly 
wondering whether you’ve used a 
word correctly? 
    4     3     2     1     0 
15. Do you have trouble making up 
your mind? 
    4     3     2     1     0 
16. Do you find you forget 
appointments? 
    4     3     2     1     0 
17. Do you forget where you put 
something like a newspaper or a 
book? 
    4     3     2     1     0 
18. Do you find you accidentally 
throw away the thing you want 
and keep what you meant to 
throw away – as in the example 
of throwing away the matchbox 
and putting the used match in 
your pocket? 
    4     3     2     1     0 
19. Do you daydream when you 
ought to be listening to 
something? 
    4     3     2     1     0 
20. Do you find you forget people’s 
names? 
    4     3     2     1     0 
21. Do you start doing one thing at 
home and get distracted into 
doing something else 
(unintentionally)? 
    4     3     2     1     0 
22. Do you find you can’t quite 
remember something although 
    4     3     2     1     0 
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it’s “on the tip of your tongue”? 
  Very 
often 
Quite often Occasion
-   ally 
 
Very  
rarely 
Never 
 
23. Do you find you forget what you 
came to the shops to buy? 
    4     3     2     1     0 
24. Do you drop things?     4     3     2     1     0 
25. Do you find you can’t think of 
anything to say? 
    4     3     2     1     0 
 
 
Reproduced by permission from the British Journal of Clinical Psychology. 
 
 
References 
 
Broadbent, D.E., Cooper, P.F., FitzGerald, P., & Parkes, K.R. (1982). The Cognitive 
Failures Questionnaire (CFQ) and its correlates. British Journal of Clinical 
Psychology, 21, 1-16. 
 
 
 
 
 
 
 
 
 
110 
 
Montreal Cognitive Assessment Tool  
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Appendix 1.4  Life after Cardiac arrest Leaflet 
This information leaflet is intended for cardiac arrest survivors, their family members 
and caregivers. It provides information on the possible consequences of cardiac arrest, 
including potential changes in cognitive function, emotion and behaviour and how this 
can affect your daily living. It also offers expert advice about how to deal with these 
changes.  We advise you to use what is relevant to you, as all the information may not 
be relevant to you.   
Patient Information 
Cardiac arrest is defined as the sudden termination of the pumping action of the heart, 
which can be life threatening in the absence of prompt resuscitation. The brain is 
heavily dependent on the heart to receive blood and oxygen supply that are required 
for its function. During a cardiac arrest, the brain is at risk of sustaining damage, as it is 
completely deprived of blood supply. Brain damage can result in variable levels of 
consciousness, movement disorders and impairment of cognitive function. Hence, the 
consequence of a cardiac arrest is not limited to problems in the heart but has 
significant implications in brain function, which can subsequently affect quality of life in 
patients who survive this life changing event.    
During the first few months after cardiac arrest, most of the recovery of your brain will 
occur. You will notice these improvements. However, some consequences like 
emotional wellbeing and cognitive function may not improve in the short term. These 
are usually the ‘invisible consequences’ of cardiac arrest. It is important to consider 
whether you experience these problems, which may be difficult to recognise. Your 
family members, friends or a healthcare professional can help you to find out which 
changes have occurred in your functioning.  
Changes in thinking 
When brain has suffered damage, the total capacity of brain function and speed of 
thinking can be diminished. In the next section, you will read common examples of 
changes in thinking, together with some tips. 
 Forgetfulness: It is not possible to remember everything as you used to. 
Information from the past is often remembered well. In contrast, remembering 
new information has become more difficult.  
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Tip: Use a diary. This will unburden your brain and prevent you from forgetting 
things. 
 Slowness: Thinking goes slower and daily activities take more time and 
energy. 
Tip: Make sure to plan enough time for the things you want to do. Make choice 
and try to say ‘no’. 
 Concentration: It is difficult to focus your attention 
Tip: Try to work in a quiet environment to avoid being distracted and improve 
your performance.  
 Multi-tasking: It has become difficult to do two things at once such as cooking 
and talking. 
Tip: Plan your activities one after the other instead of at the same time. 
 Planning: Planning, organising and keeping an overview are more difficult 
now. 
Tip: Plan beforehand how you are going to execute your activities, write this 
down and look at it regularly. 
 Fatigue: Activities which were easy before will now take more energy. You 
feel tired more quickly. 
Tip: Try to break your activities into smaller ones and take regular breaks 
 Agitation: You can feel exhausted more easily. This can lead to irritation or 
agitation.  
Tip: The tips above will help will diminish the chance of becoming agitated. 
Changed feelings 
The memories of the cardiac arrest itself are rare, but the fact that it happened can 
make one feel very anxious. Often people are afraid of a recurrence of the event and 
this can lead to avoidance of certain activities, which in itself generates more fear and 
insecurity. It is better to pick up your activities gradually which gives you more 
confidence in your functioning. Occasionally, you may benefit from talking to a health 
care professional who may be able to offer expert advice about dealing with this 
situation. Feelings of depression are also quite common and can emerge even after a 
few months. It is important to find out whether this is the case for you. Treating 
depression is possible and can consist of counselling and/or medication. 
Changes in behaviour 
Brain damage can lead to changes in behaviour, which is can be very diverse. Some 
people can become impulsive, easily agitated or disinhibited, while others can become 
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more passive and show lack of initiative. Sometimes the person is not aware of these 
changes, which can be a burden to family members and caregivers.  
Relaxation 
It is vital to find time to relax especially as usual daily activities can be more stressful, 
than before cardiac arrest.  Physical activity is a form of relaxation, as it has a positive 
influence on endurance and health. Other people relax by listening to music or 
performing another leisure activity. It can also help just to do nothing for a while. 
Family members and caregivers 
A cardiac arrest is a major life changing event not only for the patient but also close 
family members, friends and caregivers. On the one hand, you are happy that he/she 
survived the cardiac arrest; on the other hand there can be fear and grief about the 
things cardiac arrest has changed. 
Different person 
A cardiac arrest can change your close relative or friend. Some partners say ‘He is not 
the same person anymore’ or ‘I have another wife now’. This can indeed be the case if 
the cardiac arrest led to brain damage, which changes the way in which one feels, 
thinks or behaves. This can lead to changes in relationship. You may have to take on 
additional responsibilities, which can be quite stressful. Sometimes changes occur 
within the relationship itself or in the area of intimacy or sexuality. It is important to talk 
about these changes to try to find solutions. A health care professional can help you 
with that.  
Take care of yourself 
Family members and caregivers can be worried about recurrence of the cardiac arrest. 
Sometimes these worries can be so pronounced that the person who had the cardiac 
arrest is never left alone. This is not necessarily the best solution for everyone 
involved. It is important to try and regain confidence, which may take time.  
Being a partner or a close relative, it is important that you also take care of your own 
health. Strain and depression are often seen in caregivers. Try to notice when you feel 
burdened and ask for help. Try to arrange some leisure time and relaxation for yourself. 
Finding a balance between activity and rest is also a challenge for the caregivers. 
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